STAT6 degraders and uses thereof
Patent Information
- Application Number
- PCT/CN2026/091964
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-09-26
- Filing Date
- 2026-04-21
- Publication Date
- 2026-10-29
Smart Images

Figure CN2026091964_29102026_PF_FP_ABST
Abstract
Description
STAT6 DEGRADERS AND USES THEREOF
[0001] Cross-reference to related applications
[0002] The present disclosure claims the benefits of the PCT application No. PCT / CN2025 / 090447 entitled “STAT6 DEGRADERS AND USES THEREOF” filed April 22, 2025, the PCT application No. PCT / CN2025 / 097478 entitled “STAT6 DEGRADERS AND USES THEREOF” filed May 27, 2025, the PCT application No. PCT / CN2025 / 099464 entitled “STAT6 DEGRADERS AND USES THEREOF” filed June 6, 2025, the PCT application No. PCT / CN2025 / 111140 entitled “STAT6 DEGRADERS AND USES THEREOF” filed July 29, 2025, the PCT application No. PCT / CN2025 / 112153 entitled “STAT6 DEGRADERS AND USES THEREOF” filed August 01, 2025, the PCT application No. PCT / CN2025 / 116391 entitled “STAT6 DEGRADERS AND USES THEREOF” filed August 22, 2025, the PCT application No. PCT / CN2025 / 119376 entitled “STAT6 DEGRADERS AND USES THEREOF” filed September 05, 2025, the PCT application No. PCT / CN2025 / 120529 entitled “STAT6 DEGRADERS AND USES THEREOF” filed September 10, 2025, the PCT application No. PCT / CN2025 / 124463 entitled “STAT6 DEGRADERS AND USES THEREOF” filed September 26, 2025, which are incorporated herein by their entireties.FIELD
[0003] The present disclosure relates to compounds and methods useful for the modulation of signal transducer and activator of transcription 6 ( “STAT6” ) via ubiquitination and / or degradation by compounds according to the present disclosure. The disclosure also provides pharmaceutically acceptable compositions comprising compounds of the present disclosure and methods of using said compositions in the treatment of various disorders.BACKGROUND
[0004] STAT6 (Signal transducers and activators of transcription 6) is a multifunctional protein with dual functions in signal transduction and transcription activation. It belongs to the STAT protein family and is primarily activated by IL-4 and IL-13, playing a crucial role in immune response regulation.
[0005] Under normal physiological conditions, STAT6 is involved in regulating various biological processes, including the proliferation and differentiation of immune cells, development and class switching of B cells, differentiation of Th2 cells, and production of IgE. It is essential for maintaining the normal function and balance of the immune system.SUMMARY
[0006] The present disclosure provides a compound and a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a deuterated thereof, which exhibiting high degradation activity against STAT6, as well as high liver microsomal stability and bioavailability.
[0007] One aspect of the present disclosure relates to a compound of Formula I, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a deuterated compound thereof,
[0008] wherein:
[0009] X1 is selected from the group consisting of N and CH;
[0010] ring A is a ring selected from the group consisting of aryl; 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, spiro, or bridged carbocyclyl, 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, tricyclic, spiro or bridged heterocyclyl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered monocyclic, or bicyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0011] ring C is a ring selected from the group consisting of aryl; 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0012] ring B is a ring selected from the group consisting of aryl; 4-7 membered saturated or partially unsaturated carbocyclyl, 4-7 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-15 membered saturated or partially unsaturated tricyclic heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-15 membered tricyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0013] L1 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from the group consisting of aryl, 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl, 6-16 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl; 4-10 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 6-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-14 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0014] L3 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, -C0-6 alkyl-CO-, -C0-6 alkyl-CONR1-, -C0-6 alkyl-CONR1-C0-6 alkyl -CO-C0-6 alkyl -, -C0-6 alkyl-SO2-, -C0-6 alkyl-S (O) 2NR1-, or -C0-6 alkyl-NR1-;
[0015] L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (O) NH-, -C (S) -, -CHF-. -CF2-, -NR1-, -O-, -S-, or -S (O) 2;
[0016] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;
[0017] each of Ra1, Ra2 and Ra3 is independently selected from the group consisting of CN, hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated carbocyclyl or heterocyclyl;
[0018] wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;
[0019] Ra1, Ra2, Ra3, R3 and R4 are optionally substituted by one or more R5;
[0020] R5 is selected from the group consisting of oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated carbocyclyl or heterocyclyl;
[0021] R5 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR3R4;
[0022] each of Rb1, Rb2 and Rb3 is independently selected from the group consisting of CN, hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0023] each of Rc1, Rc2, Rc3 and Rc4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONR1-C0-6 alkyl, -C0-6 alkyl-SO2-C0-6 alkyl, -C0-6 alkyl-S (O) 2NR1R2, -C0-6 alkyl-NR1R2, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl; each of Rc1, Rc2, Rc3 and Rc4 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated carbocyclyl, or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, and C1-6 alkoxy; and
[0024] each of n1, n2, n3, n4, n5, n6, n7, n8, n9 and n10 is independently selected from the group consisting of 0, 1, and 2.
[0025] Another aspect of the present disclosure relates to a compound of Formula VIII, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a deuterated compound thereof,
[0026] wherein,
[0027] X1 is selected from the group consisting of N and CH;
[0028] ring A is a ring selected from the group consisting of aryl, and 5-10 membered monocyclic, bicyclic, or tricyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0029] ring C is a ring selected from the group consisting of aryl, 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0030] ring B is a ring selected from the group consisting of aryl, 4-7 membered saturated or partially unsaturated carbocyclyl, 4-7 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-10 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-15 membered saturated or partially unsaturated tricyclic heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 8-15 membered tricyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0031] L1 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from the group consisting of aryl, 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl, 6-16 membered saturated or partially unsaturated spiro carbocyclyl, 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl, 4-10 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 6-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-14 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0032] L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (O) NH-, -C (S) -, -CHF-, -CF2-, -NR1-, -O-, -S-, or -S (O) 2;
[0033] L4 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, -C0-6 alkyl-CO-, -C0-6 alkyl-CONR1-, -C0-6 alkyl-SO2-, -C0-6 alkyl-S (O) 2NR1-, or -C0-6 alkyl-NR1-;
[0034] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;
[0035] each of Ra1, Ra2 and Ra3 is independently selected from the group consisting of CN, hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0036] wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;
[0037] Ra1, Ra2, Ra3, R3 and R4 are optionally substituted by one or more R5;
[0038] R5 is selected from the group consisting of oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0039] R5 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR3R4;
[0040] each of Rb1, Rb2 and Rb3 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0041] each of Rc1 and Rc2 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NHR3C (O) -C1-6 alkyl, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONHR1, -C0-6 alkyl-SO2-C1-6 alkyl, -C0-6 alkyl-S (O) 2NR1-C1-6 alkyl, -C0-6 alkyl-NR1R2, -CO-C1-6 alkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl; and
[0042] each of Rc1 and Rc2 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl, or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, and C1-6 alkoxy;
[0043] each of L1, L2, and L4 is optionally substituted by one or more more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, and C1-6 alkoxy;
[0044] ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0045] ring D is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl; and
[0046] Cy1 is a ring selected from the group consisting of 12-16 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered saturated or partially unsaturated monocyclic heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 12-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,
[0047] Another aspect of the present disclosure relates to a method for treating an STAT6-mediated disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of the compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure , or the pharmaceutical composition of the present disclosure .DETAILED DESCRIPTION
[0048] In the following description, certain specific details are included to provide a comprehensive understanding of the various disclosed embodiments. However, those skilled in the art will recognize that embodiments may be achieved without the use of one or more of these specific details and with the use of other methods, components, materials, etc.
[0049] Unless otherwise required in this disclosure, throughout the specification and subsequent claims, the words “including” and “comprising” are to be interpreted in an open-ended, inclusive sense, i.e., “including, without limitation” .
[0050] As used in this disclosure and the appended claims, singular referents without indication of quantity include plural referents unless the context clearly indicates otherwise.
[0051] Throughout this specification, references to “an embodiment” or “embodiments” or “in another embodiment” or “in some embodiments” means to include in at least one embodiment a specific reference element, structure or feature related to that embodiment as described in that embodiment. Accordingly, the phrases “in an embodiment” or “in an embodiment” or “in another embodiment” or “in some embodiments” appearing at various places throughout the specification are intended to mean that at least one embodiment includes a specific reference element or feature related to that embodiment as described therein. “in some embodiments” need not all refer to the same embodiment. In addition, specific elements, structures, or features may be combined in one or more embodiments in any suitable manner.
[0052] It should be understood that the singular form of the article “one” (corresponding to the English words “a” , “an” , and “the” ) is used in the specification of the present disclosure and the appended claims. “the” ) is used in the claims in the singular form to include objects in the plural unless the context explicitly states otherwise. Thus, for example, reference to an extended-release tablet comprising “pharmaceutically acceptable excipients” includes one pharmaceutically acceptable excipient or two or more pharmaceutically acceptable excipients.
[0053] It should be understood that the singular form of the article “a” (corresponding to the English “a” , “an” , and “the” ) used in this disclosure and the accompanying claims includes plural objects unless otherwise explicitly stated in the text. Therefore, for example, a sustained-release tablet containing “pharmaceutically acceptable excipients” includes one pharmaceutically acceptable excipient or two or more pharmaceutically acceptable excipients.
[0054] I. Definition
[0055] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. A dash at the front or end of a chemical group is a matter of convenience to indicate the point of attachment to a parent moiety; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A prefix such as “Cu-v” or “Cu-Cv” indicates that the following group has from u to v carbon atoms, where u and v are integers. For example, “C1-6 alkyl” or “C1-C6 alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms. “C3-C10 cycloalkyl” describes a cycloalkyl group with a total of 3 to 10 carbon atoms.
[0056] The terms “and / or” are used in this disclosure to denote “and” or “or” unless otherwise indicated.
[0057] is a single bond or a double bond. For example, means cyclohexane or cyclohexene;
[0058] When the connecting groups listed do not specify their direction of connection, the direction of connection is arbitrary. For example, in A-L1-R1 where the connecting group L1 is -M-W-, the -M-W-can connect A and R1 as the left-to-right reading order to form A-M-W-R1, or it can connect ring A and R1 in the opposite direction to the left-to-right order to form A-W-M-R1. The combinations of the connecting groups, substituents, and / or their variants are only permitted if such combinations would result in stable compounds.
[0059] “Alkyl” is a monovalent or divalent linear or branched saturated hydrocarbon radical. For example, an alkyl group can have 1 to 50 carbon atoms (i.e., C1-50 alkyl) , or 1 to 10 carbon atoms (i.e., C1-10 alkyl) or 1 to 8 carbon atoms (i.e., C1-8 alkyl) or 1 to 6 carbon atoms (i.e., C1-6 alkyl) or 1 to 4 carbon atoms (i.e., C1-4 alkyl) or 1 to 3 carbon atoms (i.e., C1-3 alkyl) . Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3) , ethyl (Et, -CH2CH3) , 1-propyl (n-Pr, n-propyl, -CH2CH2CH3) , 2-propyl (i-Pr, i-Propyl, -CH (CH3) 2) , 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3) , 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH (CH3) 2) , 2-butyl (s-Bu, s-butyl, -CH (CH3) CH2CH3) , 2-methyl-2-propyl (t-Bu, t-butyl, -C (CH3) 3) , 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3) , 2-pentyl (-CH (CH3) CH2CH2CH3) , 3-pentyl (-CH (CH2CH3) 2) , 2-methyl-2-butyl (-C (CH3) 2CH2CH3) , 3-methyl-2-butyl (-CH (CH3) CH (CH3) 2) , 3-methyl-1-butyl (-CH2CH2CH (CH3) 2) , 2-methyl-1-butyl (-CH2CH (CH3) CH2CH3) , 1-hexyl (-CH2CH2CH2CH2CH2CH3) , 2-hexyl (-CH (CH3) CH2CH2CH2CH3) , 3-hexyl (-CH (CH2CH3) (CH2CH2CH3) ) , 2-methyl-2-pentyl (-C (CH3) 2CH2CH2CH3) , 3-methyl-2-pentyl (-CH (CH3) CH (CH3) CH2CH3) , 4-methyl-2-pentyl (-CH (CH3) CH2CH (CH3) 2) , 3-methyl-3-pentyl (-C (CH3) (CH2CH3) 2) , 2-methyl-3-pentyl (-CH (CH2CH3) CH (CH3) 2) , 2, 3-dimethyl-2-butyl (-C (CH3) 2CH (CH3) 2) , 3, 3-dimethyl-2-butyl (-CH (CH3) C (CH3) 3, and octyl (- (CH2) 7CH3) . Alkyl groups can be unsubstituted or substituted.
[0060] The alkyl group may be optionally substituted, i.e., substituted or unsubstituted. When substituted, the substituent group is individually and independently selected from one or more of the following: deuterium, cycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, thiol, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-acylamino, N-acyl amino, S-sulfinylamino, N-sulfinylamino, C-carboxyl, O-carboxyl, isocyanato, cyanothio, isothiocyanato, nitro, methylsilyl, trihalomethanesulfonyl, -NR'R" (R' and R" are alkyl groups as defined in the present disclosure) or amino groups including mono-and di-substituted amino groups, and protected derivatives thereof.
[0061] In some embodiments, exemplary examples of alkyl groups that can be used in the present disclosure include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, and hexyl. Whenever a substituent is described as being “optionally substituted” , the substituent may be substituted with one of the above substituents.
[0062] “Alkoxy” refers to the group -O-alkyl, where alkyl is as defined above. For example, C1-4 alkoxy refers to an -O-alkyl group with 1 to 4 carbons. Alkoxy groups can be unsubstituted or substituted.
[0063] “Alkoxyalkyl” is an alkoxy group attached to an alkyl as defined above, such that the alkyl is divalent. For example, C2-6 alkoxyalkyl includes -CH2-OMe, -CH2-O-iPr, -CH2-CH2-OMe, -CH2-CH2-O-CH2-CH3, and -CH2-CH2-O-tBu. Alkoxyalkyl groups can be unsubstituted or substituted.
[0064] “Alkenyl” is a monovalent or divalent linear or branched hydrocarbon radical with at least one carbon-carbon double bond. For example, an alkenyl group can have 2 to 8 carbon atoms (i.e., C2-8 alkenyl) or 2 to 6 carbon atoms (i.e., C2-6 alkenyl) or 2 to 4 carbon atoms (i.e., C2-4 alkenyl) . Examples of alkenyl groups include, but are not limited to, ethenyl (-CH=CH2) , allyl (-CH2CH=CH2) , and -CH2-CH=CH-CH3. Alkenyl groups can be unsubstituted or substituted.
[0065] “Alkynyl” is a monovalent or divalent linear or branched hydrocarbon radical with at least one carbon-carbon triple bond. For example, an alkynyl group can have 2 to 8 carbon atoms (i.e., C2-8 alkynyl) or 2 to 6 carbon atoms (i.e., C2-6 alkynyl) or 2 to 4 carbon atoms (i.e., C2-4 alkynyl) . Examples of alkynyl groups include, but are not limited to, acetylenyl (-C≡CH) , propargyl (-CH2C≡CH) , and -CH2-C≡C-CH3. Alkynyl groups can be unsubstituted or substituted.
[0066] “Oxo” as used herein refers to =O.
[0067] “Halogen” or “halo” refers to fluoro (-F) , chloro (-Cl) , bromo (-Br) and iodo (-I) .
[0068] “Haloalkyl” is an alkyl as defined herein, wherein one or more hydrogen atoms of the alkyl are independently replaced by a halogen, which may be the same or different, such that the alkyl is divalent. The alkyl group and the halogen can be any of those described above. In some embodiments, the haloalkyl defines the number of carbon atoms in the alkyl portion, e.g., C1-4 haloalkyl includes CF3, CH2F, CHF2, CH2CF3, CH2CH2CF3, CCl2CH2CH2CH3, and C (CH3) 2 (CF2H) . Haloalkyl groups can be unsubstituted or substituted.
[0069] “Haloalkoxy” is an alkoxy as defined herein, wherein one or more hydrogen atoms of the alkyl in the alkyoxy are independently replaced by a halogen, which may be the same or different, such that the alkyl is divalent. The alkoxy group and the halogen can be any of those described above. In some embodiments, the haloalkoxy defines the number of carbon atoms in the alkyl portion, e.g., C1-4 haloalkoxy includes OCF3, OCH2F, OCH2CF3, OCH2CH2CF3, OCCl2CH2CH2CH3, and OC (CH3) 2 (CF2H) . Haloalkoxy groups can be unsubstituted or substituted.
[0070] “Cycloalkyl” or “carbocyclyl” is a monovalent or divalent single all carbon ring or a multiple all carbon ring system wherein the ring in each instance is a non-aromatic saturated or unsaturated ring. For example, in some embodiments, a cycloalkyl group has 3 to 12 carbon atoms, 3 to 10 carbon atoms, 3 to 8 carbon atoms, 3 to 6 carbon atoms, 3 to 5 carbon atoms, or 3 to 4 carbon atoms. Exemplary single ring cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, and cyclooctyl. Cycloalkyl also includes multiple condensed ring systems (e.g., ring systems comprising 2 rings) with about 7 to 12 carbon atoms. The rings of the multiple ring system can be connected to each other via fused, spiro, or bridged bonds when allowed by valency requirements. Exemplary multiple ring cycloalkyl groups include octahydropentalene, bicyclo [2.2. 1] heptane, bicyclo [2.2.2] octane, bicyclo [2.2.2] oct-2-ene, and spiro [2.5] octane. Cycloalkyl groups can be unsubstituted or substituted. The term “cycloalkyl” is intended to include a cycloalkyl group as defined above option substituted by one or more groups selected from the following substituents: cycloalkyl, aryl, heteroaryl, heteroaliphatic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thio carbonyl, isocyanate, cyanothionyl, isothiocyanate, nitro, -NR'R " (R'and R" are alkyl groups as defined in the present disclosure) or amino groups including mono-and di-substituted amino groups, and protected derivatives thereof.
[0071] In some embodiments, “C3-6 cycloalkyl” refers to a cycloalkyl group as defined above with three to six carbon atoms. C3-6 cycloalkyl groups may be optionally substituted as defined above for cycloalkyl.
[0072] In some embodiments, “C3-8 cycloalkyl” refers to a cycloalkyl group with from three to eight carbon atoms as defined above. C3-8 cycloalkyl groups may be optionally substituted as defined above for cycloalkyl.
[0073] In some embodiments, the term “C3-15 cycloalkyl” refers to a cycloalkyl group as defined above with from three to fifteen carbon atoms. C3-15 cycloalkyl groups may be optionally substituted as defined above for cycloalkyl.
[0074] “Membered” as used herein refers to the number of atoms that make up a ring in a cyclic group. A prefix such as “x-y membered” indicates that the following group has from u to v atoms, where u and v are integers. For example, in some embodiments, “5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl” is utilized to characterize carbocyclyl or heterocyclyl groups that comprise 5 to 12 atoms, and these carbocyclyl or heterocyclyl groups include those with 5, 6, 7, 8, 9, 10, 11, and 12 atoms, when defining a heterocycle, the “5 to 12 atoms” encompasses both carbon atoms and heteroatoms. In some embodiments, “5-10 membered monocyclic, bicyclic, or tricyclic heteroaryl” is utilized to characterize heteroaryl groups that comprise 5 to 10 atoms, and these heteroaryl groups include those with 5, 6, 7, 8, 9, and 10 atoms, and the “5 to 12 atoms” encompasses both carbon atoms and heteroatoms. In some embodiments, “3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl” is utilized to characterize carbocyclyl or heterocyclyl groups that comprise 3 to 10 atoms, and these carbocyclyl or heterocyclyl groups include those with 3, 4, 5, 6, 7, 8, 9, and 10 atoms. In some embodiments, “4-7 membered saturated or partially unsaturated carbocyclyl” is utilized to characterize carbocyclyl or heterocyclyl groups that comprise 4 to 7 atoms, and these carbocyclyl groups include those with 4, 5, 6, and 7 atoms. In some embodiments, “4-7 membered saturated or partially unsaturated heterocyclyl” is utilized to heterocyclyl groups that comprise 4 to 7 atoms, and these carbocyclyl groups include those with 4, 5, 6, and 7 atoms. In some embodiments, “8-10 membered bicyclic saturated or partially unsaturated heterocyclyl” is utilized to heterocyclyl groups that comprise 8 to 10 atoms, and these carbocyclyl groups include those with 8, 9, and 10 atoms. In some embodiments, “5-6 membered heteroaryl” is utilized to heteroaryl groups that comprise 5 to 6 atoms, and these carbocyclyl groups include those with5, and 6 atoms. In some embodiments, “8-15 membered saturated or partially unsaturated tricyclic heterocyclyl” is utilized to heteroaryl groups that comprise 8 to 15 atoms, and these carbocyclyl groups include those with 8, 9, 10, 11, 12, 13, 14 and 15 atoms. In some embodiments, “6-16 membered saturated or partially unsaturated spiro carbocyclyl” is utilized to heteroaryl groups that comprise 6 to 16 atoms, and these carbocyclyl groups include those with 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 atoms. In some embodiments, “8-14 membered bicyclic saturated or partially unsaturated heterocyclyl” is utilized to heterocyclyl groups that comprise 8 to 14 atoms, and these carbocyclyl groups include those with 8, 9, 10, 11, 12, 13, and 14 atoms.
[0075] "Monocyclic" refers to the groups consisting of a single ring structure. This ring can be a carbocycle , heterocycle, aromatic ring or heterocycle, Monocyclic group can be saturated or unsaturated.
[0076] “Bicyclic” refers to the groups consisting of two rings that are connected to each other. These rings can either be separate or share one or more atoms or bonds. Bicyclic systems include spirocycles, fused rings and bridged rings. This ring can be a carbocycle, a heterocycle, aromatic ring or heterocycle. Bicyclic group can be saturated or unsaturated.
[0077] “Tricyclic” refers to the groups consisting of three rings. These rings can be connected in various configurations, such as each ring being connected to the others through shared atoms or bonds. Tricyclic systems include spirocycles, fused rings and bridged rings. This ring can be a carbocycle, heterocycle, aromatic ring or heteroaromatic ring. Tricyclic group can be saturated or unsaturated.
[0078] “Spirocyclic” refers to the groups consisting of two or more rings that are connected through one common atom, which is known as a spiro atom. This atom is part of both rings, and the rings are otherwise not connected through any other atoms or bonds. This ring can be a carbocycle or a heterocycle. Spirocyclic group can be saturated or unsaturated.
[0079] “Heterocyclyl” or “heterocycle” or “heterocycloalkyl” or “heterocyclic” or “heterocyclic ring” as used herein interchangeably herein, refers to a single saturated or partially unsaturated non-aromatic ring or a non-aromatic multiple ring system that has at least one heteroatom in the ring (i.e., at least one annular (i.e., ring-shaped) heteroatom selected from oxygen, nitrogen, and sulfur) . Unless otherwise specified, a heterocyclyl group has from 3 to about 20 annular atoms, for example from 3 to 12 annular atoms, for example from 4 to 12 annular atoms, 4 to 10 annular atoms, or 3 to 8 annular atoms, or 3 to 6 annular atoms, or 3 to 5 annular atoms, or 4 to 6 annular atoms, or 4 to 5 annular atoms. Thus, the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6 or 7-membered rings) with from about 1 to 6 annular carbon atoms and from about 1 to 3 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The rings of the multiple condensed ring (e.g. bicyclic heterocyclyl) system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. Heterocycles include, but are not limited to, azetidine, aziridine, imidazolidine, morpholine, oxirane (epoxide) , oxetane, thietane, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, quinuclidine, 2-oxa-6-azaspiro [3.3] heptan-6-yl, 6-oxa-1-azaspiro [3.3] heptan-1-yl, 2-thia-6-azaspiro [3.3] heptan-6-yl, 2, 6-diazaspiro [3. 3] heptan-2-yl, 2-azabicyclo [3.1.0] hexan-2-yl, 3-azabicyclo [3.1.0] hexanyl, 2-azabicyclo [2.1.1] hexanyl, 2-azabicyclo [2.2.1] heptan-2-yl, 4-azaspiro [2.4] heptanyl, 5-azaspiro [2.4] heptanyl,
[0080] and the like. Heterocyclyl groups can be unsubstituted or substituted.
[0081] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
[0082] The term “aliphatic” or “aliphatic group” , as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated orthat contains one or more units ofunsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon thatis completely saturated or that contains one or more units of unsaturation, but which is not aromatic (alsoreferred to herein as "carbocycle, " “cycloaliphatic” or “cycloalkyl” ) , that has a single point of attachmentto the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms.
[0083] In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphaticgroups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl” ) refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest ofthe molecule. In some embodiments, a carbocyclic ring may be a 5-12 membered bicyclic, bridged bicyclic, or spirocyclic ring. A carbocyclic ring may include one or more oxo (=O) or thioxo (=S) substituent. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl) alkyl, (cycloalkenyl) alkyl or (cycloalkyl) alkenyl.
[0084] As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, with at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, wherea “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen) . In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclic group include:
[0085] The term “lower haloalkyl” refers to a C1-4 straight or branched alkyl group that is substituted with one or more halogen atoms.
[0086] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3, 4-dihydro-2H-pyrrolyl) , NH (as in pyrrolidinyl) or NR+ (as in N-substituted pyrrolidinyl) ) . When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring with 0–3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3, 4–dihydro–2H–pyrrolyl) , NH (as in pyrrolidinyl) , or +NR (as in N–substituted pyrrolidinyl) .
[0087] As used herein, the term “bivalent C1-50 (or C1-6) saturated or unsaturated, straight or branched, hydrocarbon chain” , refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
[0088] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., – (CH2) n–, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
[0089] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
[0090] As used herein, the term “cyclopropylenyl” refers to a bivalent cyclopropyl group of the following structure:
[0091] The term “aryl” used alone or as part of a larger moiety as in “aralkyl, ” “aralkoxy, ” or “aryloxyalkyl, ” refers to monovalent or divalent, monocyclic or bicyclic ring systems with a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring. ” In certain embodiments of the present disclosure, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl, ” as it is used herein, is a group in which an aromatic ring is fused to one or more non–aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like. When an "aryl group" refers to a divalent group, the term “aryl” is also referred to as "arylenyl" , (e.g., phenylenyl) .
[0092] The terms “heteroaryl” and “heteroar–, ” used alone or as part of a larger moiety, e.g., “heteroaralkyl, ” or “heteroaralkoxy, ” refer to groups with 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; with 6, 10, or 14 electrons shared in a cyclic array; and with, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar–” , as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido [2, 3–b] –1, 4–oxazin–3 (4H) –one. A heteroaryl group may be monocyclic, bicyclic, bridged bicyclic, or spirocyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring, ” “heteroaryl group, ” or “heteroaromatic, ” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted. The term “heteroaryl” includes monovalent and divalent radicals. When it refers to a divalent group, the term “heteroaryl” is also referred to as "heteroarylenyl" , (e.g., pyridylenyl) .
[0093] As used herein, the term “partially unsaturated” refers to a chain group or a ring group moiety that includes at least one double or triple bond. when it defines a ring gtoup, the term “partially unsaturated” is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
[0094] As described herein, compounds of the disclosure may contain “substituted” moieties. In general, the term “substituted” means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable, ” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
[0095] “Substituted” as used herein refers to wherein one or more hydrogen atoms of the group are independently replaced by one or more substituents (e.g., 1, 2, 3, or 4 or more) as indicated. The substituent is selected from the following substituents, but are not limited to: alkyl, cycloalkyl, aryl, heteroaryl, heteroaryl, hydroxy, protected hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylsulfanyl, cyano, halogenated, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl O-thiocarbamoyl, Ν-thiocarbamoyl, C-acylamino, Ν-acylamino, S-sulfinylamino, Ν-sulfinylamino, C-carboxylic, protected C-carboxylic, O-carboxylic, isocyanatocarbonyl, cyanothiocyanatocarbonyl, isothiocyanatocarbonyl, nitro, methyldimethylsilanyl, trihalomethanesulfonyl, -NR'R" (R' and R" are alkyl groups as defined in this disclosure) or a protected amino group.
[0096] Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; – (CH2) 0–4Ro ; – (CH2) 0–4ORo; -O (CH2) 0-4Ro, –O– (CH2) 0–4C (O) OR○; – (CH2) 0–4CH (OR○) 2; – (CH2) 0–4SRo; – (CH2) 0–4Ph, which may be substituted with R○; – (CH2) 0–4O (CH2) 0–1Ph which may be substituted with R○; –CH=CHPh, which may be substituted with R○; – (CH2) 0–4O (CH2) 0–1-pyridyl which may be substituted with R○; –NO2; –CN; –N3; – (CH2) 0–4N (R○) 2; – (CH2) 0–4N (R○) C (O) R○; –N (R○) C (S) R○; – (CH2) 0–4N (R○) C (O) NR○2; -N (R○) C (S) NR○2; – (CH2) 0–4N (R○) C (O) OR○; –N (R○) N (R○) C (O) R○; -N (R○) N (R○) C (O) NR○2; -N (R○) N (R○) C (O) OR○; – (CHC (O) R○; –C (S) R○; – (CH2) 0–4C (O) OR○; – (CH2) 0–4C (O) SR○; - (CH2) 0–4C (O) OSiR○3; – (CH2) 0–4OC (O) R○; –OC (O) (CH2) 0–4S R○; – (CH2) 0–4SC (O) R○; – (CH2) 0–4C (O) 2) 0–4NR○2; –C (S) NR○2; –C (S) SR○; –SC (S) SR○, - (CH2) 0–4OC (O) NR○2; -C (O) N (OR ) R○; –C (O) C (O) R○; –C (O) CH2C (O) R○; –C (NOR ) R○; - (CH2) 0–4SSR○; – (CH2) 0–4S (O) 2R ; – (CH2) 0–4S (O) 2OR○; – (CH2) 0–4OS (O) 2R○; –S (O) 2NR○2; – (CH2) 0–4S (O) R○; -N (R ) S (O) 2NR○2; –N (R○) S (O) 2R○; –N (OR ) R○; –C (NH) NR○2; – (CH2) 0–4P (O) 2R○; – (CH2) 0–4P (O) R○2; – (CH2) 0–4OP (O) R○2; – (CH2) 0–4OP (O) (OR ) 2; SiR3; – (C1–4 straight or branched alkylene) O–N (R○) 2; or – (C1–4 straight or branched alkylene) C (O) O–N (R○) 2, wherein each R○ may be substituted as defined below and is independently hydrogen, C1–6 aliphatic, –CH2Ph, –O (CH2) 0–1Ph, -CH2- (5-6 membered heteroaryl ring) , or a 3–6–membered saturated, partially unsaturated, or aryl ring with 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, not withstanding the definition above, two independent occurrences of R○ , taken together with their intervening atom (s) , form a 3–12–membered saturated, partially unsaturated, or aryl mono–or bicyclic ring with 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.
[0097] Suitable monovalent substituents on R○ (or the ring formed by taking two independent occurrences of R○ together with their intervening atoms) , are independently halogen, – (CH2) 0–2R’ , – (haloR’ ) , – (CH2) 0–2OH, – (CH2) 0–2OR ‘, – (CH2) 0–2CH (OR’ ) 2; -O (haloR’ ) , –CN, –N3, – (CH2) 0–2C (O) R’ , - (CH2) 0–2C (O) OH, - (CH2) 0-2C (O) OR’ , - (CH2) 0-2SR’ , - (CH2) 0-2SH, - (CH2) 0-2NH 2, - (CH2) 0-2NHR’ , - (CH2) 0-2NR’ 2, -NO2, -SiR’ 3, -OSiR’ 3, -C (O) SR’ - (C1-4 straight or branched alkylene) C (O) OR’ , or -SSR’ wherein each R’ is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from C1–4 aliphatic, -CH2Ph, -O (CH2) 0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring with 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R○ include =O and =S.
[0098] Suitable divalent substituents on a saturated carbon atom of an “optionally substituted” group include the following: =O, =S, =NNR*2, =NNHC (O) R*, =NNHC (O) OR*, =NNHS (O) 2R*, =NR*, =NOR*, –O (C (R*2) ) 2–3O–, or –S (C (R*2)) 2–3S–, wherein each independent occurrence of R*is selected from hydrogen, C1–6 aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring with 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: –O (CR*2) 2–3O–, wherein each independent occurrence of R*is selected from hydrogen, C1–6 aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring with 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0099] Suitable substituents on the aliphatic group of R*include halogen, –R’ , - (haloR’ ) , -OH, –OR’ , –O (haloR’ ) , –CN, –C (O) OH, –C (O) OR’ , –NH2, –NHR’ , –NR’2, or –NO2, wherein each R’ is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1–4 aliphatic, –CH2Ph, –O (CH2) 0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring with 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0100] "Bivalent" refers to a chemical group or structure that is capable of forming two chemical bonds. It indicates that the group has two valence bonds available for connecting to other parts of a molecule or different molecules.
[0101] A “compound of the present disclosure” includes compound disclosed herein, including the general Formula and the specific compounds, for example a compound of the present disclosure includes compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV, but also includes the compound of the examples.
[0102] “Pharmaceutically acceptable excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
[0103] “Therapeutically effective amount” or “effective amount” as used herein refers to an amount that is effective to elicit the desired biological or medical response, including the amount of a compound that, when administered to a subject for treating a disease, is sufficient to affect such treatment for the disease. The effective amount will vary depending on the compound, the disease, and its severity and the age, weight, etc., of the subject to be treated. The effective amount can include a range of amounts. As is understood in the art, an effective amount may be in one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved. Suitable doses of any co-administered compounds may optionally be lowered due to the combined action (e.g., additive or synergistic effects) of the compounds.
[0104] “Co-administration” as used herein refers to administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound of the present disclosure is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the present disclosure within seconds or minutes. In some embodiments, a unit dose of a compound of the present disclosure is administered first, followed, after a period of hours (e.g., 1-12 hours) , by administration of a unit dose of one or more additional therapeutic agents. In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours) , by administration of a unit dose of a compound of the present disclosure. Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more additional therapeutic agents, such that therapeutically effective amounts of each agent are present in the body of the subject.
[0105] Provided are also pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds described herein.
[0106] “Pharmaceutically acceptable” refers to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
[0107] The compounds described herein may be prepared and / or formulated as pharmaceutically acceptable salts or when appropriate as a free base. Pharmaceutically acceptable salts are non-toxic salts of a free base form of a compound that possesses the desired pharmacological activity of the free base. These salts may be derived from inorganic or organic acids or bases. For example, a compound that contains a basic nitrogen may be prepared as a pharmaceutically acceptable salt by contacting the compound with an inorganic or organic acid. Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1, 4-dioates, hexyne-1, 6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulfonates, besylates, xylenesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates, and mandelates. Lists of other suitable pharmaceutically acceptable salts are found in Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Wiliams and Wilkins, Philadelphia, Pa., 2006.
[0108] Examples of “pharmaceutically acceptable salts” of the compounds disclosed herein also include salts derived from an appropriate base, such as an alkali metal (for example, sodium, potassium) , an alkaline earth metal (for example, magnesium) , ammonium and N (C1-C4 alkyl) 4+. Also included are base addition salts, such as sodium or potassium salts.
[0109] Provided are also compounds described herein or pharmaceutically acceptable salts, isomers, or a mixture thereof, in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule. As known in the art, the deuterium atom is a non-radioactive isotope of the hydrogen atom. Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof when administered to a mammal. See, e.g., Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism” , Trends Pharmacol. Sci., 5 (12) : 524-527 (1984) . Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
[0110] Examples of isotopes that can be incorporated into the disclosed compounds also include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 31P, 32P, 35S, 18F, 36Cl, 123I, and 125I, respectively. Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of Formula I can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
[0111] The compounds of the embodiments disclosed herein, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, tautomer, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R) -or (S) -or, as (D) -or (L) -for amino acids, as well as deuterated analogs thereof. The chemical formula shown in the present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-) , (R) -and (S) -, or (D) -and (L) -isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC) . When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. Where compounds are represented in their chiral form, it is understood that the embodiment encompasses, but is not limited to, the specific diastereomerically or enantiomerically enriched form. Where chirality is not specified but is present, it is understood that the embodiment is directed to either the specific diastereomerically or enantiomerically enriched form; or a racemic or scalemic mixture of such compound (s) . As used herein, “scalemic mixture” is a mixture of stereoisomers at a ratio other than 1: 1.
[0112] “Stereoisomer” as used herein refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers” , which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.
[0113] “Tautomer” as used herein refers to a proton shift from one atom of a molecule to another atom of the same molecule. In some embodiments, the present disclosure includes tautomers of said compounds. The tautomers of the compounds provided in the present disclosure can be prepared by the same methods and possess identical physicochemical properties, pharmaceutical activities and pharmacokinetic properties. For example, in the present disclosure, the following groups represent a pair of tautomers.
[0114] Even where only one form of tautomers is recited in the general formula and specific compounds, the other form is also substantially encompassed within the scope of protection of the present disclosure.
[0115] “Prevention” or “preventing” means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
[0116] “Prodrug” as used herein refers to a derivative of a drug that upon administration to the human body is converted to the parent drug according to some chemical or enzymatic pathway. In some embodiments, a prodrug is a biologically inactive derivative of a drug that upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway.
[0117] “Treatment” or “treat” or “treating” as used herein refers to an approach for obtaining beneficial or desired results. For purposes of the present disclosure, beneficial or desired results include, but are not limited to, alleviation of a symptom and / or diminishment of the extent of a symptom and / or preventing a worsening of a symptom associated with a disease or condition. In one embodiment, “treatment” or “treating” includes one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and / or diminishing the extent of the disease or condition) ; b) slowing or arresting the development of one or more symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, delaying the worsening or progression of the disease or condition) ; and c) relieving the disease or condition, e.g., causing the regression of clinical symptoms, ameliorating the disease state, delaying the progression of the disease, increasing the quality of life, and / or prolonging survival. “At risk individual” as used herein refers to an individual who is at risk of developing a condition to be treated. An individual “at risk” may or may not have detectable disease or condition, and may or may not have displayed detectable disease prior to the treatment of methods described herein. “At risk” denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of a disease or condition and are known in the art. An individual with one or more of these risk factors has a higher probability of developing the disease or condition than an individual without these risk factor (s) .
[0118] II. Compounds and compositions
[0119] One aspect of the present disclosure relates to a compound, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a deuterated compound thereof of Formula I:
[0120] wherein:
[0121] X1 is selected from the group consisting of N and CH;
[0122] ring A is a ring selected from the group consisting of aryl; 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, spiro, or bridged carbocyclyl, 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, tricyclic, spiro or bridged heterocyclyl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered monocyclic, or bicyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0123] ring C is a ring selected from the group consisting of aryl; 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0124] ring B is a ring selected from the group consisting of aryl; 4-7 membered saturated or partially unsaturated carbocyclyl, 4-7 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-15 membered saturated or partially unsaturated tricyclic heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-15 membered tricyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0125] L1 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from the group consisting of aryl, 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl, 6-16 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl; 4-10 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 6-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-14 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0126] L3 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, -C0-6 alkyl-CO-, -C0-6 alkyl-CONR1-, -C0-6 alkyl-CONR1-C0-6 alkyl -CO-C0-6 alkyl -, -C0-6 alkyl-SO2-, -C0-6 alkyl-S (O) 2NR1-, or -C0-6 alkyl-NR1-;
[0127] L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (O) NH-, -C (S) -, -CHF-. -CF2-, -NR1-, -O-, -S-, or -S (O) 2;
[0128] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;
[0129] each of Ra1, Ra2 and Ra3 is independently selected from the group consisting of CN, hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated carbocyclyl or heterocyclyl;
[0130] wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;
[0131] Ra1, Ra2, Ra3, R3 and R4 are optionally substituted by one or more R5;
[0132] R5 is selected from the group consisting of oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated carbocyclyl or heterocyclyl;
[0133] R5 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR3R4;
[0134] each of Rb1, Rb2 and Rb3 is independently selected from the group consisting of CN, hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0135] each of Rc1, Rc2, Rc3 and Rc4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONR1-C0-6 alkyl, -C0-6 alkyl-SO2-C0-6 alkyl, -C0-6 alkyl-S (O) 2NR1R2, -C0-6 alkyl-NR1R2, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl; each of Rc1, Rc2, Rc3 and Rc4 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated carbocyclyl, or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, and C1-6 alkoxy; and
[0136] each of n1, n2, n3, n4, n5, n6, n7, n8, n9 and n10 is independently selected from the group consisting of 0, 1, and 2.
[0137] Another aspect of the present disclosure relates to a compound of Formula VIII, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a deuterated compound thereof,
[0138] wherein,
[0139] X1 is selected from the group consisting of N and CH;
[0140] ring A is a ring selected from the group consisting of aryl, and 5-10 membered monocyclic, bicyclic, or tricyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0141] ring C is a ring selected from the group consisting of aryl, 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0142] ring B is a ring selected from the group consisting of aryl, 4-7 membered saturated or partially unsaturated carbocyclyl, 4-7 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-10 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-15 membered saturated or partially unsaturated tricyclic heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 8-15 membered tricyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0143] L1 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from the group consisting of aryl, 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl, 6-16 membered saturated or partially unsaturated spiro carbocyclyl, 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl, 4-10 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 6-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-14 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0144] L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (O) NH-, -C (S) -, -CHF-, -CF2-, -NR1-, -O-, -S-, or -S (O) 2;
[0145] L4 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, -C0-6 alkyl-CO-, -C0-6 alkyl-CONR1-, -C0-6 alkyl-SO2-, -C0-6 alkyl-S (O) 2NR1-, or -C0-6 alkyl-NR1-;
[0146] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;
[0147] each of Ra1, Ra2 and Ra3 is independently selected from the group consisting of CN, hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0148] wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;
[0149] Ra1, Ra2, Ra3, R3 and R4 are optionally substituted by one or more R5;
[0150] R5 is selected from the group consisting of oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0151] R5 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR3R4;
[0152] each of Rb1, Rb2 and Rb3 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0153] each of Rc1 and Rc2 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NHR3C (O) -C1-6 alkyl, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONHR1, -C0-6 alkyl-SO2-C1-6 alkyl, -C0-6 alkyl-S (O) 2NR1-C1-6 alkyl, -C0-6 alkyl-NR1R2, -CO-C1-6 alkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl; and
[0154] each of Rc1 and Rc2 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl, or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, and C1-6 alkoxy;
[0155] each of L1, L2, and L4 is optionally substituted by one or more more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, and C1-6 alkoxy;
[0156] ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0157] ring D is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl; and
[0158] Cy1 is a ring selected from the group consisting of 12-16 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered saturated or partially unsaturated monocyclic heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 12-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,
[0159] In some embodiments, the compound according to Formula VIII, wherein L1 is phenyl or 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, L1 is optionally substituted by one or more more substituents independently selected from the group consisting of CN, halogen, oxo, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, C1-6 alkoxy and C1-6 haloalkoxy.
[0160] In some embodiments, the compound according to Formula VIII, wherein Cy1 is a ring selected from the group consisting of
[0161] In some embodiments, the compound according to Formula I, wherein the compound has a structure of Formula XIV,
[0162] X1 is selected from the group consisting of N and CH;
[0163] each of X6, X7, X8, X9, and X10 is independently selected from the group consisting of N and CRx;
[0164] Z1 is selected from the group consisting of NRp, O, S, C (O) , S (O) , S (O) 2 and CRxRy;
[0165] Z2 is absent or selected from the group consisting of NRp, O, S, C (O) , SO, S (O) 2 and CRxRy;
[0166] Z3 is absent or selected from the group consisting of NRp, O, S, C (O) , SO, S (O) 2 and CRxRy;
[0167] each of Rp, Rx and Ry is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalkyl;
[0168] ring A is a ring selected from the group consisting of C6-10 aryl, and 5-10 membered monocyclic, bicyclic, or tricyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0169] ring C is a ring selected from the group consisting of C6-10 aryl; 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0170] ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0171] ring G is a ring selected from the group consisting of C6-10 aryl, 5-10 membered heteroaryl and 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl; wherein ring G is optionally substituted by one or more substituents independently selected from the group consisting of CN, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C3-8 cycloalkyl and C1-6 haloalkoxy;
[0172] L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (O) NH-, -C (S) -, -CHF-. -CF2-, -NR1-, -O-, -S-, or -S (O) 2;
[0173] L4 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, -C0-6 alkyl-CO-, -C0-6 alkyl-CONR1-, -C0-6 alkyl-SO2-, -C0-6 alkyl-S (O) 2NR1-, or -C0-6 alkyl-NR1-;
[0174] each of Ra1, Ra2 and Ra3 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, -C1-6 alky-CO-, -S (O) 2NR3R4, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0175] wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;
[0176] Ra1, Ra2, Ra3, R3 and R4 are optionally substituted by one or more R5;
[0177] R5 is selected from the group consisting of oxo, halogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0178] R5 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR3R4-;
[0179] each of Rc1 and Rc2 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, C1-6 alkyl-CO-, -S (O) 2NR3R4, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C0-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic, carbocyclyl or heterocyclyl;
[0180] each of Rc1 and Rc2 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl, or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, and C1-6 alkoxy.
[0181] In some embodiments, the compound according to Formula XIV, wherein ring G is a ring selected from the group consisting of C6-10 aryl and 5-6 membered heteroaryl, wherein C6-10 aryl and 5-6 membered heteroaryl are optionally substituted by one or more substituents independently selected from the group consisting of CN, C3-8 cycloalkyl, halogen, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 haloalkoxy.
[0182] In some embodiments, the compound according to Formula I, Formula VIII, and Formula XIV, wherein ring A is 5-10 membered bicyclic heteroaryl with 1-4 nitrogen atoms.
[0183] In some embodiments, the compound according to Formula I, Formula VIII, and Formula XIV, wherein ring A is a ring selected from the group consisting of
[0184] wherein each of X2, X3, X4 and X5 is independently selected from the group consisting of N and CH.
[0185] In some embodiments, the compound according to Formula I, Formula VIII, and Formula XIV, wherein ring A is a ring selected from the group consisting of
[0186] wherein each of X2, and X4 is independently selected from the group consisting of
[0187] N and CH.
[0188] In some embodiments, the compound according to Formula I, Formula VIII, and Formula XIV, wherein Ra1 and Ra2 are independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0189] Ra3 is -C (O) NR3R4, and
[0190] R3 and R4 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl.
[0191] In some embodiments, the compound according to Formula I, and Formula VIII, wherein ring B is a ring selected from the group consisting of aryl and 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0192] In some embodiments, the compound according to Formula I, Formula VIII, and Formula XIV, wherein ring C is a ring selected from the group consisting of 5-6 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0193] or ring C is a ring selected from the group consisting of
[0194] wherein is a single bond or a double bond.
[0195] In some embodiments, the compound according to Formula VIII, and Formula XIV, wherein ring D is 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
[0196] In some embodiments, the compound according to Formula I, Formula VIII, and Formula XIV, wherein L2 is selected from the group consisting of a covalent bond, -C (O) NH-and -NH-.
[0197] In some embodiments, the compound according to Formula VIII, and Formula XIV, wherein L4 is -C0-6 alkyl-CO-.
[0198] In some embodiments, the compound according to Formula I, wherein the compound has a structure of Formula IX,
[0199] wherein,
[0200] is a single bond or a double bond;
[0201] X1 is selected from the group consisting of N and CH;
[0202] ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0203] ring D is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0204] Cy1 is a ring selected from the group consisting of 8-14 membered saturated or partially unsaturated monocyclic heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 12-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,
[0205] Cy1 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, and C1-6 alkyl;
[0206] Cy2 is a ring selected from the group consisting of C6-10 aryl, 5-10 membered heteroaryl, 8-14 membered saturated or partially unsaturated carbocyclyl, and 8-14 membered saturated or partially unsaturated heterocyclyl;
[0207] Cy2 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalky;
[0208] each of Ra1, Rb1, Rb2, Rb3 and Rb4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and CN;
[0209] each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;
[0210] or R3 and R4 together with N atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic heterocyclyl; and
[0211] R6 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl.
[0212] In some embodiments, the compound according to Formula IX, wherein the compound has a structure of Formula IX-1 or Formula IX-2,
[0213] Wherein ring D, Ra1, Rb1, Rb2, Rb3, Rb4, R3, R4, R6, Cy1, and Cy2 are as defined in Formula IX.
[0214] In some embodiments, the compound according to Formula I, wherein the compound has a structure of Formula X,
[0215] wherein,
[0216] is a single bond or a double bond;
[0217] X1 is selected from the group consisting of N and CH;
[0218] ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0219] ring D is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0220] Cy1 is a ring selected from the group consisting of 8-14 membered saturated or partially unsaturated monocyclic heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 12-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,
[0221] Cy1 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, and C1-6 alkyl;
[0222] Cy2 is a ring selected from the group consisting of C6-10 aryl, 5-10 membered heteroaryl, 8-14 membered saturated or partially unsaturated carbocyclyl and 8-14 membered saturated or partially unsaturated heterocyclyl;
[0223] Cy2 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalky;
[0224] each of Ra1, Rb1, Rb2, Rb3 and Rb4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and CN;
[0225] each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl;
[0226] or R3 and R4 together with N atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic heterocyclyl; and
[0227] R6 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl.
[0228] In some embodiments, the compound according to Formula IX, Formula IX-1, Fomula IX-2, and Formula X, wherein Cy2 is selected from the group consisting of phenyl and 5-6 membered heteroaryl, wherein phenyl or 5-6 membered heteroaryl is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, CN, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, and C3-6 cycloalky.
[0229] In some embodiments, the compound according to Formula IX, Formula IX-1, Fomula IX-2 and Formula X, wherein Cy2 is selected from the group consisting of phenyl and pyridyl, wherein phenyl or pyridyl is optionally substituted by one or more substituents independently selected from the group consisting of F, Cl, -CH3, -CF3, -O-CH3, -O-CHF2, -O-CF3, cyclopropyl, and -CN.
[0230] In some embodiments, the compound according to Formula I, wherein the compound has a structure of Formula XIII (a) or XIII (b) ,
[0231] wherein,
[0232] is a single bond or a double bond;
[0233] ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0234] ring D is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0235] Cy1 is a ring selected from the group consisting of 8-14 membered saturated or partially unsaturated monocyclic heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 12-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,
[0236] Cy1 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, and C1-6 alkyl;
[0237] ring E and ring F are each independently selected from the group consisting of aryl and 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0238] each of ring E and ring F is optionally substituted by one or more substituents independently selected from the group consisting of oxo, CN, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, and C3-8 cycloalky;
[0239] each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl;
[0240] or R3 and R4 together with N atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic heterocyclyl;
[0241] Ra1 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and CN; and
[0242] R6 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl.
[0243] In some embodiments, the compound according to Formula IX, Formula IX-1, Fomula IX-2, Fomula X, Fomula XIII (a) , and Fomula XIII (b) , wherein ring D is 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, wherein 5-6 membered heteroaryl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl.
[0244] In some embodiments, the compound according to Formula IX, Formula IX-1, Fomula IX-2, Fomula X, Fomula XIII (a) , and Fomula XIII (b) , wherein ring D is selected from the group consisting of
[0245] ring D is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl.
[0246] In some embodiments, the compound according to Formula IX, Formula IX-1, Fomula IX-2, Fomula X, Fomula XIII (a) , and Fomula XIII (b) , wherein Cy1 is 12-16 membered saturated tricyclic spiro heterocyclyl with 1-5 nitrogen atoms.
[0247] In some embodiments, the compound according to Formula IX, Formula IX-1, Fomula IX-2, Fomula X, Fomula XIII (a) , and Fomula XIII (b) , wherein Cy1 is
[0248] wherein m1, m2, m3, m4, m5 and m6 are each independently selected from integers of 1 to 2; and the sum of m1, m2, m3, m4, m5 and m6 is an integer from 8 to 12.
[0249] In some embodiments, the compound according to Formula IX, Formula IX-1, Fomula IX-2, Fomula X, Fomula XIII (a) , and Fomula XIII (b) , wherein Cy1 is selected from the group consisting of
[0250] In some embodiments, the compound according to Fomula XIII (a) , and Fomula XIII (b) , wherein ring E and ring F are each independently selected from the group consisting of phenyl and 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and
[0251] each of ring E and ring F is optionally substituted by one or more substituents independently selected from the group consisting of oxo, CN, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalky.
[0252] In some embodiments, the compound according to Fomula XIII (a) , and Fomula XIII (b) , wherein ring E and ring F are each independently selected from the group consisting of phenyl and pyridyl, wherein phenyl and pyridyl are optionally substituted by one or more substituents independently selected from the group consisting of F, -CH3, -CF3, -O-CH3, -O-CHF2, -O-CF3, cyclopropyl, and -CN.
[0253] In some embodiments, the compound according to Formula I, wherein the compound has a structure of Formula XV,
[0254] wherein,
[0255] is a single bond or a double bond;
[0256] each of Z4, Z5, Z6, Z7, Z8 is independently selected from the group consisting of N and CRz;
[0257] Rz is independently selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalkyl;
[0258] each of R3 and R4 is independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, C3-8 halocycloalkyl and 3-10 membered heterocycloalkyl;
[0259] Ra1 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalkyl;
[0260] L2 is absent, -C (O) NH-, or NH;
[0261] X1 is selected from the group consisting of N and CH;
[0262] each of X6, X7, X8, X9, and X10 is independently selected from the group consisting of N and CRx;
[0263] Z1 is selected from the group consisting of NRp, O, S, C (O) , S (O) , S (O) 2 and CRxRy;
[0264] Z2 is absent or selected from the group consisting of NRp, O, S, C (O) , SO, S (O) 2 and CRxRy;
[0265] Z3 is absent or selected from the group consisting of NRp, O, S, C (O) , SO, S (O) 2 and CRxRy; and
[0266] each of Rp, Rx and Ry is independently selected from the group consisting of hydrogen, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalkyl.
[0267] In some embodiments, the compound according to Formula XV, wherein each of X1, X6 and X7 is independently selected from the group consisting of N and CH.
[0268] In some embodiments, the compound according to Formula XV, wherein each of X8, X9 and X10 is independently selected from the group consisting of N and CRx, and Rx is independently selected from the group consisting of CN, hydrogen, halogen, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, and C3-6 cycloalkyl.
[0269] In some embodiments, the compound according to Formula XV, wherein Z1 is CH2; Z2 is selected from the group consisting of NH, O, and S; and Z3 is absent. In some embodiments, each of R3 and R4 is independently selected from the group consisting of methyl, ethyl and cyclopropyl.
[0270] In some embodiments, the compound has a structure of Formula II,
[0271] wherein:
[0272] X1 is N or CH;
[0273] each of X2, X3, X4, X5, X6, X7, and X8 is independently selected from the group consisting of –C (Rx) =, –C (Rx) -, -N=, -S-, and -O-;
[0274] wherein Rx is selected from the group consisting of H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and C1-6 haloalkyl;
[0275] ring B is a ring selected from the group consisting of aryl, naphthalenyl, 4-7 membered saturated or partially unsaturated carbocyclyl, 4-7 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-10 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-15 membered saturated or partially unsaturated tricyclic heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0276] L1 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1R2-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1R2-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1R2-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from the group consisting of aryl; 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl; 6-16 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl; 4-10 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 6-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-14 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0277] L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (S) -, -CH2-. -CF2-, -NR1R2-, -O-, -S-, or -S (O) 2;
[0278] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, and C1-6 haloalkyl;
[0279] Ra1 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0280] wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl;
[0281] or Ra1, R3 and R4 are optionally substituted by one or more R5;
[0282] R5 is selected from the group consisting of H, oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0283] R5 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, and -C (O) NR9R10;
[0284] each of Rb1, Rb2 and Rb3 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0285] each of R6, R7, R8, R9 and R10 is independently selected from the group consisting of hydrogen, oxo, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONHR1, -C0-6 alkyl-SO2-C1-6 alkyl, -C0-6 alkyl-S (O) 2NHR1, -C0-6 alkyl-NR1R2, -CO-C1-6 alkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0286] or each of R6, R7 and R8 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, and C1-6 alkoxy;
[0287] or R6 and R7 together with carbon atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0288] or R7 and R8 together with carbon atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl; and
[0289] each of n7, n8 and n9 is independently selected from 0, 1, or 2.
[0290] In some embodiments, the compound has a structure of Formula III,
[0291] wherein:
[0292] ring C is a ring selected from the group consisting of aryl, 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur; and
[0293] ring A is a ring selected from the group consisting of C6-10 aryl and 5-to 10-membered heteroaryl;
[0294] ring B, L1, L2, X1, Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc1, Rc2, n1, n4, n5, n6, n7, n8, and n9 are as defined in Formula I.
[0295] In some embodiments, the compound has a structure of Formula IV,
[0296] wherein:
[0297] each of X2, X3, X4, X5, X6, X7, and X8 is independently selected from the group consisting of –C (Rx) =, –C (Rx) -, -N=, -S-, and -O-;
[0298] wherein Rx is selected from the group consisting of H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and C1-6 haloalkyl;
[0299] L1 is a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1R2-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1R2-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1R2-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from aryl; 8-10 membered bicyclic aryl; 3-7 membered saturated or partially unsaturated carbocyclyl, 6-11 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl; 4-7 membered saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 6-11 membered saturated or partially unsaturated spiro heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0300] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, and C1-6 haloalkyl;
[0301] Ra1 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0302] wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl;
[0303] or Ra1, R3 and R4 are optionally substituted by one or more R5;
[0304] R5 is selected from the group consisting of H, oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0305] R5 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR9R10;
[0306] each of R6, R7, R8, R9 and R10 is independently selected from the group consisting of hydrogen, oxo, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONHR1, -C0-6 alkyl-SO2-C1-6 alkyl, -C0-6 alkyl-S (O) 2NHR1, -C0-6 alkyl-NR1R2, -CO-C1-6 alkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0307] or each of R6, R7 and R8 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, and C1-6 alkoxy;
[0308] or R6 and R7 together with carbon atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0309] or R7 and R8 together with carbon atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl.
[0310] In some embodiments, the compound has a structure of Formula V,
[0311] wherein:
[0312] each of X2, X3, X4, X5, X6, X7, and X8 is independently selected from the group consisting of –C (Rx) =, –C (Rx) -, -N=, -S-, and -O-;
[0313] wherein Rx is selected from the group consisting of H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl and C1-6 haloalkyl;
[0314] L1 is a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1R2-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1R2-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1R2-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from aryl; 8-10 membered bicyclic aryl; 3-7 membered saturated or partially unsaturated carbocyclyl; 6-11 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl; 4-7 membered saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 6-11 membered saturated or partially unsaturated spiro heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-10 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0315] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;
[0316] Ra1 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0317] wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl;
[0318] or Ra1, R3 and R4 are optionally substituted by one or more R5;
[0319] R5 is selected from the group consisting of H, oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0320] R5 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR9R10;
[0321] each of R6, R7, R8, R9 and R10 is independently selected from the group consisting of hydrogen, oxo, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONHR1, -C0-6 alkyl-SO2-C1-6 alkyl, -C0-6 alkyl-S (O) 2NHR1, -C0-6 alkyl-NR1R2, -CO-C1-6 alkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0322] or each of R6, R7 and R8 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, and C1-6 alkoxy;
[0323] or R6 and R7 together with carbon atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0324] or R7 and R8 together with carbon atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl.
[0325] In some embodiments, the compound has a structure of Formula VI,
[0326] wherein:
[0327] X1 is N or CH;
[0328] ring A is a ring selected from the group consisting of aryl; 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered monocyclic, bicyclic, or tricyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0329] ring C is a ring selected from the group consisting of 9-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 9-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0330] ring B is a ring selected from the group consisting of aryl; 4-7 membered saturated or partially unsaturated carbocyclyl; 4-7 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-10 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-15 membered saturated or partially unsaturated tricyclic heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-15 membered tricyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0331] L1 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1R2-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1R2-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1R2-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from the group consisting of aryl; 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl; 6-16 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl; 4-10 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 6-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-14 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0332] L3 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, -C0-6 alkyl-CO-, -C0-6 alkyl-CONR1-, -C0-6 alkyl-SO2-, -C0-6 alkyl-S (O) 2NR1-, or -C0-6 alkyl-N R1 R2-;
[0333] L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (S) -, -CH2-. -CF2-, -NR1R2-, -O-, -S-, or -S (O) 2;
[0334] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;
[0335] each of Ra1, Ra2 and Ra3 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0336] wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;
[0337] or Ra1, Ra2, Ra3, R3 and R4 are optionally substituted by one or more R5;
[0338] R5 is selected from the group consisting of H, oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0339] R5 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR3R4;
[0340] each of Rb1, Rb2 and Rb3 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl;
[0341] each of Rc1, Rc2, Rc3 and Rc4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NHR3C (O) -C1-6 alkyl, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONHR1, -C0-6 alkyl-SO2-C1-6 alkyl, -C0-6 alkyl-S (O) 2NR1-C1-6 alkyl, -C0-6 alkyl-NR1R2, -CO-C1-6 alkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl; and
[0342] each of Rc1, Rc2 , Rc3 and Rc4 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl, or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, and C1-6 alkoxy.
[0343] In some embodiments, the compound has a structure of Formula VII,
[0344] wherein:
[0345] X1 is N or CH;
[0346] ring A is a ring selected from the group consisting of aryl, and 5-10 membered monocyclic, bicyclic, or tricyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0347] ring C is a ring selected from the group consisting of 9-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 9-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0348] ring B is a ring selected from the group consisting of aryl; 4-7 membered saturated or partially unsaturated carbocyclyl; 4-7 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-10 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-15 membered saturated or partially unsaturated tricyclic heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-15 membered tricyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0349] L1 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1R2-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1R2-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1R2-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from the group consisting of aryl; 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl; 6-16 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl; 4-10 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 6-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-14 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0350] L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (S) -, -CH2-. -CF2-, -NR1R2-, -O-, -S-, or -S (O) 2;
[0351] L4 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, -C0-6 alkyl-CO-, -C0-6 alkyl-CONR1-, -C0-6 alkyl-SO2-, -C0-6 alkyl-S (O) 2NR1-, or -C0-6 alkyl-N R1 R2-;
[0352] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;
[0353] each of Ra1, Ra2 and Ra3 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0354] wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;
[0355] or Ra1, Ra2, Ra3, R3 and R4 are optionally substituted by one or more R5;
[0356] R5 is selected from the group consisting of H, oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0357] R5 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR3R4;
[0358] each of Rb1, Rb2 and Rb3 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl;
[0359] each of Rc1, Rc2, Rc3 and Rc4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NHR3C (O) -C1-6 alkyl, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONHR1, -C0-6 alkyl-SO2-C1-6 alkyl, -C0-6 alkyl-S (O) 2NR1-C1-6 alkyl, -C0-6 alkyl-NR1R2, -CO-C1-6 alkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl; and
[0360] each of Rc1, and Rc2 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl, or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, and C1-6 alkoxy;
[0361] each of L1, L2, and L4 is optionally substituted by one or more halogen;
[0362] ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur; and
[0363] ring D is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, 4-10 membered heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 5-12 membered heteroaryl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0364] In some embodiments, the compound according to Formula II-VII, wherein Ra1 is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, -NHR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0365] each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl;
[0366] R3 and R4 are optionally substituted by one or more R5;
[0367] R5 is selected from the group consisting of H, oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;
[0368] R5 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, -C (O) NR9R10;
[0369] each of R9 and R10 is independently selected from the group consisting of hydrogen, oxo, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl; and
[0370] each of R9 and R10 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl.
[0371] In some embodiments, the compound according to Formula III, IV, or VII, ring A is 5-10 membered monocyclic, bicyclic, or tricyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
[0372] In some embodiments, the compound according to Formula III, IV, or VII, ring A is a ring selected from the group consisting of
[0373] wherein each of X2, X3, X4 and X5 is independently selected from the group consisting of N and CH.
[0374] In some embodiments, the compound according to Formula III, IV, or VII, ring A is a ring selected from the group consisting of
[0375] wherein each of X2, and X4 is independently selected from the group consisting of
[0376] N and CH.
[0377] In some embodiments, the compound according to Formula II, III, IV, or VII, ring B is a ring selected from the group consisting of C5-10 aryl, 5-10 membered heteroaryl,
[0378] wherein ring D is C5-10 aryl, or 5-10 membered heteroaryl.
[0379] In some embodiments, the compound according to Formula II, III, VI or VII, L2 is a covalent bond or -NR1R2-; wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl.
[0380] In some embodiments, the compound according to Formula III, VI or VII, ring C is a ring selected from the group consisting of 9-10 membered partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 9-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
[0381] In some embodiments, the compound according to Formula III, VI or VII, ring C is a ring selected from the group consisting of
[0382] wherein is a single bond or a double bond.
[0383] In some embodiments, the compound according to Formula VII, ring D is 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
[0384] In some embodiments, the compound has a structure of Formula XI,
[0385] wherein,
[0386] X1 is N or CH;
[0387] ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0388] ring D is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0389] Cy2 is a ring selected from the group consisting of 11-14 membered saturated or partially unsaturated carbocyclyl and 11-14 membered saturated or partially unsaturated heterocyclyl;
[0390] Cy2 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalky;
[0391] L3 is a covalent bond or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L3 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from aryl, 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl, 6-11 membered saturated or partially unsaturated spiro carbocyclyl, 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl, 4-7 membered saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 6-11 membered saturated or partially unsaturated spiro heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0392] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;
[0393] each of Ra1, Rb1, Rb2, Rb3 and Rb4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and CN;
[0394] each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl;
[0395] or R3 and R4 together with N atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, and spirocyclic heterocyclyl; and
[0396] R6 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl.
[0397] In some embodiments, the compound has a structure of Formula XII,
[0398] wherein,
[0399] ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0400] ring D is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;
[0401] Cy2 is a ring selected from the group consisting of 11-14 membered saturated or partially unsaturated carbocyclyl and 11-14 membered saturated or partially unsaturated heterocyclyl;
[0402] Cy2 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalky;
[0403] L3 is a covalent bond or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L3 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from aryl, 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl, 6-11 membered saturated or partially unsaturated spiro carbocyclyl, 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl, 4-7 membered saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 6-11 membered saturated or partially unsaturated spiro heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0404] wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;
[0405] each of Ra1, Rb1, Rb2, Rb3 and Rb4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and CN;
[0406] each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl;
[0407] or R3 and R4 together with N atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, and spirocyclic heterocyclyl; and
[0408] R6 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl.
[0409] In some embodiments, the compound has a structure of Formula XI or XII, Cy2 is selected from the group consisting of
[0410] In some embodiments, the compound, or stereoisomer, pharmaceutically acceptable salt, or deuterated compound thereof of Formula I, the compound is selected from the group consisting of
[0411] Pharmaceutical composition
[0412] Another aspect of the present disclosure provides a pharmaceutical composition that comprise the compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure, and a pharmaceutically acceptable excipient.
[0413] In some embodiments, the pharmaceutical composition comprising the compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure may be prepared with one or more pharmaceutically acceptable excipients, the excipients may be selected in accordance with conventional practice. Tablets may contain excipients, including flow aids, fillers, binders, and the like. Aqueous compositions may be prepared in a sterile form and may generally be isotonic when intended to be delivered by means other than oral administration.
[0414] In some embodiments, the compositions may comprise excipients, such as those set forth in Rowe et al, Handbook of Pharmaceutical Excipients, 6th edition, American Pharmacists Association, 2009. Excipients may include ascorbic acid and other antioxidants, chelating agents such as ethylenediaminetetraacetic acid, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid, and the like. In some embodiments, the compositions are provided in solid dosage forms, including solid oral dosage forms.
[0415] The pharmaceutical composition may be prepared by any of the methods well known in the art of pharmacy, including oral administration. Such methods include the step of bringing into association the active ingredient (e.g., a compound of the present disclosure or a pharmaceutical salt thereof) with one or more pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical compositions are prepared by unifor mly and intimately bringing into association the active ingredient with liquid excipients or finely divided solid excipients or both, and then, if desired, shaping the product. Techniques and formulations generally are found in Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Wiliams and Wilkins, Philadelphia, Pa., 2006.
[0416] In some embodiments, the pharmaceutical compositions of the present disclosure are presented in unit dosage form, including but not limited to capsules, sachets, or tablets, each containing a predetermined amount of the active ingredient. In one embodiment, the pharmaceutical composition is a tablet.
[0417] The pharmaceutical composition disclosed herein comprises one or more of the compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure, as well as pharmaceutically acceptable excipients and, optionally, other therapeutic agents. The pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration. When intended for oral use, for example, tablets, lozenges, ingots, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups, or elixirs may be prepared. Compositions for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more excipients, including sweeteners, flavoring agents, coloring agents, and preservatives, to provide palatable formulations. Tablets containing the active ingredient with a non-toxic pharmaceutically acceptable excipient are acceptable and said excipient is suitable for the production of tablets. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
[0418] The amount of active ingredients that may be combined with the inactive ingredients to produce a dosage form may vary depending upon the intended treatment subject and the mode of administration. For example, in some embodiments, a dosage form for oral administration to humans may contain approximately 1 to 1000 mg of active material formulated with an appropriate and convenient amount of a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient varies from about 5%to about 95%of the total compositions (weight: weight) .
[0419] In some embodiments, the pharmaceutical composition of the present disclosure does not contain an agent that affects the rate at which the active ingredient is metabolized. Thus, it is understood that pharmaceutical compositions comprising a compound of the present disclosure in one aspect do not comprise an agent that would affect (e.g., slow, hinder or retard) the metabolism of a compound of the present disclosure or any other active ingredient administered separately, sequentially or simultaneously with a compound of the present disclosure. It is also understood that any of the methods, kits, articles of manufacture, and the like detailed herein in one aspect do not comprise an agent that would affect (e.g., slow, hinder or retard) the metabolism of a compound of the present disclosure or any other active ingredient administered separately, sequentially or simultaneously with a compound of the present disclosure.
[0420] In some embodiments, the above-described pharmaceutical compositions are for use in humans or animals.
[0421] The present disclosure also includes compounds of the present disclosure which are administered as a single active ingredient of a pharmaceutically acceptable composition that may be prepared by conventional methods known in the art, for example, by combining the active ingredient to a pharmaceutically acceptable, therapeutically inert organic and / or inorganic carrier or excipient, or by mixing therewith.
[0422] The present disclosure provided herein are uses of the compounds of the present disclosure as a second or other active ingredient, said second or other active ingredient being synergistic with other active ingredients in known drugs, or the compounds of the present disclosure being administered with such drugs.
[0423] The compounds of the present disclosure may also be used in the form of a prodrug or other suitably modified form that releases the active ingredient in vivo.
[0424] Method of treatment
[0425] Another aspect of the present disclosure provides a method for treating an STAT6-mediated disease or condition is selected from the group consisting of cancer, a neurodegenerative disorder, a viral disease, an autoimmune disease, an inflammatory disorder, a hereditary disorder, a hormone-related disease, a metabolic disorder, conditions associated with organ transplantation, immunodeficiency disorders, a destructive or overgrowing bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, liver disease, pathologic immune conditions involving Τ cell activation, a cardiovascular disorder, or a CNS disorder.
[0426] In some embodiments, the STAT6-mediated disease or condition is selected from the group consisting of chronic obstructive pulmonary disease (COPD) , acute respiratory distress syndrome (ARDS) , atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, nasal polyps, chronic rhinosinusitis, eczema, urticarial, psoriasis, and alopecia.
[0427] The compound of the present disclosure (also referred to herein as the active ingredients) or the pharmaceutical composition of the present disclosure can be administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual) , transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intratumoral, intrathecal and epidural) , and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient. An advantage of certain compound disclosed herein is that they are orally bioavailable and can be dosed orally.
[0428] A compound of the present disclosure may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer. In one variation, the compound is administered on a daily or intermittent schedule for the duration of the individual’s life.
[0429] The dosage or dosing frequency of a compound of the present disclosure may be adjusted over the course of the treatment, based on the judgment of the administering physician.
[0430] The compound may be administered to an individual (e.g., a human) in an effective amount. In some embodiments, the compound is administered once daily.
[0431] The compound can be administered by any useful route and means, such as by oral or parenteral (e.g., intravenous) administration. Therapeutically effective amounts of the compound may include from about 0.00001 mg / kg body weight per day to about 10 mg / kg body weight per day, such as from about 0.0001 mg / kg body weight per day to about 10 mg / kg body weight per day, or such as from about 0.001 mg / kg body weight per day to about 1 mg / kg body weight per day, or such as from about 0. 01 mg / kg body weight per day to about 1 mg / kg body weight per day, or such as from about 0.05 mg / kg body weight per day to about 0.5 mg / kg body weight per day, or such as from about 0.3 mg to about 30 mg per day, or such as from about 30 mg to about 300 mg per day.
[0432] A compound of the present disclosure may be combined with one or more additional therapeutic agents in any dosage amount of the compound of the present disclosure (e.g., from 1 mg to 1000 mg of the compound) . Therapeutically effective amounts may include from about 1 mg per dose to about 1000 mg per dose, such as from about 50 mg per dose to about 500 mg per dose, or such as from about 100 mg per dose to about 400 mg per dose, or such as from about 150 mg per dose to about 350 mg per dose, or such as from about 200 mg per dose to about 300 mg per dose. Other therapeutically effective amounts of the compound of the present disclosure are about 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or about 500 mg per dose. Other therapeutically effective amounts of the compound of the present disclosure are about 100 mg per dose, or about 125, 150, 175, 200, 225, 250, 275, 300, 350, 400, 450, or about 500 mg per dose. A single dose can be administered hourly, daily, or weekly. For example, a single dose can be administered once every 1 hour, 2, 3, 4, 6, 8, 12, 16 or once every 24 hours. A single dose can also be administered once every 1 day, 2, 3, 4, 5, 6, or once every 7 days. A single dose can also be administered once every 1 week, 2, 3, or once every 4 weeks. In some embodiments, a single dose can be administered once every week. A single dose can also be administered once every month.
[0433] Kits that comprise the compound e, the stereoisomers, the pharmaceutically acceptable salts, or the deuterated compound thereof, are also included in the present disclosur
[0434] In some embodiments, a kit further includes a label and / or instructions for the use of the compounds in the treatment of the indications, such as the diseases or conditions described herein.
[0435] In some embodiments, the kit comprises a compound of the present disclosure, or pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.
[0436] EXAMPLES
[0437] Example 1. Synthesis
[0438] The compounds of the disclosure may be prepared using methods disclosed herein and routine modifications thereof which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein.
[0439] The synthesis of typical compounds of Formula I, or a pharmaceutically acceptable salt thereof, e.g., compounds with structures described by one or more of Formula I, or other formulas or compounds disclosed herein, may be accomplished as described in the following examples.
[0440] General Syntheses
[0441] Typical embodiments of compounds in accordance with the present disclosure may be synthesized using the general reaction schemes and / or examples described below. It will be apparent, given the description herein that the general schemes may be altered by substituting the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Starting materials are typically obtained from commercial sources or synthesized using published methods for synthesizing compounds that are embodiments of the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group, the identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. Group labels (e.g., R1, R2) used in the reaction schemes herein are for illustrative purposes only and unless otherwise specified, do not necessarily match by name or function the labels used elsewhere to describe compounds of Formula (I) , (II) , (III) , (IV) , (V) , (VI) , (VII) , (VIII) , (IX) , (X) , (XI) , (XII) , (XIII) , (XIV) , (XV) , or aspects or fragments thereof.
[0442] Synthetic Reaction Parameters
[0443] The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc. ) are given; other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
[0444] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein.
[0445] Furthermore, the compounds of the present disclosure may contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
[0446] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA) . Others may be prepared by procedures or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley and Sons, 1991) , Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplemental (Elsevier Science Publishers, 1989) organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991) , March's Advanced Organic Chemistry, (John Wiley, and Sons, 5thEdition, 2001) , and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989) .
[0447] The terms “solvent” , “inert organic solvent” , or “inert solvent” refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ( “THF” ) , N, N-dimethylformamide ( “DMF” ) , chloroform, methylene chloride (or dichloromethane) , diethyl ether, methanol, pyridine and the like) . Unless specified to the contrary, the solvents used in the reactions of the present disclosure are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
[0448] The term “q.s. ” means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%) .
[0449] Compounds as provided herein may be synthesized according to the general schemes provided below. In the Schemes below, it should be appreciated that each of the compounds shown therein may have protecting groups as required present at any step. Standard protecting groups are well within the prevue of one skilled in the art.
[0450] The synthesis of the present disclosure compounds employs extensive metal-coupling reactions. The general synthetic method is as follows:
[0451] General Procedure for Metal-Catalyzed Cross-Coupling:
[0452] Buchwald-Hartwig Cross Coupling Reaction:
[0453] General Procedure 1:
[0454] A solution of amine (1 equiv) , halide (1 equiv) , Pd2 (dba) 3 (0.1 equiv) , BINAP (0.2 equiv) or Xphos (0.2 equiv) and tBuONa (2-4 equiv) in dioxane (5 mL) under N2 was refluxed for 4-8 hours. After cooling, the reaction mixture was filtered, and the filtrate was collected and concentrated. The residue was purified by column chromatography to afford the compound.
[0455] General Procedure 2:
[0456] To a solution of amine (1.0 equiv) and halide (1.0 equiv) in DMF (5 mL) were added cesium carbonate (2.0–4.0 equiv) and Pd-PEPPSI-IPent catalyst (0.1 equiv) . The mixture was then stirred at 100 ℃ for 2–6 h. After cooling to room temperature, the reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography to afford the desired compound.
[0457] Suzuki Coupling Reaction:
[0458] General Procedure 3:
[0459] A solution of halide (1 equiv) , boronate ester (1.0-2.0 equiv) , potassium carbonate (3 equiv) and dichloro [1, 1-Bis (di-Tert-Butylphosphino) Ferrocene] Palladium (II) (0.1 eq) in a mixture solution of 1, 4-Dioxane / H2O (5-10 V, v / v=4: 1) was stirred at 100 ℃ for 2-4h under N2. After cooling, the reaction mixture was filtered, and the filtrate was collected and concentrated. The residue was purified by silica gel chromatography to afford the compound.
[0460] Resolution methods for chiral compounds
[0461] General Chiral SFC Method:
[0462] Racemic compound was dissolved in isopropanol at 30 mg / mL. Chiral preparative SFC was performed on a Chiralcel OD-H column (30 × 250 mm, 5 μm) eluting with CO2 / isopropanol (82: 18) at 120 mL / min, 135 bar backpressure, 38℃. The first-eluting enantiomer (peak 1) and second-eluting enantiomer (peak 2) were collected separately and concentrated in vacuo toafford the resolved enantiomers.
[0463] General Chiral Preparative HPLC Method:
[0464] Column: Daicel CHIRALPAK IH, 250*4.6 mm, 5μm; Mobile phase A: CAN; Mobile phase B: IPA; Wavelength (nm) : 254nm;
[0465] Gradient:
[0466] A. SYNTHESIS OF THE INTERMEDIATES
[0467] Intermediate I-1
[0468] To a solution of 1, 4-dibromo-2, 3-difluorobenzene (500 mg, 1.84 mmol) and tert-butyl piperazine-1-carboxylate (377 mg, 2.02 mmol) in toluene (10 mL) were added 2, 2'-bis (diphenylphosphino) -1, 1'-binaphthalene (68.7 mg, 0.11 mmol) , tris (dibenzylideneacetone) dipalladium (101 mg, 0.11 mmol) , and sodium tert-butoxide (212 mg, 2.21 mmol) . The mixture was stirred at 85 ℃ for 16 h. After cooling, the reaction mixture was concentrated and purified by silica gel chromatography (PE / EtOAc, 0–10%) to afford tert-butyl 4- (4-bromo-2, 3-difluorophenyl) piperazine-1-carboxylate (450 mg, 64.87%yield) . ES / MS: m / z 377.1 [M+H] +.
[0469] To a solution of tert-butyl 4- (4-bromo-2, 3-difluorophenyl) piperazine-1-carboxylate (450 mg, 1.19 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (2.30 g, 20.2 mmol) . The mixture was stirred at room temperature for 1 h. The reaction was diluted with ethyl acetate, quenched with aqueous NaHCO3, and extracted with EtOAc. The combined organic layers were dried, filtered, and concentrated to afford 1- (4-bromo-2, 3-difluorophenyl) piperazine (330 mg, 99.8%yield) . ES / MS: m / z 277.0 [M+H] +.
[0470] To a solution of 1- (4-bromo-2, 3-difluorophenyl) piperazine (300 mg, 1.08 mmol) in N, N-dimethylformamide (5 mL) was added 1, 2-difluoro-4-methoxy-5-nitrobenzene (200 mg, 1.08 mmol) and potassium carbonate (300 mg, 2.16 mmol) . The mixture was stirred at 80 ℃ for 16 h. Upon completion, the reaction mixture was quenched with water and filtered. The filter cake was washed with acetonitrile and dried to afford 1- (4-bromo-2, 3-difluorophenyl) -4- (2-fluoro-5-methoxy-4-nitrophenyl) piperazine (380 mg, 78.7%yield) . ES / MS: m / z 446.0 [M+H] +.
[0471] To a solution of 1- (4-bromo-2, 3-difluorophenyl) -4- (2-fluoro-5-methoxy-4-nitrophenyl) piperazine (600 mg, 1.34 mmol) in N, N-dimethylformamide (10 mL) was added hypodiboric acid (360 mg, 4.02 mmol) and 4, 4'-bipyridine (42 mg, 0.27 mmol) . The mixture was stirred at room temperature for 5 min. Water (10 mL) was added, and the reaction mixture was filtered. The filter cake was washed with water to afford 4- (4- (4-bromo-2, 3-difluorophenyl) piperazin-1-yl) -5-fluoro-2-methoxyaniline (530 mg, 94.7%yield) . ES / MS: m / z 416.1 [M+H] +.
[0472] To a solution of 4- (4- (4-bromo-2, 3-difluorophenyl) piperazin-1-yl) -5-fluoro-2-methoxyaniline (130 mg, 0.31 mmol) in N, N-dimethylformamide (2 mL) was added 3-bromopiperidine-2, 6-dione (89 mg, 0.46 mmol) and sodium hydrogencarbonate (78 mg, 0.93 mmol) . The mixture was stirred at 80 ℃ for 16 h. After cooling, the mixture was diluted with ethyl acetate and extracted. The combined organic layers were concentrated and purified by silica gel chromatography to afford 3- ( (4- (4- (4-bromo-2, 3-difluorophenyl) piperazin-1-yl) -5-fluoro-2-methoxyphenyl) amino) piperidine-2, 6-dione (57 mg, 34.6%yield) . ES / MS: m / z 527.1 [M+H] +.
[0473] Intermediate I-1a
[0474] Followed the preparation of Intermediate I-1, the Intermediate I-1a was obtained.
[0475] Intermediate I-2
[0476] To a solution of 1-bromo-4-iodobenzene (2.0 g, 7.07 mmol) in dioxane (20 mL) was added tert-butyl piperazine-1-carboxylate (1.32 g, 7.07 mmol) , cesium carbonate (3.46 g, 10.6 mmol) , Pd2 (dba) 3 (0.65 g, 0.71 mmol) , and XPhos (0.67 g, 1.41 mmol) . The mixture was stirred at 100 ℃ under nitrogen for 5 h. After cooling, the mixture was concentrated to give a crude product, which was purified by silica gel chromatography to afford tert-butyl 4- (4-bromophenyl) piperazine-1-carboxylate (1.8 g, 74.6%yield) . ES / MS: m / z 341.1 [M+H] +.
[0477] To a solution of hydrogen chloride in ethyl acetate (2.0 M) was added tert-butyl 4- (4-bromophenyl) piperazine-1-carboxylate (0.9 g, 2.64 mmol) . The mixture was stirred at room temperature for 2 h and filtered to afford 1- (4-bromophenyl) piperazine hydrochloride (0.7 g, 95.6%yield) . ES / MS: m / z 277.0 [M+H] +.
[0478] Intermediate I-3
[0479] A solution of 3- (5-bromo-3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-1-yl) piperidine-2, 6-dione (5 g, 14.79 mmol) , 2- (2-bromoethyl) -1, 3-dioxolane (2.68 g, 14.79 mmol) , [Ir (dtbbpy) (dF (CF3) ppy) 2] PF6 (337 mg, 0.30 mmol) , dichloro (4, 4'-di-tert-butyl-2, 2'-bipyridine) nickel (175 mg, 0.44 mmol) , tris (trimethylsilyl) silane (5.5 g, 22.2 mmol) , and 2, 6-lutidine (7.93 g, 74 mmol) in 1, 2-dimethoxyethane (100 mL) was stirred and irradiated with a 4 × 50 W (455 nm) blue LED lamp. Cooling water was used to maintain the reaction temperature at 25 ℃ for 18 h. The mixture was concentrated and purified by silica gel chromatography to afford 3- (5- (2- (1, 3-dioxolan-2-yl) ethyl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-1-yl) piperidine-2, 6-dione (1.3 g, 24.5%yield) . ES / MS: m / z 360.1 [M+H] +.
[0480] A solution of 3- (5- (2- (1, 3-dioxolan-2-yl) ethyl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-1-yl) piperidine-2, 6-dione (0.5 g, 1.39 mmol) in formic acid (5 mL) was stirred at 40 ℃ for 3 h. The mixture was concentrated to afford 3- (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-5-yl) propanal (450 mg) , which was used without further purification.
[0481] To a solution of 1- (4-bromophenyl) piperazine (386 mg, 1.39 mmol) in dichloromethane (5 mL) was added triethylamine (141 mg, 1.39 mmol) . The mixture was stirred at room temperature for 30 min. Then 3- (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-5-yl) propanal and sodium triacetoxyborohydride (594 mg, 2.8 mmol) were added. The mixture was stirred overnight at room temperature, then concentrated and purified by silica gel chromatography to afford 3- (5- (3- (4- (4-bromophenyl) piperazin-1-yl) propyl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-1-yl) piperidine-2, 6-dione (0.42 g, 55.9%yield) . ES / MS: m / z 540.2 [M+H] +.
[0482] Intermediate I-4
[0483] A solution of 4-bromoaniline (5.0 g, 29.1 mmol) , methyl hydrazinecarboxylate (2.9 g, 32.0 mmol) , 1, 1, 1-triethoxyethane (5.2 g, 32.0 mmol) , and p-toluenesulfonic acid (0.5 g, 2.91 mmol) in 1-butanol was refluxed overnight. The mixture was concentrated and purified by silica gel chromatography to afford 4- (4-bromophenyl) -2, 5-dimethyl-2, 4-dihydro-3H-1, 2, 4-triazol-3-one (1.4 g, 18.0%yield) . ES / MS: m / z 268.0 [M+H] +.
[0484] A solution of 4- (4-bromophenyl) -2, 5-dimethyl-2, 4-dihydro-3H-1, 2, 4-triazol-3-one (1.0 g, 3.73 mmol) , 4, 4, 4', 4', 5, 5, 5', 5'-octamethyl-2, 2'-bi (1, 3, 2-dioxaborolane) (0.99 g, 3.91 mmol) , [1, 1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) dichloromethane adduct (0.3 g, 0.37 mmol) , and potassium acetate (0.55 g, 5.6 mmol) in dioxane was stirred at 85 ℃ for 5 h. The mixture was concentrated and purified by silica gel chromatography to afford 2, 5-dimethyl-4- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl) -2, 4-dihydro-3H-1, 2, 4-triazol-3-one (0.82 g, 69.75%yield) . ES / MS: m / z 316.2 [M+H] +.
[0485] Intermediate I-5
[0486] A solution of methyl 4-chloro-1H-indole-7-carboxylate (6.0 g, 28.6 mmol) , di-tert-butyl dicarbonate (9.34 g, 42.8 mmol) , triethylamine (4.33 g, 42.8 mmol) , and DMAP (0.35 g, 2.86 mmol) in tetrahydrofuran was stirred at room temperature overnight. The mixture was concentrated and purified by silica gel chromatography to afford 1- (tert-butyl) 7-methyl 4-chloro-1H-indole-1, 7-dicarboxylate (7.6 g, 85.7%yield) . ES / MS: m / z 310.1 [M+H] +.
[0487] To a solution of 1- (tert-butyl) 7-methyl 4-chloro-1H-indole-1, 7-dicarboxylate (6.75 g, 21.8 mmol) in tetrahydrofuran (50 mL) was added LiHMDS (32.7 mL, 1.0 M in THF) at -78 ℃. The mixture was stirred for 1 h at -78 ℃. A solution of carbon tetrabromide (7.95 g, 23.9 mmol) in THF (30 mL) was added to the mixture at -78 ℃, and stirred for 3 h while warming gradually to room temperature. The reaction mixture was quenched with saturated aqueous ammonium chloride solution, followed by the addition of water and ethyl acetate. The organic phase was separated, dried, and concentrated. The residue was purified by silica gel chromatography to afford 1- (tert-butyl) 7-methyl 2-bromo-4-chloro-1H-indole-1, 7-dicarboxylate (2.7 g, 31.9%yield) . ES / MS: m / z 388.0 [M+H] +.
[0488] To a solution of 1- (tert-butyl) 7-methyl 2-bromo-4-chloro-1H-indole-1, 7-dicarboxylate (1.0 g, 2.57mmol) in DCM (15mL) was added TFA (10 mL) . The mixture was stirred for 4 hours at room temperature. The mixture was concentrated to afford methyl 2-bromo-4-chloro-1H-indole-7-carboxylate (0.7 g, 94.3%yield) . ES / MS: m / z 287.9 [M+H] +.
[0489] To a solution of methyl 2-bromo-4-chloro-1H-indole-7-carboxylate (228 mg, 0.79 mmol) and cesium carbonate (386 mg, 1.19 mmol) in N, N-dimethylformamide (5 mL) was added iodoethane (0.13 g, 0.83 mmol) at room temperature. The mixture was stirred at 80 ℃ for 4 h. After cooling, water (10 mL) was added dropwise, and the mixture was stirred for 1 h. The mixture was filtered, and the filter cake was washed with water (10 mL) and dried to afford methyl 2-bromo-4-chloro-1-ethyl-1H-indole-7-carboxylate (0.19 g, 85.6%yield) . ES / MS: m / z 316.0 [M+H] +.
[0490] A solution of methyl 2-bromo-4-chloro-1-ethyl-1H-indole-7-carboxylate (0.19 g, 0.6 mmol) , I-4 (0.19 g, 0.6 mmol) , cesium carbonate (0.29 g, 0.9 mmol) , and [1, 1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) dichloromethane adduct (0.048 g, 0.06 mmol) in a mixture of 1, 4-dioxane (3 mL) and water (1 mL) was stirred at 90 ℃ for 4 h. After cooling, the pH was adjusted to 5–7 with aqueous HCl. Ethyl acetate (5 mL) and water (5 mL) were added, and the mixture was extracted. The organic layer was separated, dried, and concentrated. The residue was purified by silica gel chromatography to afford 4-chloro-2- (4- (1, 3-dimethyl-5-oxo-1, 5-dihydro-4H-1, 2, 4-triazol-4-yl) phenyl) -1-ethyl-1H-indole-7-carboxylic acid (0.12 g, 48.7%yield) . ES / MS: m / z 411.1 [M+H] +.
[0491] Intermediate I-6
[0492] A solution of I-5 (60 mg, 0.146 mmol) , 3-amino-N-methylbenzamide (24.1 mg, 0.16 mmol) , HATU (72 mg, 0.19 mmol) , and DIPEA (24.5 mg, 0.19 mmol) in dichloromethane (2 mL) was stirred overnight at room temperature. The mixture was concentrated and purified by silica gel chromatography to afford 4-chloro-2- (4- (1, 3-dimethyl-5-oxo-1, 5-dihydro-4H-1, 2, 4-triazol-4-yl) phenyl) -1-ethyl-N- (3- (methylcarbamoyl) phenyl) -1H-indole-7-carboxamide (56 mg, 70.6%yield) . ES / MS: m / z 543.2 [M+H] +.
[0493] Intermediate I-7
[0494] A solution of 4-chloro-2- (4- (1, 3-dimethyl-5-oxo-1, 5-dihydro-4H-1, 2, 4-triazol-4-yl) phenyl) -1-ethyl-N- (3- (methylcarbamoyl) phenyl) -1H-indole-7-carboxamide (56 mg, 0.1 mmol) , 4, 4, 4', 4', 5, 5, 5', 5'-octamethyl-2, 2'-bi (1, 3, 2-dioxaborolane) (27.1 mg, 0.108 mmol) , potassium acetate (14.7 mg, 0.15 mmol) , and [1, 1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) dichloromethane adduct (8 mg, 0.01 mmol) in 1, 4-dioxane (2 mL) was stirred at 90 ℃ for 5 h. After cooling, the mixture was concentrated and purified by silica gel chromatography to afford 2- (4- (1, 3-dimethyl-5-oxo-1, 5-dihydro-4H-1, 2, 4-triazol-4-yl) phenyl) -1-ethyl-N- (3- (methylcarbamoyl) phenyl) -4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indole-7-carboxamide (50 mg, 76.4%yield) . ES / MS: m / z 635.3 [M+H] +.
[0495] Intermediate I-8: 3- (4- (4- (4-bromo-2, 3-difluorophenyl) piperazin-1-yl) -3-fluorophenyl) piperidine-2, 6-dione
[0496] A round-bottom flask was charged with ethyl 2- (4-bromo-3-fluorophenyl) acetate (5 g, 19.15 mmol) , tert-butyl piperazine-1-carboxylate (5.35 g, 28.72 mmol) , Pd2 (dba) 3 (0.88 g, 0.96 mmol) , XPhos (0.91 g, 1.92 mmol) , cesium carbonate (9.36 g, 28.72 mmol) , and 1, 4-dioxane (50 mL) . The reaction mixture was stirred at 100 ℃ overnight. The mixture was filtered through and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography eluting with petroleum ether / ethyl acetate to afford tert-butyl 4- (4- (2-ethoxy-2-oxoethyl) -2-fluorophenyl) piperazine-1-carboxylate (4.82 g, 68.69%yield) . ES / MS: m / z 367.2 [M+H] +.
[0497] To a solution of tert-butyl 4- (4- (2-ethoxy-2-oxoethyl) -2-fluorophenyl) piperazine-1-carboxylate (4.8 g, 13.10 mmol) in dichloromethane (30 mL) was added trifluoroacetic acid (7.67 g, 67.31 mmol) . The reaction mixture was stirred at room temperature overnight. The solvent was removed in vacuo. The residue was basified with saturated aqueous sodium bicarbonate (100 mL) and extracted with dichloromethane (30 mL × 3) . The combined organic layers were concentrated to afford ethyl 2- (3-fluoro-4- (piperazin-1-yl) phenyl) acetate (3.47 g, 99.47%yield) . ES / MS: m / z 267.2 [M+H] +.
[0498] A round-bottom flask was charged with ethyl 2- (3-fluoro-4- (piperazin-1-yl) phenyl) acetate (0.85 g, 3.19 mmol) , 1, 4-dibromo-2, 3-difluorobenzene (4.34 g, 15.95 mmol) , Pd2 (dba) 3 (0.18 g, 0.19 mmol) , BINAP (0.12 g, 0.19 mmol) , cesium carbonate (1.56 g, 4.79 mmol) , and toluene (30 mL) . The reaction mixture was stirred at 85 ℃under nitrogen for 20 h. The mixture was filtered through and the filtrate was concentrated in vacuo. The residue was purified by column chromatography eluting with petroleum ether / ethyl acetate to afford ethyl 2- (4- (4- (4-bromo-2, 3-difluorophenyl) piperazin-1-yl) -3-fluorophenyl) acetate (0.685 g, 46.93%yield) . ES / MS: m / z 457.1 [M+H] +.
[0499] To a solution of ethyl 2- (4- (4- (4-bromo-2, 3-difluorophenyl) piperazin-1-yl) -3-fluorophenyl) acetate (0.51 g, 1.12 mmol) and acrylamide (0.40 g, 5.60 mmol) in N, N-dimethylformamide (10 mL) was added potassium tert-butoxide (0.13 g, 1.12 mmol) at 0 ℃. The reaction mixture was stirred at 0 ℃ for 30 min. A precipitate formed upon addition of saturated aqueous ammonium chloride (50 mL) . The solid was collected by filtration and washed with petroleum ether / ethyl acetate (2: 1, 100 mL) to afford 3- (4- (4- (4-bromo-2, 3-difluorophenyl) piperazin-1-yl) -3-fluorophenyl) piperidine-2, 6-dione (0.33 g, 61.35%yield) . ES / MS: m / z 482.1 [M+H] +.
[0500] Intermediate I-9: 3- (4- (4- (1- (4-bromo-2, 3-difluorophenyl) piperidin-4-yl) piperazin-1-yl) -3-fluorophenyl) piperidine-2, 6-dione
[0501] To a solution of 1-bromo-2-fluoro-4-iodobenzene (1 g, 3.32 mmol) and 2, 6-bis (benzyloxy) -3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine (1.66 g, 3.99 mmol) in 1, 4-dioxane (20 mL) / water (5 mL) were added potassium carbonate (1.67 g, 12.05 mmol) and tetrakis (triphenylphosphine) palladium (0) (0.38 g, 0.33 mmol) . The mixture was stirred at 100 ℃ for 16 h. Upon completion, the reaction was quenched with water, extracted with ethyl acetate, and filtered. The filtrate was concentrated and purified by silica gel chromatography (petroleum ether / ethyl acetate, 0–10%) to afford 2, 6-bis (benzyloxy) -3- (4-bromo-3-fluorophenyl) pyridine (1.0 g, 64.8%yield) . ES / MS: m / z 464.1 [M+H] +.
[0502] To a solution of tert-butyl piperazine-1-carboxylate (2 g, 10.74 mmol) and benzyl 4-oxopiperidine-1-carboxylate (7.52 g, 32.22 mmol) in 1, 2-dichloroethane (30 mL) was added acetic acid (1.61 g, 26.85 mmol) . The mixture was stirred at 40 ℃ for 0.5 h. Then sodium triacetoxyborohydride (9.10 g, 42.96 mmol) was added, and the mixture was stirred at 40 ℃ for 16 h. Upon completion, the reaction was quenched with saturated aqueous sodium bicarbonate, extracted with dichloromethane, and filtered. The filtrate was concentrated, diluted with dichloromethane (10 mL) , and treated with trifluoroacetic acid (3 mL) . The mixture was stirred at room temperature for 4 h, concentrated, and purified by silica gel chromatography (dichloromethane / ethyl acetate 5: 1, 0.1%triethylamine) to afford benzyl 4- (piperazin-1-yl) piperidine-1-carboxylate trifluoroacetate (0.7 g, 27%yield) .
[0503] To a solution of 2, 6-bis (benzyloxy) -3- (4-bromo-3-fluorophenyl) pyridine (1.0 g, 2.15 mmol) and benzyl 4- (piperazin-1-yl) piperidine-1-carboxylate trifluoroacetate (652 mg, 2.15 mmol) in 1, 4-dioxane (20 mL) were added XPhos G3 (182 mg, 0.21 mmol) and sodium tert-butoxide (826 mg, 8.6 mmol) . The mixture was stirred at 90 ℃for 12 h. Upon completion (monitored by TLC, dichloromethane / methanol 10: 1) , the reaction mixture was concentrated and purified by silica gel chromatography (dichloromethane / methanol, 0–5%) to afford benzyl 4- (4- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -2-fluorophenyl) piperazin-1-yl) piperidine-1-carboxylate (500 mg, 33.8%yield) . ES / MS: m / z 687.3 [M+H] +.
[0504] To a solution of benzyl 4- (4- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -2-fluorophenyl) piperazin-1-yl) piperidine-1-carboxylate (500 mg, 0.73 mmol) in 2, 2, 2-trifluoroethanol (10 mL) was added palladium on carbon (150 mg) , and the mixture was stirred under a hydrogen atmosphere at room temperature for 16 h. Upon completion (monitored by LCMS) , the reaction mixture was filtered and washed with N, N-dimethylformamide. The filtrate was concentrated to afford 3- (3-fluoro-4- (4- (piperidin-4-yl) piperazin-1-yl) phenyl) piperidine-2, 6-dione (80 mg, 29.35%yield) . ES / MS: m / z 375.2 [M+H] +.
[0505] A round-bottom flask was charged with 1, 4-dibromo-2, 3-difluorobenzene (100 mg, 0.37 mmol) , 3- (3-fluoro-4- (4- (piperidin-4-yl) piperazin-1-yl) phenyl) piperidine-2, 6-dione (70 mg, 0.19 mmol) , 2, 2'-bis (diphenylphosphino) -1, 1'-binaphthalene (46 mg, 0.074 mmol) , tris (dibenzylideneacetone) dipalladium (68 mg, 0.074 mmol) , and cesium carbonate (241 mg, 0.74 mmol) in toluene (5 mL) . The mixture was degassed by nitrogen for 5 min and then stirred at 90 ℃ for 16 h. The mixture was concentrated and purified by preparative HPLC to afford 3- (4- (4- (1- (4-bromo-2, 3-difluorophenyl) piperidin-4-yl) piperazin-1-yl) -3-fluorophenyl) piperidine-2, 6-dione (30 mg, 28.38%yield) . ES / MS: m / z 565.1 [M+H] +.
[0506] Intermediate I-10: 6- (2- (2- (1H-pyrazol-1-yl) ethyl) -1H-benzo [d] imidazol-6-yl) -7-fluoro-N, N-dimethyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indole-2-carboxamide
[0507] To a solution of 4-bromo-2-nitroaniline (5 g, 23.04 mmol) and 4-dimethylaminopyridine (0.56 g, 4.61 mmol) in tetrahydrofuran (50 mL) was added dropwise triethylamine (6.99 g, 69.12 mmol) and di-tert-butyl dicarbonate (7.55 g, 34.56 mmol) at room temperature under nitrogen. The reaction mixture was then stirred at 60 ℃ for 16 h. The mixture was partitioned between ethyl acetate (200 mL) and water (50 mL) . The organic layer was washed with 10%citric acid, dried over sodium sulfate, and evaporated to dryness. The crude product was purified by silica gel chromatography eluting with petroleum ether / ethyl acetate (0–30%) to afford tert-butyl N- (4-bromo-2-nitrophenyl) carbamate (4.3 g, 58.85%yield) . ES / MS: m / z 317.0 [M+H] +.
[0508] To a solution of tert-butyl N- (4-bromo-2-nitrophenyl) carbamate (2 g, 6.31 mmol) and 4, 4'-bipyridine (0.099 g, 0.63 mmol) in N, N-dimethylformamide (15 mL) was added dropwise tetrahydroxydiboron (1.70g, 18.93mmol) at 0 ℃ under nitrogen. The reaction mixture was then stirred at room temperature for 30 min. The mixture was partitioned between ethyl acetate (100 mL) and water (50 mL) . The organic layer was washed with water three times, dried over sodium sulfate, and evaporated to dryness. tert-Butyl N- (2-amino-4-bromophenyl) carbamate (1.8 g) was obtained and used without further purification.
[0509] To a solution of tert-butyl N- (2-amino-4-bromophenyl) carbamate (1.7 g, 5.92 mmol) and 3- (1H-pyrazol-1-yl) propanoic acid (996 mg, 7.10 mmol) in N, N-dimethylformamide (20 mL) was added dropwise 2- (7-aza-1H-benzotriazol-1-yl) -1, 1, 3, 3-tetramethyluronium hexafluorophosphate (3.38 g, 8.88 mmol) and N, N-diisopropylethylamine (2.2 g, 17.0 mmol) at 10 ℃ under nitrogen. The reaction mixture was then stirred at room temperature for 2 h. The mixture was partitioned between ethyl acetate (200 mL) and saturated aqueous sodium bicarbonate (50 mL) . The organic layer was washed with water three times, dried over sodium sulfate, and evaporated to dryness. The crude product was purified by silica gel chromatography eluting with petroleum ether / ethyl acetate (0–60%) to afford tert-butyl (2- (3- (1H-pyrazol-1-yl) propanamido) -4-bromophenyl) carbamate (2.4 g, 99%yield) . ES / MS: m / z 409.1 [M+H] +.
[0510] To a solution of tert-butyl N- (4-bromo-2- (3- (1H-pyrazol-1-yl) propanamido) phenyl) carbamate (2.0 g, 4.89 mmol) in dimethyl sulfoxide (20 mL) was added dropwise acetic acid and sulfuric acid at room temperature under nitrogen. The reaction mixture was then stirred at 70 ℃ for 16 h. Ammonium hydroxide was added to adjust the pH to 7–8. The mixture was extracted with ethyl acetate (200 mL ×2) . The organic layer was dried over sodium sulfate and evaporated to dryness. The crude product was purified by silica gel chromatography eluting with dichloromethane / methanol (0–8%) to afford 2- (2- (1H-pyrazol-1-yl) ethyl) -6-bromo-1H-benzo [d] imidazole (1.1 g, 77.3%yield) .
[0511] To a solution of 2- (2- (1H-pyrazol-1-yl) ethyl) -6-bromo-1H-benzo [d] imidazole (1.15 g, 3.95 mmol) and bis (pinacolato) diboron (2.01 g, 7.9 mmol) in 1, 4-dioxane (20 mL) was added [1, 1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) (289 mg, 0.40 mmol) and potassium acetate at room temperature under nitrogen. The reaction mixture was then stirred at 100 ℃ for 4 h. After removal of the solvent, the crude product was purified by silica gel chromatography eluting with dichloromethane / methanol (0–8%) to afford 2- (2- (1H-pyrazol-1-yl) ethyl) -6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-benzo [d] imidazole (1.2 g, 89.8%yield) . ES / MS: m / z 339.2 [M+H] +.
[0512] To a solution of 6-bromo-4-chloro-7-fluoro-N, N-dimethyl-1H-indole-2-carboxamide (108 mg, 0.34 mmol) and 2- (2- (1H-pyrazol-1-yl) ethyl) -6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-benzo [d] imidazole (172 mg, 0.51 mmol) in 1, 4-dioxane (5.0 mL) and water was added [1, 1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) dichloromethane adduct (28 mg, 0.034 mmol) and potassium carbonate at room temperature under nitrogen. The reaction mixture was then stirred at 80 ℃ for 4 h. After removal of the solvent, the crude product was purified by silica gel chromatography eluting with dichloromethane / methanol (0–8%) to afford 6- (2- (2- (1H-pyrazol-1-yl) ethyl) -1H-benzo [d] imidazol-6-yl) -4-chloro-7-fluoro-N, N-dimethyl-1H-indole-2-carboxamide (100 mg, 65.6%yield) . ES / MS: m / z 451.1 [M+H] +.
[0513] To a solution of 4-chloro-7-fluoro-N, N-dimethyl-6- (2- (2- (1H-pyrazol-1-yl) ethyl) -1H-benzo [d] imidazol-6-yl) -1H-indole-2-carboxamide (100 mg, 0.22 mmol) and bis (pinacolato) diboron (140 mg, 0.55 mmol, 100%purity) in 1, 4-dioxane (5.0 mL) was added XPhos G3 (19 mg, 0.022 mmol) and potassium acetate at room temperature under nitrogen. The reaction mixture was then stirred at 100 ℃ for 4 h. After removal of the solvent, the crude product was purified by silica gel chromatography eluting with dichloromethane / methanol (0–8%) to afford 7-fluoro-N, N-dimethyl-6- (2- (2- (1H-pyrazol-1-yl) ethyl) -1H-benzo [d] imidazol-6-yl) -4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indole-2-carboxamide (I-10) (65 mg, 54.03%yield) . ES / MS: m / z 543.3 [M+H] +.
[0514] Intermediate I-11
[0515] A mixture of I-11a (25 g, 93 mmol) and methyl 2-cyanoacetate (23.2 g, 233.8 mmol) was cooled to -15 ℃. Ammonia methanol solution (75 mL, 7 M) was added dropwise to the mixture at -10 ℃. The mixture was then stirred overnight at 0 ℃. Water (100 mL) was added, and the mixture was adjusted to pH 1.2 with 50%aqueous sulfuric acid at 70 ℃, then stirred for 2 h. The mixture was filtered, and the solid was washed with water and dried to afford I-11b (26 g, 92.6%yield) . ES / MS: m / z 301.2 [M+H] +.
[0516] To a solution of I-11b (26 g, 65 mmol) in water (15 mL) was added sulfuric acid (98%, 45 mL) at 135 ℃, and the mixture was stirred for 0.5 h. The mixture was then stirred at 200 ℃ for 0.5 h. After cooling to room temperature, the mixture was stirred overnight. The solid was obtained by filtration and dried. The solid was dissolved in dichloromethane (30 mL) , and triethylamine (31.1 g, 310 mmol) and benzyl chloroformate (11.1 g, 65 mmol) were added at 0 ℃. The mixture was stirred overnight. After removal of the solvent, the crude product was purified by silica gel chromatography eluting with dichloromethane / methanol (0–20%) to afford I-11c (8.3 g, 23.76%yield) .
[0517] To a solution of I-11c (8.3 g, 20.6 mmol) in acetic anhydride (40 mL) was added ammonium acetate (3.2 g, 41.2 mmol) . The mixture was heated to 160 ℃ for 8 h. After cooling to room temperature, water (100 mL) and ethyl acetate (100 mL) were added. The mixture was extracted, and the organic layer was concentrated to afford I-11d (7.5 g, 94.83%yiled) .
[0518] To a solution of I-11d (7.5 g, 19.5 mmol) in tetrahydrofuran (50 mL) was added dropwise lithium aluminum hydride in tetrahydrofuran (2.5 M, 23.4 mL) at -10 ℃. The mixture was stirred for 4 h. The reaction was quenched with saturated aqueous ammonium chloride, and ethyl acetate (100 mL) was added. The mixture was extracted, and the organic layer was washed with water, then concentrated and purified by silica gel chromatography eluting with dichloromethane / methanol (0–10%) to afford benzyl 3, 12-diazadispiro [5.2.59.26] hexadecane-3-carboxylate (I-11) (2.3 g, 33.1%yield) . ES / MS: m / z 357.2 [M+H] +.
[0519] Intermediate I-12
[0520] To a solution of methyl 2-azaspiro [3.5] nonane-7-carboxylate hydrochloride (5 g, 22.8 mmol) and triethylamine (5.76 g, 57 mmol) in dichloromethane (25 mL) was added di-tert-butyl dicarbonate (5.97 g, 27.4 mmol) . The mixture was stirred for 4 h. Water (25 mL) was added, and the mixture was extracted. The organic layer was washed with brine and concentrated to afford I-12a (5.8 g, 89.94%yield) . ES / MS: m / z 284.2 [M+H] +.
[0521] To a solution of I-12a (5.8 g, 20.5 mmol) in tetrahydrofuran (20 mL) was added lithium diisopropylamide in tetrahydrofuran (25 mL, 1 M) at -78 ℃. A solution of methyl chloroformate (2.3 g, 24.6 mmol) in tetrahydrofuran (10 mL) was added dropwise to the mixture at -78 ℃. The mixture was stirred at -78 ℃ for 1 h, then quenched with water and extracted with ethyl acetate. The organic layer was concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate, 100: 1 to 10: 1) to afford I-12b (4.8 g, 68.69%yield) . ES / MS: m / z 342.2 [M+H] +.
[0522] To a solution of I-12b (4.8 g, 14.1 mmol) in ethanol (20 mL) was added sodium borohydride (1.88 g, 49.4 mmol) at room temperature. The mixture was stirred overnight, then quenched with water and extracted with ethyl acetate. The organic layer was concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate, 100: 1 to 10: 1) to afford I-12c (2.7 g, 67.29%yield) . ES / MS: m / z 286.2 [M+H] +.
[0523] To a solution of I-12c (2.7 g, 9.46 mmol) and triethylamine (2.87 g, 28.4 mmol) in dichloromethane (20 mL) was added dropwise a solution of methanesulfonic anhydride (4.13 g, 23.7 mmol) in dichloromethane (10 mL) at 0 ℃. The mixture was stirred for 3 h. Triethylamine (2.87 g, 28.4 mmol) was then added, and the mixture was stirred for 0.5 h. (2, 4-Dimethoxyphenyl) methanamine (1.58 g, 9.46 mmol) was added, and the mixture was heated to 70 ℃ and stirred overnight. The mixture was quenched with water and extracted with dichloromethane. The organic layer was concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate, 100: 1 to 10: 1) to afford I-12d (1.2 g, 30.45%yiled) . ES / MS: m / z 417.3 [M+H] +.
[0524] To a solution of I-12d (1.2 g, 2.88 mmol) in dichloromethane (12 mL) was added trifluoroacetic acid (12 mL) at 0 ℃. The mixture was stirred for 4 h. The mixture was quenched with water and adjusted to pH 7.0 with saturated aqueous sodium carbonate. The mixture was extracted with dichloromethane. The organic layer was concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate, 100: 1 to 5: 1) to afford 2- (2, 4-dimethoxybenzyl) -2, 9-diazadispiro [3.2.37.24] dodecane (I-12) (0.75 g, 82.27%yield) . ES / MS: m / z 317.2 [M+H] +.
[0525] Intermediate I-13, Intermediate I-14, Intermediate I-15
[0526] Following the preparation of Intermediate I-11, Intermediate I-13 was prepared from the tert-butyl 7-oxo-2-azaspiro [3.5] nonane-2-carboxylate; Intermediate I-14 was prepared from the tert-butyl 6-oxo-2-azaspiro [3.3] heptane-2-carboxylate; Intermediate I-15 was prepared from the tert-butyl 2-oxo-7-azaspiro [3.5] nonane-7-carboxylate;
[0527] Intermediate I-14A
[0528] To a solution of (methoxymethyl) triphenylphosphonium chloride (25.79 g, 75.22 mmol) in tetrahydrofuran (80 mL) was added potassium tert-butoxide (9.38 g, 83.58 mmol) , and the mixture was stirred at 0 ℃ for 20 min. Then tert-butyl 2-oxo-7-azaspiro [3.5] nonane-7-carboxylate (10 g, 41.79 mmol) in tetrahydrofuran (20 mL) was added, and the mixture was stirred at 25 ℃ for 2 h. Upon completion (monitored by TLC, petroleum ether / ethyl acetate 2: 1, and LCMS) , the reaction mixture was extracted with ethyl acetate (50 mL × 3) . The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate, 10–30%) to afford tert-butyl 2- (methoxymethylene) -7-azaspiro [3.5] nonane-7-carboxylate (10.2 g, 91.3%yield) . ES / MS: m / z 268.2 [M+H] +.
[0529] To a solution of tert-butyl 2- (methoxymethylene) -7-azaspiro [3.5] nonane-7-carboxylate (10.2 g, 38.52 mmol) in acetonitrile (60 mL) and water (20 mL) was added trifluoroacetic acid (6.59 g, 57.78 mmol) , and the mixture was stirred at 25 ℃ for 2 h under nitrogen. Upon completion (monitored by TLC, petroleum ether / ethyl acetate 2: 1) , the reaction was quenched with saturated aqueous sodium bicarbonate to pH ~8 and extracted with ethyl acetate (50 mL × 3) . The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo to afford tert-butyl 2-formyl-7-azaspiro [3.5] nonane-7-carboxylate (9.7 g, 99.39%yield) as a colorless oil, which was used directly in the next step. ES / MS: m / z 254.2 [M+H] +.
[0530] To a solution of tert-butyl 2-formyl-7-azaspiro [3.5] nonane-7-carboxylate (9.7 g, 38.31 mmol) in methanol (100 mL) was added formaldehyde (11.49 g, 383.1 mmol) and sodium hydroxide (0.23 g, 5.75 mmol) , and the mixture was stirred at 25 ℃ for 4 h under nitrogen. The reaction mixture was extracted with ethyl acetate (50 mL × 3) . The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate, 0–30%) to afford tert-butyl 2-formyl-2- (hydroxymethyl) -7-azaspiro [3.5] nonane-7-carboxylate (6.54 g, 60.3%yield) . ES / MS: m / z 284.2 [M+H] +.
[0531] To a solution of tert-butyl 2-formyl-2- (hydroxymethyl) -7-azaspiro [3.5] nonane-7-carboxylate (6.54 g, 23.1 mmol) in dichloromethane (65 mL) was added phenylmethanamine (2.72 g, 25.4 mmol) and acetic acid (3.47 g, 57.75 mmol) , and the mixture was stirred at 25 ℃ for 0.5 h. Sodium triacetoxyborohydride (19.58 g, 92.4 mmol) was then added, and the mixture was stirred at 25 ℃ for 4 h. The reaction mixture was extracted with ethyl acetate (50 mL × 3) . The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol, 0–10%) to afford tert-butyl 2- [ (benzylamino) methyl] -2- (hydroxymethyl) -7-azaspiro [3.5] nonane-7-carboxylate (7.08 g, 81.96%yield) . ES / MS: m / z 375.3 [M+H] +.
[0532] To a solution of tert-butyl 2- [ (benzylamino) methyl] -2- (hydroxymethyl) -7-azaspiro [3.5] nonane-7-carboxylate (7.08 g, 18.9 mmol) in dichloromethane (100 mL) was added triphenylphosphine (9.94 g, 37.8 mmol) and diethyl azodicarboxylate (4.08 g, 23.40 mmol, 100%purity) , and the mixture was stirred at 25 ℃ for 2 h. The reaction mixture was extracted with ethyl acetate (50 mL × 3) . The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol, 0–10%) to afford tert-butyl 2-benzyl-2, 9-diazadispiro [3.1.56.14] dodecane-9-carboxylate (4.99 g, 74.11%yield) . ES / MS: m / z 357.2 [M+H] +.
[0533] To a solution of tert-butyl 2-benzyl-2, 9-diazadispiro [3.1.56.14] dodecane-9-carboxylate (4.99 g, 14.0 mmol) in 1, 4-dioxane was added palladium on carbon (500 mg, 10 wt %) . The mixture was stirred at 50 ℃ under a hydrogen atmosphere for 4 h. After cooling, the reaction mixture was filtered, and the filtrate was concentrated and purified by silica gel column chromatography (dichloromethane / methanol, 0–10%) to afford tert-butyl 2, 9-diazadispiro [3.1.56.14] dodecane-9-carboxylate (I-14A) (3.5 g, 93.87%yield) . ES / MS: m / z 267.2 [M+H] +.
[0534] Intermediate I-14B
[0535] Following the preparation of Intermediate I-14A, Intermediate I-14B was prepared from tert-butyl 7-oxo-2-azaspiro [3.5] nonane-2-carboxylate. ES / MS: m / z 267.2 [M+H] +.
[0536] Intermediates: Linker-CRBNs
[0537] Wherein, Z1, Z2, Z3 is N or C (Rd) ; n1 is 1 or 2; n2 is 0 or 1; n3 is 1 or 2; Ra, Rb, Rc is F, Cl, OH, CN, methyl, ethyl, cyclopropyl, methoxy, haloalkyl, haloalkoxy.
[0538] These intermediates can be synthesized following General Preparation 1 or General Preparation 2.
[0539] General preparation 1:
[0540] The spiro-heterocycle is first coupled with the bromide in a Buchwald–Hartwig cross-coupling, then hydrogenated over Pd / C, and finally subjected to a second Buchwald–Hartwig reaction with the same bromide to furnish the target compound.
[0541] General preparation 2:
[0542] The Boc-protected spiro-heterocycle is first coupled with the bromide in a Buchwald–Hartwig cross-coupling, followed by treatment with trifluoroacetic acid to remove the Boc group and one benzyl group. The resulting intermediate is then subjected to a second coupling with an aryl or heteroaryl halide, and finally reduced with Pd / C to afford the target compound.
[0543] The syntheses of Intermediate I-18, and Intermediate I-23 are provided as specific working examples, corresponding to the detailed procedures of General Preparation 1 and General Preparation 2, respectively.
[0544] Intermediate I-18:
[0545] A solution of I-18a (300 mg, 1 mmol) , 2, 6-bis (benzyloxy) -3- (4-bromo-3-fluorophenyl) pyridine (463 mg, 1 mmol) , Pd2 (dba) 3 (91.5 mg, 0.1 mmol) , BINAP (122.4 mg, 0.2 mmol) , and sodium tert-butoxide (192 mg, 2 mmol) in 1, 4-dioxane (5 mL) was refluxed under nitrogen for 6 h. After cooling, the reaction mixture was filtered, and the filtrate was concentrated to afford an oil, which was purified by column chromatography to give I-18b (250 mg, 36.61%yield) . ES / MS: m / z 684.3 [M+H] +.
[0546] To a solution of I-18b (200 mg, 0.29 mmol) in 2, 2, 2-trifluoroethanol (5 mL) was added palladium on carbon (20 mg, 10 wt %) . The mixture was stirred at 50 ℃ under a hydrogen atmosphere for 4 h. After cooling, the reaction mixture was filtered, and the filtrate was concentrated to afford I-18c (85 mg, 78.24%yield) . ES / MS: m / z 372.2 [M+H] +.
[0547] A solution of I-18c (50 mg, 0.13 mmol) , 1, 4-dibromo-2, 3-difluorobenzene (36 mg, 0.13 mmol) , Pd2 (dba) 3 (11.9 mg, 0.013 mmol) , BINAP (16.2 mg, 0.026 mmol) , and cesium carbonate (85 mg, 0.26 mmol) in 1, 4-dioxane (5 mL) was refluxed under nitrogen for 8 h. After cooling, the reaction mixture was filtered, and the filtrate was concentrated to afford an oil, which was purified by column chromatography to give 3- (4- (2- (4-bromo-2, 3-difluorophenyl) -2, 9-diazadispiro [3.1.56.14] dodecan-9-yl) -3-fluorophenyl) piperidine-2, 6-dione (I-18) (20 mg, 26.42%yield) . ES / MS: m / z 562.1 [M+H] +.
[0548] Following the preparation of Intermediate I-18, Intermediate I-16, I-17, I-19, I-20, I-21 were preparation from the the corresponding commercialized reagents
[0549] Intermediate I-22:
[0550] Following the procedure for the preparation of Intermediate I-18, Intermediate I-22 was synthesized via sequential Buchwald-Hartwig Cross Coupling Reaction (General Procedure 1) , reduction, and a second Buchwald-Hartwig Cross Coupling Reaction (General Procedure 1) .
[0551] Intermediate I-23:
[0552] Intermediate I-23:
[0553] To a solution of tert-butyl 2, 9-diazadispiro [3.1.56.14] dodecane-9-carboxylate (2.3 g, 8.63 mmol) and 2, 6-bis (benzyloxy) -3- (4-bromo-3-fluorophenyl) pyridine (6.81 g, 14.67 mmol) in 1, 4-dioxane (35.0 mL) were added XPhos G3 (0.73 g, 0.86 mmol) and tert-BuONa (2.49 g, 25.89 mmol) at room temperature under nitrogen atmosphere. The reaction mixture was then stirred at 100 ℃ overnight under nitrogen. After removal of the solvent by evaporation, the crude product was purified by silica gel column chromatography, eluting with petroleum ether / ethyl acetate (0%to 12%) , to afford tert-butyl 2- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -2-fluorophenyl) -2, 9-diazadispiro [3.1.56.14] dodecane-9-carboxylate (2.4 g, 42.78%yield) . ES / MS: m / z 650.3 [M+H] +.
[0554] To a solution of tert-butyl 2- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -2-fluorophenyl) -2, 9-diazadispiro [3.1.56.14] dodecane-9-carboxylate (2.4 g, 3.69 mmol) in DCM (6.0 mL) was added dropwise TFA (18.0 mL) at room temperature under nitrogen atmosphere. The reaction mixture was then stirred at 30 ℃ for 2 h. After concentration in vacuo, the crude residue was dissolved in EtOH (3.0 mL) and added to aqueous NaHCO (60 mL) at 0 ℃, then stirred at room temperature for 30 min. After filtration, the solid was suspended in iPrOH (7 mL) and stirred at room temperature for 30 min. The mixture was then filtered, and the solid was dried in vacuo at 45 ℃ for 16 h to afford the crude product (2.2 g) , which was used in the next step without further purification.
[0555] To a solution of 3- (4- (2, 9-diazadispiro [3.1.56.14] dodecan-2-yl) -3-fluorophenyl) -6- (benzyloxy) pyridin-2 (3H) -one (1.50 g, 3.26 mmol) and 1-bromo-4-chloro-2, 3-difluorobenzene (1.482 g, 6.52 mmol) in 1, 4-dioxane (20.0 mL) were added methanesulfonato (2-dicyclohexylphosphino-2′, 6′-di-i-propoxy-1, 1′-biphenyl) (2′-amino-1, 1′-biphenyl-2-yl) palladium (II) (27.3 mg, 0.03 mmol) and tert-BuONa (1.06 g, 11.07 mmol) at room temperature under nitrogen atmosphere. The reaction mixture was then stirred at 100 ℃ overnight. After removal of the solvent by evaporation, the crude product was dissolved in DMF (8 mL) , and 10%acetic acid was added to adjust the pH to 3–4. The mixture was filtered, and the solid was washed with HO. The solid was then dissolved in THF / MeOH (10: 1, 60.0 mL) and dioxane (6.0 mL) , and the mixture was stirred at 70 ℃ for 1 h. Activated carbon (150 mg) was added, and stirring was continued at 70 ℃ for 1 h. After filtration, the solvent was removed in vacuo to afford the crude product (1.5 g) , which was used in the next step without further purification.
[0556] To a solution of 6- (benzyloxy) -3- (4- (9- (4-chloro-2, 3-difluorophenyl) -2, 9-diazadispiro [3.1.56.14] dodecan-2-yl) -3-fluorophenyl) pyridin-2 (3H) -one (1.5 g, 2.47 mmol) and potassium bromide (1.47 g, 12.35 mmol) in 1, 4-dioxane / H2O (4: 1, 30.0 mL) was added dropwise palladium on carbon (0.300 g, 10%Pd) at room temperature under hydrogen atmosphere. The reaction mixture was then stirred at 30 ℃ for 3 days under hydrogen atmosphere. After filtration, the solvent was removed in vacuo. The solid was suspended in EtOH (7.0 mL) and stirred at room temperature for 1 h. The mixture was then filtered, and the solid was dried in vacuo at 45 ℃ for 16 h to afford 3- (4- (9- (4-chloro-2, 3-difluorophenyl) -2, 9-diazadispiro [3.1.56.14] dodecan-2-yl) -3-fluorophenyl) piperidine-2, 6-dione (I-23) (0.7 g, 54.6%yield) . ES / MS: m / z 518.2 [M+H] +.
[0557] Following the procedure described for the preparation of Intermediate I-23, the following intermediates were synthesized using the appropriate starting materials (halide) and Dispiro compound:
[0558] Intermediate I-24
[0559] To a solution of tert-butyl 4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 2, 3, 6-tetrahydropyridine-1-carboxylate (9 g, 29.11 mmol) in dichloromethane (50.0 mL) was added dropwise HCl (4 M in dioxane, 50.0 mL) at 0 ℃ under nitrogen atmosphere. The reaction mixture was then stirred at room temperature for 2 h. After removal of the solvent by evaporation, MTBE (30 mL) was added to the residue. The mixture was stirred at room temperature for 10 min, filtered, and the solid was collected to afford 5- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 2, 3, 6-tetrahydropyridine hydrochloride (8.1 g) . ES / MS: m / z 210.2 [M+H] +.
[0560] To a solution of 3- (1H-pyrazol-1-yl) propanoic acid (4.2 g, 29.97 mmol) in pyridine (34.0 mL) was added dropwise a solution of 5- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 2, 3, 6-tetrahydropyridine hydrochloride (6.89 g, 35.96 mmol) and 4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 2, 3, 6-tetrahydropyridine at 0 ℃under nitrogen atmosphere. The reaction mixture was then stirred at room temperature for 12 h. After removal of the solvent by evaporation, the crude residue was washed with ethyl acetate and 0.1 M HCl (3 ×20 mL) . The organic layer was separated, washed with brine (50 mL) , dried over Na2SO4, and concentrated in vacuo to afford 3- (1H-pyrazol-1-yl) -1- (5- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -3, 6-dihydropyridin-1 (2H) -yl) propan-1-one (I-24) (7.6 g, 76.56%yield) . ES / MS: m / z 332.2 [M+H] +.
[0561] Intermediate I-25
[0562] To a solution of 4-bromo-2-chloro-5-fluorobenzaldehyde (24.5 g, 103 mmol) and ethyl 2-azidoacetate (53.3 g, 412 mmol) in methanol (350 mL) was added sodium methoxide (22.3 g, 412 mmol, 76.4 mL of 5.4 M solution) at -10 ℃. The mixture was then stirred at room temperature for 5 h. Aqueous 2 N HCl was added to the reaction mixture, which was then extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The crude product was purified by column chromatography (EtOAc / PE = 0–3%) to afford methyl 2-azido-3- (4-bromo-2-chloro-5-fluorophenyl) acrylate (10.5 g, 13.98%yield) . ES / MS: m / z 333.9 [M+H] +.
[0563] Methyl 2-azido-3- (4-bromo-2-chloro-5-fluorophenyl) prop-2-enoate (10.0 g, 29.9 mmol) was dissolved in xylene (150 mL) , and the mixture was stirred at 140 ℃ for 4 h. After cooling to room temperature, the reaction mixture was filtered, and the filter cake was dried under reduced pressure to afford methyl 6-bromo-4-chloro-7-fluoro-1H-indole-2-carboxylate (4.4 g, 48.02%yield) . ES / MS: m / z 305.9 [M+H] +.
[0564] To a solution of methyl 6-bromo-4-chloro-7-fluoro-1H-indole-2-carboxylate (4.40 g, 14.4 mmol) in methanol (25 mL) and water (25 mL) was added lithium hydroxide (1.03 g, 43.1 mmol, 2 N, 22 mL) . The mixture was stirred at 60 ℃ for 4 h. Aqueous 1 N HCl (450 mL) was added to the mixture, which was then extracted with EtOAc. The combined organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure to afford 6-bromo-4-chloro-7-fluoro-1H-indole-2-carboxylic acid (3.80 g, 90.51%yield) . ES / MS: m / z 291.9 [M+H] +.
[0565] To a solution of 6-bromo-4-chloro-7-fluoro-1H-indole-2-carboxylic acid (3.80 g, 13.0 mmol) , 2- (7-aza-1H-benzotriazol-1-yl) -1, 1, 3, 3-tetramethyluronium hexafluorophosphate (5.93 g, 15.6 mmol) , and ethyldiisopropylamine (8.39 g, 65.0 mmol) in DMF (50 mL) was added dimethylamine hydrochloride (1.59 g, 19.5 mmol) at 0 ℃. The mixture was then stirred at room temperature for 3 h. Upon completion, water was added to the mixture, and stirring was continued for 30 min. The reaction mixture was filtered, and the filter cake was washed with water and dried in vacuo to afford 6-bromo-4-chloro-7-fluoro-N, N-dimethyl-1H-indole-2-carboxamide (I-25) (4.02 g, 96.83%yield) . ES / MS: m / z 319.0 [M+H] +.
[0566] Intermediate I-26
[0567] To a round-bottom flask were added 6-bromo-4-chloro-7-fluoro-N, N-dimethyl-1H-indole-2-carboxamide (1.0 g, 3.13 mmol) , 3- (1H-pyrazol-1-yl) -1- (5- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 2, 3, 6-tetrahydropyridin-1-yl) propan-1-one (1.14 g, 3.44 mmol) , [1, 1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) (0.23 g, 0.31 mmol) , potassium carbonate (0.87 g, 6.26 mmol) , 1, 4-dioxane (20 mL) , and water (1 mL) . The reaction mixture was stirred at 100 ℃ for 16 h. The insoluble solid was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography eluting with DCM / MeOH to afford 4-chloro-7-fluoro-N, N-dimethyl-6- (1- (3- (1H-pyrazol-1-yl) propanoyl) -1, 2, 5, 6-tetrahydropyridin-3-yl) -1H-indole-2-carboxamide (1.168 g, 84.08%yield) .
[0568] To a solution of 4-chloro-7-fluoro-N, N-dimethyl-6- (1- (3- (1H-pyrazol-1-yl) propanoyl) -1, 2, 5, 6-tetrahydropyridin-3-yl) -1H-indole-2-carboxamide (164.24 mg, 0.37 mmol) , XPhos G3 (93.96 mg, 0.11 mmol) , and bis (pinacolato) diboron (187.92 mg, 0.74 mmol) in 1, 4-dioxane (5 mL) was added potassium acetate (145.25 mg, 1.48 mmol) . The mixture was stirred at 80 ℃ for 2 h, then concentrated and purified by silica gel chromatography (DCM / MeOH 10: 1) to afford 6- (1- (3- (1H-pyrazol-1-yl) propanoyl) -1, 2, 5, 6-tetrahydropyridin-3-yl) -7-fluoro-N, N-dimethyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indole-2-carboxamide (I-26, 158 mg, 80%yield) . ES / MS: m / z 536.3 [M+H] +.
[0569] Intermediate I-26a
[0570] Followed the preparation of Intermediate I-26, Intermediate I-26a was obtained. ES / MS: m / z 537.3 [M+H] +.
[0571] Intermediate I-27
[0572] To a solution of I-27a (1.75 g, 9.93 mmol) in DCM (10 mL) were added TBSCl (1.50 g, 9.93 mmol) and 1H-imidazole (1.01 g, 14.9 mmol) . The mixture was stirred at room temperature for 4 h. Water was added, and the mixture was extracted to obtain the organic layer, which was concentrated to give an oil. Purification by column chromatography eluting with PE afforded I-27b (2.23 g) .
[0573] To a solution of I-27b (290 mg, 1.00 mmol) in DCM (5 mL) were added Tf2O (282 mg, 1.00 mmol) and DIPEA (194 mg, 1.50 mmol) . The mixture was stirred at room temperature for 2 h. Water was added, and the mixture was extracted to obtain the organic layer, which was concentrated to give I-27c (422 mg) .
[0574] A solution of I-27c (422 mg, 1.00 mmol) , benzyl piperazine-1-carboxylate (220 mg, 1.00 mmol) , Pd2 (dba) 3 (91.5 mg, 0.100 mmol) , BINAP (124 mg, 0.200 mmol) , and Cs2CO3 (652 mg, 2.00 mmol) in 1, 4-dioxane (10 mL) was stirred at reflux under N2 for 6 h. After cooling, the reaction mixture was filtered, and the filtrate was concentrated to give an oil. Purification by column chromatography afforded I-27d (120 mg) .
[0575] A solution of I-27d (120 mg, 0.24 mmol) and 10%Pd / C (10 mg) in MeOH (5 mL) was stirred under H2 at room temperature for 2 h. The reaction mixture was filtered, and the filtrate was concentrated to give I-27 (85 mg) . ES / MS: m / z 359.2 [M+H] +.
[0576] Intermediate I-28
[0577] A solution of I-28a (358 mg, 1.00 mmol) , 2, 6-bis (benzyloxy) -3- (4-bromo-3-fluorophenyl) pyridine (463 mg, 1.00 mmol) , Pd2 (dba) 3 (91.5 mg, 0.100 mmol) , BINAP (122 mg, 0.200 mmol) , and tBuONa (192 mg, 2.00 mmol) in 1, 4-dioxane (5 mL) was stirred at reflux under N2 for 6 h. After cooling, the reaction mixture was filtered, and the filtrate was concentrated to give an oil. Purification by column chromatography afforded I-28b (301 mg) . ES / MS: m / z 742.4 [M+H] +.
[0578] To a solution of I-28b (300 mg, 0.40 mmol) in 2, 2, 2-trifluoroethanol (5 mL) was added 10%Pd / C (30 mg) . The mixture was stirred under H2 at 50 ℃ for 4 h. After cooling, the reaction mixture was filtered, and the filtrate was concentrated to afford I-28c (220 mg) .
[0579] To a solution of I-28c (220 mg, 0.39 mmol) in TBAF (1 M in THF, 5 mL) was stirred at room temperature for 4 h. The mixture was concentrated to give a solid, which was dissolved in EtOAc and washed with brine. The organic layer was concentrated to afford I-28d (170 mg) . ES / MS: m / z 450.2 [M+H] +.
[0580] To a solution of I-28d (112 mg, 0.25 mmol) in DCM (5 mL) were added Tf2O (70 mg, 0.25 mmol) and DIPEA (65 mg, 0.50 mmol) . The mixture was stirred at room temperature for 2 h. Water was added, and the mixture was extracted to obtain the organic layer, which was concentrated to give I-28 (142 mg) . ES / MS: m / z 582.2 [M+H] +.
[0581] Intermediate I-29
[0582] To a solution of I-29a (1.00 g, 2.22 mmol) and 2, 2, 2-trifluoroacetamide (0.750 g, 6.67 mmol) in THF (10 mL) was added NaH (60%in oil, 0.360 g, 8.89 mmol) slowly at 0 ℃. Upon completion of the addition, the mixture was heated to reflux for 4 h. After cooling, the reaction was quenched by the addition of H2O at 0 ℃. EtOAc was added, and the mixture was extracted to obtain the organic layer, which was concentrated to give I-29b, which was used without further purification in the next step.
[0583] I-29b was dissolved in MeOH / H2O (10 mL / 2 mL) , and NaOH (355 mg, 8.88 mmol) was added. The mixture was refluxed for 6 h. After cooling, the reaction mixture was concentrated to give I-29c, which was used without further purification in the next step.
[0584] I-29c was dissolved in EtOAc (10 mL) , and (Boc) 2O (270 mg, 1.25 mmol) was added. The mixture was stirred at room temperature for 1 h. Brine was added, and the mixture was extracted. The organic layer was concentrated, and the residue was purified by column chromatography to afford I-29 (123 mg) .
[0585] Intermediate I-30
[0586] Intermediate I-30 was prepared following the synthetic route for Intermediate I-18. I-30a was obtained via Buchwald–Hartwig cross-coupling of I-29 with 3- (4-bromo-3-fluorophenyl) -1- (4-methoxybenzyl) piperidine-2, 6-dione. Subsequent treatment of I-30a with trifluoroacetic acid at room temperature afforded I-30b, which was then subjected to a second Buchwald–Hartwig cross-coupling to deliver I-30.
[0587] Intermediate I-31
[0588] To a solution of I-26 (200 mg, 0.37 mmol) and 1, 4-dibromo-2, 3-difluorobenzene (200 mg, 0.74 mmol) in 1, 4-dioxane (2 mL) and H2O (0.2 mL) were added K2CO3 (102 mg, 0.74 mmol) and Pd (dppf) 2Cl2 (27.1 mg, 0.037 mmol) . The mixture was stirred at 90 ℃ for 2 h under N2. After cooling, H2O and EtOAc were added. The mixture was extracted, and the organic layer was concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH 10: 1) to afford I-31 (190 mg, 84.71%yield) . ES / MS: m / z 600.1 [M+H] +.
[0589] Intermediate I-32
[0590] To a solution of tert-butyl 2, 9-diazadispiro [3.2.37.24] dodecane-2-carboxylate (1.05 g, 3.94 mmol) and 1-bromo-4-iodo-2-methoxybenzene (1.48 g, 4.73 mmol) in 1, 4-dioxane (26 mL) were added Pd2 (dba) 3 (0.11 g, 0.20 mmol) , BINAP (0.25 g, 0.39 mmol) , and NaOtBu (0.38 g, 3.94 mmol) . The mixture was stirred at 130 ℃ under microwave irradiation for 1 h. After cooling to room temperature, the reaction was quenched by the addition of H2O (15 mL) , and the resulting mixture was extracted with EtOAc (3 × 40 mL) . The combined organic layers were concentrated, and the residue was purified by silica gel column chromatography (PE / EtOAc 4: 1) to afford tert-butyl 9- (4-bromo-3-methoxyphenyl) -2, 9-diazadispiro [3.2.37.24] dodecane-2-carboxylate (670 mg, 37.7%yield) . ES / MS: m / z 451.2 [M+H] +.
[0591] Trifluoroacetic acid (7.67 g, 67.3 mmol) was added dropwise to a solution of tert-butyl 9- (4-bromo-3-methoxyphenyl) -2, 9-diazadispiro [3.2.37.24] dodecane-2-carboxylate (650 mg, 1.44 mmol) in DCM (30 mL) at room temperature. The mixture was stirred for 2 h, and the solvent was removed by evaporation to afford 2- (4-bromo-3-methoxyphenyl) -2, 9-diazadispiro [3.2.37.24] dodecane (550 mg) , which was used without further purification. ES / MS: m / z 351.1 [M+H] +.
[0592] A solution of 5-bromo-2, 3-difluoropyridine (1.95 g, 10.1 mmol) and 2, 6-bis (benzyloxy) -3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine (4.61 g, 11.1 mmol) in 1, 4-dioxane (80 mL) and H2O (8 mL) was treated with [1, 1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) (0.44 g, 0.60 mmol) and K2CO3 (4.17 g, 30.2 mmol) . The mixture was stirred at 90–95 ℃ under N2 for 5 h. Upon completion, 1, 4-dioxane was removed. To the residue was added EtOAc (100 mL) , and the resulting mixture was washed with H2O (3 × 50 mL) and brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE / EtOAc 10: 1) to afford 5- (2, 6-bis (benzyloxy) pyridin-3-yl) -2, 3-difluoropyridine (3.56 g, 87.6%yield) . ES / MS: m / z 405.1 [M+H] +.
[0593] A solution of 5- (2, 6-bis (benzyloxy) pyridin-3-yl) -2, 3-difluoropyridine (3.56 g, 8.80 mmol) in 2, 2, 2-trifluoroethanol (60 mL) was hydrogenated over Pd / C (0.37 g, 3.52 mmol Pd) using a hydrogen balloon for 4 h. The reaction mixture was filtered and concentrated to afford 3- (5, 6-difluoropyridin-3-yl) piperidine-2, 6-dione (2.02 g) , which was used in the next step without further purification. ES / MS: m / z 227.1 [M+H] +.
[0594] A mixture of 2- (4-bromo-3-methoxyphenyl) -2, 9-diazadispiro [3.2.37.24] dodecane (550 mg, 1.57 mmol) , 3- (5, 6-difluoropyridin-3-yl) piperidine-2, 6-dione (330 mg, 1.46 mmol) , and ethyldiisopropylamine (1.05 g, 5.84 mmol) in DMSO (25 mL) was heated at 140 ℃ for 1 h under microwave irradiation. After cooling to room temperature, the mixture was washed with H2O and brine, extracted with EtOAc (3 × 50 mL) , and the combined organic extracts were dried (Na2SO4) and concentrated. Purification by column chromatography (silica gel, DCM / EtOAc) afforded 3- (6- (9- (4-bromo-3-methoxyphenyl) -2, 9-diazadispiro [3.2.37.24] dodecan-2-yl) -5-fluoropyridin-3-yl) piperidine-2, 6-dione (477 mg, 58.8%yield) . ES / MS: m / z 557.1 [M+H] +.
[0595] Following the preparation of Intermediate I-32, Intermediates I-33 and I-34 were obtained.
[0596] Intermediate I-35
[0597] To a solution of 1, 2-difluoro-4-nitrobenzene (5.00 g, 31.4 mmol) and tert-butyl 3- (hydroxymethyl) piperazine-1-carboxylate (7.48 g, 34.6 mmol) in DMSO (50 mL) was added DIPEA (8.12 g, 62.9 mmol) dropwise at 10 ℃ under N2. The reaction mixture was then stirred at 120 ℃ for 16 h. The residue was partitioned between EtOAc (200 mL) and H2O (4 × 50 mL) . The organic layer was washed with H2O, dried (Na2SO4) , and concentrated. The crude product was purified by silica gel column chromatography (PE / EtOAc 0–40%) to afford 35a (8.10 g) . ES / MS: m / z 356.2 [M+H] +.
[0598] To a solution of tert-butyl 4- (2-fluoro-4-nitrophenyl) -3- (hydroxymethyl) piperazine-1-carboxylate (7.60 g, 21.4 mmol) in DMF (80 mL) was added NaH (1.71 g, 42.8 mmol) portionwise at 0 ℃ under N2. The reaction mixture was then stirred at room temperature for 1 h. The residue was partitioned between EtOAc (300 mL) and H2O (4 × 50 mL) . The organic layer was washed with H2O, dried (Na2SO4) , and concentrated to give 35b (7.70 g) , which was used in the next step without purification. ES / MS: m / z 336.1 [M+H] +.
[0599] To a solution of 35b (7.10 g, 21.2 mmol) and 4, 4'-bipyridine (0.330 g, 2.12 mmol) in DMF (56 mL) was added hypodiboric acid (5.69 g, 63.5 mmol) dropwise at 0 ℃under N2. The reaction mixture was then stirred at room temperature for 0.5 h. The residue was partitioned between EtOAc (200 mL) and H2O (4 × 50 mL) . The organic layer was washed with brine, dried (Na2SO4) , and concentrated to give 35c (7.00 g) , which was used in the next step without purification. ES / MS: m / z 306.2 [M+H] +.
[0600] To a solution of 35c (5.90 g, 19.3 mmol) in MeCN (60 mL) was added p-toluenesulfonic acid (6.65 g, 38.6 mmol) at room temperature under N2. After stirring for 10 min, a solution of NaNO2 (2.67 g, 38.6 mmol) in H2O (5 mL) and KI (9.62 g, 58.0 mmol) in H2O (4 mL) was added at 0 ℃. The reaction was stirred at room temperature for 4 h. The residue was partitioned between DCM (300 mL) and aq NaHSO3 (100 mL) . The organic layer was washed with aq NaHCO3 (100 mL) , dried (Na2SO4) , and concentrated. The crude product was purified by silica gel column chromatography (PE / EtOAc 0–10%) to afford 35d (2.80 g, Rf 0.2, PE / EtOAc 5: 1) . ES / MS: m / z 417.1 [M+H] +.
[0601] To a solution of 35d (1.80 g, 3.59 mmol) and 2, 6-bis (benzyloxy) -3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine (2.25 g, 5.38 mmol) in 1, 4-dioxane (25 mL) and H2O (5 mL) were added Pd (PPh3) 4 (0.410 g, 0.359 mmol) and K2CO3 at room temperature under N2. The reaction mixture was then stirred at 90 ℃ for 2 h. After concentration, the crude product was purified by silica gel column chromatography (PE / EtOAc 0–15%) to afford 35e (2.00 g) .
[0602] To a solution of 35e (500 mg, 0.860 mmol) in DCM (3 mL) was added TFA (15.4 g, 135 mmol) dropwise at room temperature under N2. The reaction mixture was then stirred at room temperature for 16 h. The residue was partitioned between EtOAc (10 mL) and aq NaHCO3 (20 mL) . After filtration, the solid was collected and dried in vacuo to give the crude product (450 mg) , which was used in the next step without purification. ES / MS: m / z 390.2 [M+H] +.
[0603] To a solution of 35f (400 mg, 1.03 mmol) and 1-bromo-4-chloro-2, 3-difluorobenzene (469 mg, 2.06 mmol) in 1, 4-dioxane (50 mL) were added Pd2 (dba) 3 (94.3 mg, 0.103 mmol) , BINAP (128 mg, 0.206 mmol) , and NaOtBu (297 mg, 3.09 mmol) at room temperature under N2. The reaction mixture was then stirred at 100 ℃overnight. After concentration, the crude product was purified by silica gel column chromatography (DCM / EtOAc 0–15%) to afford 35g (350 mg) . ES / MS: m / z 536.1 [M+H] +.
[0604] To a solution of 35g (50.0 mg, 0.0930 mmol) in THF (20 mL) was added Pt / C (36.3 mg, 0.186 mmol Pt) at room temperature under H2. The reaction mixture was then stirred at 50 ℃ for 16 h. After filtration and concentration, Intermediate I-35 (20.0 mg) was obtained. ES / MS: m / z 448.1 [M+H] +.
[0605] Intermediate I-53
[0606] To a suspension of (methoxymethyl) triphenylphosphonium chloride (12.9 g, 37.6 mmol) in THF (75 mL) was added potassium tert-butoxide (4.69 g, 41.8 mmol) at 0 ℃ under N2. After stirring for 0.5 h, a solution of tert-butyl 7-oxo-2-azaspiro [3.5] nonane-2-carboxylate (5.00 g, 20.9 mmol) in THF was added at 0 ℃, and the mixture was stirred at room temperature overnight. The mixture was acidified to pH 3–4 with aqueous citric acid and extracted with EtOAc (3 × 50 mL) . The combined organic layers were washed with brine (80 mL) , dried (Na2SO4) , and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc 5: 1) to afford tert-butyl 7- (methoxymethylene) -2-azaspiro [3.5] nonane-2-carboxylate (3.97 g, 71.1%yield) . ES / MS: m / z 268.2 [M+H] +.
[0607] To a solution of tert-butyl 7- (methoxymethylene) -2-azaspiro [3.5] nonane-2-carboxylate (3.97 g, 14.9 mmol) in MeCN (110 mL) and H2O (30 mL) was added TFA (5.08 g, 44.6 mmol) . The mixture was stirred at room temperature overnight, then quenched with NaHCO3 and extracted with EtOAc (3 × 30 mL) . The combined organic layers were washed with brine (40 mL) , dried (Na2SO4) , and concentrated under reduced pressure to afford tert-butyl 7-formyl-2-azaspiro [3.5] nonane-2-carboxylate (3.30 g, 87.7%yield) . ES / MS: m / z 234.2 [M+H] +
[0608] To a solution of tert-butyl 7-formyl-2-azaspiro [3.5] nonane-2-carboxylate (3.30 g, 13.0 mmol) in MeOH (80 mL) were added NaOH (52.1 mg, 1.30 mmol) and formaldehyde (5.59 g, 65.2 mmol) . The mixture was stirred at room temperature for 72 h, then concentrated under reduced pressure. The residue was extracted with EtOAc (3 × 50 mL) , and the combined organic layers were washed with brine (100 mL) , dried (Na2SO4) , and concentrated to afford tert-butyl 7-formyl-7- (hydroxymethyl) -2-azaspiro [3.5] nonane-2-carboxylate (4.10 g, 55.5%yield) . ES / MS: m / z 284.2 [M+H] +.
[0609] To a solution of tert-butyl 7-formyl-7- (hydroxymethyl) -2-azaspiro [3.5] nonane-2-carboxylate (2.90 g, 10.2 mmol) in 1, 2-dichloroethane (40 mL) were added 2-fluoro-4-iodoaniline (2.42 g, 10.2 mmol) and AcOH (1.54 g, 25.6 mmol) . The mixture was stirred at room temperature for 0.5 h, then NaBH (OAc) 3 (8.67 g, 40.9 mmol) was added. The mixture was stirred at room temperature overnight and purified by silica gel column chromatography (PE / EtOAc 4: 1) to afford tert-butyl 7- { [ (2-fluoro-4-iodophenyl) amino] methyl} -7- (hydroxymethyl) -2-azaspiro [3.5] nonane-2-carboxylate (1.18 g, 22.9%yield) . ES / MS: m / z 505.1 [M+H] +.
[0610] To a solution of tert-butyl 7- { [ (2-fluoro-4-iodophenyl) amino] methyl} -7- (hydroxymethyl) -2-azaspiro [3.5] nonane-2-carboxylate (1.18 g, 2.34 mmol) in DCM (15 mL) were added methanesulfonic anhydride (0.820 g, 4.68 mmol) and DIPEA (0.910 g, 7.02 mmol) . The mixture was stirred at room temperature for 2 h, then concentrated under reduced pressure. The residue was dissolved in 1, 2-dichloroethane (15 mL) , and DBU (1.07 g, 7.02 mmol) was added. The mixture was stirred at 80 ℃for 18 h and purified by silica gel column chromatography (PE / EtOAc 4: 1) to afford tert-butyl 9- (2-fluoro-4-iodophenyl) -2, 9-diazadispiro [3.2.37.24] dodecane-2-carboxylate (750 mg, 65.9%yield) . 1H NMR (400 MHz, CDCl3) : δ 7.25–7.19 (m, 2H) , 6.63–6.62 (m, 1H) , 6.21–6.16 (m, 1H) , 3.58 (s, 4H) , 1.69–1.60 (m, 8H) , 1.43 (s, 9H) . ES / MS: m / z 487.1 [M+H] +.
[0611] To a solution of tert-butyl 9- (2-fluoro-4-iodophenyl) -2, 9-diazadispiro [3.2.37.24] dodecane-2-carboxylate (750 mg, 1.29 mmol) in 1, 4-dioxane (10 mL) and H2O (2 mL) were added 2, 6-bis (benzyloxy) -3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine (646 mg, 1.55 mmol) , [1, 1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) ·DCM (105 mg, 0.129 mmol) , and K2CO3 (535 mg, 3.87 mmol) . The mixture was stirred at 95 ℃ for 3 h under N2, then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc 4: 1) to afford tert-butyl 9- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -2-fluorophenyl) -2, 9-diazadispiro [3.2.37.24] dodecane-2-carboxylate (320 mg, 38.3%yield) . ES / MS: m / z 650.3 [M+H] +.
[0612] To a solution of tert-butyl 9- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -2-fluorophenyl) -2, 9-diazadispiro [3.2.37.24] dodecane-2-carboxylate (2.40 g, 3.69 mmol) in DCM (6.0 mL) was added TFA (18.0 mL) dropwise at room temperature under N2. The reaction mixture was stirred at 30 ℃ for 2 h. After concentration in vacuo, the crude residue was dissolved in EtOH (3.0 mL) and added to aq NaHCO3 (60 mL) at 0 ℃. The mixture was stirred at room temperature for 30 min, filtered, and the solid was suspended in iPrOH (7 mL) . After stirring at room temperature for 30 min, the mixture was filtered, and the solid was dried in vacuo at 45 ℃ for 16 h to afford 3- (4- (2, 9-diazadispiro [3.2.37.24] dodecan-2-yl) -3-fluorophenyl) -6- (benzyloxy) pyridin-2-ol (Intermediate I-53) (1.50 g, 88%yield) . ES / MS: m / z 460.2 [M+H] +.
[0613] Intermediate I-54
[0614] Following the procedure described for the preparation of Intermediate I-53, tert-butyl 2-oxo-7-azaspiro [3.5] nonane-7-carboxylate was used as the starting material and subjected to the same synthetic sequence to afford Intermediate I-54.
[0615] General preparation 3 for Intermediates: Linker-CRBNs
[0616] Wherein, Z1, Z2, Z3 is N or C (Rd) ; n1 is 1 or 2; n2 is 0 or 1; n3 is 1 or 2; Ra, Rb, Rc and Rd is F, Cl, OH, CN, methyl, ethyl, cyclopropyl, methoxy, haloalkyl, haloalkoxy.
[0617] To a solution of formula (i) (1.0 equiv) and aryl halide or heteroaryl halide (2.0 equiv) in 1, 4-dioxane were added RuPhos Pd G3 (0.10 equiv) and NaOtBu (3.0 equiv) at room temperature under N2. The reaction mixture was stirred at 100 ℃ overnight. After concentration, the crude product was dissolved in DMF, and 10%AcOH was added to adjust to pH 3–4. The mixture was filtered, and the solid was washed with H2O. The solid was then dissolved in THF / MeOH (10: 1) and dioxane, and the mixture was stirred at 70 ℃ for 1 h. Activated carbon (10%w / w) was added, and stirring was continued at 70 ℃ for 1 h. After filtration, the solvent was removed in vacuo. The solid was used in the next step without purification.
[0618] To a solution of formula (ii) (1.0 equiv) and KBr (5.0 equiv) in 1, 4-dioxane / H2O (4: 1) was added Pd / C (20%w / w, 10%Pd purity) at room temperature. The reaction mixture was stirred at 30 ℃ for 3 days under H2. After filtration, the solvent was removed in vacuo. The solid was added to EtOH and stirred at room temperature for 1 h. The mixture was filtered, and the solid was dried in vacuo at 45 ℃ for 16 h to afford Intermediates Linker-CRBNs.
[0619] The syntheses of Intermediate I-51 are provided as specific working examples, corresponding to the detailed procedures of General Preparation 3.
[0620] Intermediate I-51
[0621] To a solution of I-53 (1.70 g, 3.69 mmol) and 4-bromo-1-chloro-2-methoxybenzene (1.63 g, 7.38 mmol) in 1, 4-dioxane (26.0 mL) were added RuPhos Pd G3 (30.9 mg, 0.369 mmol) and NaOtBu (1.06 g, 11.1 mmol) at room temperature under N2. The reaction mixture was stirred at 100 ℃ overnight. After concentration, the crude product was dissolved in DMF (8 mL) , and 10%AcOH was added to adjust to pH 3–4. The mixture was filtered, and the solid was washed with H2O. The solid was then dissolved in THF / MeOH (10: 1, 100 mL) and dioxane (12.0 mL) , and the mixture was stirred at 70 ℃ for 1 h. Activated carbon (170 mg) was added, and stirring was continued at 70 ℃ for 1 h. After filtration, the solvent was removed in vacuo to give the crude product (1.70 g) , which was used in the next step without purification. ES / MS: m / z 600.2 [M+H] +.
[0622] To a solution of 6- (benzyloxy) -3- (4- (9- (4-chloro-3-methoxyphenyl) -2, 9-diazadispiro [3.2.37.24] dodecan-2-yl) -3-fluorophenyl) pyridin-2-ol (1.70 g, 2.83 mmol) and KBr (1.68 g, 14.2 mmol) in 1, 4-dioxane / H2O (4: 1, 34.0 mL) was added Pd / C (0.34 g, 10%Pd) at room temperature. The reaction mixture was stirred at 30 ℃ for 3 days under H2. After filtration, the solvent was removed in vacuo. The solid was added to EtOH (7.0 mL) and stirred at room temperature for 1 h. The mixture was filtered, and the solid was dried in vacuo at 45 ℃ for 16 h to afford Intermediate I-51 (1.20 g, 83.7%yield) . ES / MS: m / z 512.2 [M+H] +.
[0623] B. SYNTHESIS OF THE COMPOUNDS
[0624] Compound 1
[0625] A solution of I-1 (20 mg, 38 μmol) , I-7 (24 mg, 38 μmol) , Cs2CO3 (18.5 mg, 57 μmol) , and Pd (dppf) Cl2·DCM (3 mg, 3.8 μmol) in 1, 4-dioxane (2 mL) and H2O (0.6 mL) was stirred at 100 ℃ for 5 h. After cooling, H2O (5 mL) and EtOAc (5 mL) were added. The organic layer was separated, concentrated, and purified by preparative HPLC (C18, ACN / H2O with 0.1%TFA) to afford compound 1 (9 mg, 24.1%yield) . ES / MS: m / z 985.4 [M+H] +.
[0626] Compound 125:
[0627] To a solution of 7-fluoro-N, N-dimethyl-6- (2- (2- (1H-pyrazol-1-yl) ethyl) -1H-1, 3-benzodiazol-6-yl) -4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indole-2-carboxamide (I-10) (10 mg, 0.018 mmol) and 3- (4- (4- (4-bromo-2, 3-difluorophenyl) piperazin-1-yl) -3-fluorophenyl) piperidine-2, 6-dione (I-8) (8.68 mg, 0.018 mmol) in 1, 4-dioxane (3 mL) and H2O (0.2 mL) were added Pd (dppf) Cl2·DCM (1.47 mg, 0.0018 mmol) and K2CO3 (7.4 mg, 0.054 mmol) at room temperature under N2. The reaction mixture was stirred at 90 ℃ for 3 h. After cooling, the crude product was purified by C18 flash chromatography to afford compound 125 (1.6 mg) . ESI-MS: m / z 818.3 [M+H] +.
[0628] Compound 229
[0629] To a solution of 3- (4- (9- (4-bromo-2, 3-difluorophenyl) -2, 9-diazadispiro [3.2.37.24] dodecan-2-yl) -3-fluorophenyl) piperidine-2, 6-dione (6 mg, 0.011 mmol) in 1, 4-dioxane (2 mL) and H2O (0.2 mL) were added 7-fluoro-N, N-dimethyl-6- (1- (3- (1H-pyrazol-1-yl) propanoyl) -1, 2, 5, 6-tetrahydropyridin-3-yl) -4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indole-2-carboxamide (8.83 mg, 0.017 mmol) , K2CO3 (4.6 mg, 0.033 mmol) , and Pd (dtbpf) Cl2 (1 mg, 0.0015 mmol) . The mixture was stirred at 100 ℃ for 2 h under N2, then purified by preparative HPLC to afford compound 229 (1.5 mg, 15.8%yield) . MS: m / z 891.4 [M+H] +.
[0630] Compound 230:
[0631] Following the preparation of compound 1. Compound 230 was prepared by Suzuki Coupling of Intermediate I-18 with Intermediate I-26. HNMR (400 MHz, ) δ 9.58 (d, J = 15.0 Hz, 1H) , 8.02 (s, 1H) , 7.61 (s, 1H) , 7.57 (d, J = 15.3 Hz, 1H) , 7.26 –7.21 (m, 1H) , 7.06 –7.04 (m, 1H) , 6.99 (s, 1H) , 6.98 –6.89 (m, 2H) , 6.73 (s, 1H) , 6.29 –6.24 (m, 2H) , 6.13 (d, J = 12.1 Hz, 1H) , 4.61 –4.58 (m, 2H) , 4.46 (s, 1H) , 4.25 (s, 1H) , 4.08 (s, 4H) , 3.76 –3.73 (m, 2H) , 3.56 (t, J = 5.7 Hz, 1H) , 3.38 (brs, 3H) , 3.19 (brs, 7H) , 3.05 –2.95 (m, 2H) , 2.79 –2.67 (m, 2H) , 2.33 (s, 2H) , 2.28 –2.23 (m, 2H) , 2.18 (s, 2H) , 1.85 –1.83 (m, 4H) , 1.43 (s, 2H) . MS: m / z 891.4 [M+H] +
[0632] Compound 238:
[0633] Following the preparation of compound 1. Compound 238 was prepared. 1H NMR (400 MHz, Chloroform-d) δ 9.63 (d, J = 13.3 Hz, 1H) , 8.01 (s, 1H) , 7.63 –7.51 (m, 2H) , 7.16 –7.08 (m, 1H) , 6.95 (dd, J = 13.9, 6.1 Hz, 1H) , 6.88 –6.78 (m, 3H) , 6.74 –6.69 (m, 1H) , 6.52 –6.44 (m, 1H) , 6.25 (dt, J = 12.0, 2.1 Hz, 1H) , 6.12 (ddd, J = 12.2, 3.7, 2.0 Hz, 1H) , 4.63 –4.55 (m, 2H) , 4.49 –4.40 (m, 1H) , 4.24 (s, 1H) , 4.01 (d, J = 1.9 Hz, 4H) , 3.75 (t, J = 5.8 Hz, 1H) , 3.66 (dd, J = 9.9, 5.1 Hz, 1H) , 3.55 (t, J = 5.7 Hz, 1H) , 3.45 –3.30 (m, 3H) , 3.24 –3.05 (m, 7H) , 2.99 (dt, J =12.7, 6.3 Hz, 2H) , 2.76 –2.57 (m, 3H) , 2.37 –2.29 (m, 2H) , 2.27 –2.15 (m, 2H) , 1.79 –1.73 (m, 4H) , 1.31 –1.22 (m, 3H) . MS: m / z 891.4 [M+H] +
[0634] Compound 240
[0635] Following the preparation of compound 1, Compound 240 was prepared. 1H NMR (400 MHz, Chloroform-d) δ 9.65 (d, J = 20.6 Hz, 1H) , 8.08 (s, 1H) , 7.83 (d, J = 3.6 Hz, 1H) , 7.72 (s, 1H) , 7.53 (t, J = 8.1 Hz, 1H) , 7.07 (s, 1H) , 7.06 –7.01 (m, 2H) , 6.95-6.91 (m, 1H) , 6.75-6, 72 (m, 1H) , 6.33 –6.26 (m, 1H) , 6.18 –6.09 (m, 1H) , 4.80 (q, J = 5.9 Hz, 2H) , 4.45 (s, 1H) , 4.28 (s, 1H) , 3.82 –3.72 (m, 6H) , 3.57 (t, J = 5.8 Hz, 1H) , 3.48 –3.41 (m, 4H) , 3.38 (s, 3H) , 3.18 (s, 3H) , 3.10 –3.02 (m, 2H) , 2.83-2.76 (m, 1H) , 2.73 –2.63 (m, 1H) , 2.41 –2.16 (m, 8H) , 1.86-1.84 (m, 4H) . 1.81-1.78 (m, 4H) . MS: m / z 920.4 [M+H] +
[0636] Compound 242:
[0637] Following the preparation of compound 229, Compound 242 was prepared by Suzuki Coupling (General Procedure 3) of Intermediate I-18 with Intermediate I-26a. 1H NMR (400 MHz, ) δ 9.63 (d, J = 18.4 Hz, 1H) , 8.01 (s, 1H) , 7.85 (d, J = 4.3 Hz, 1H) , 7.74 (s, 1H) , 7.72 –7.53 (m, 1H) , 7.10 –7.02 (m, 3H) , 6.94 (dd, J = 9.7, 5.9 Hz, 1H) , 6.74 (s, 1H) , 6.31 (s, 1H) , 6.15 (d, J = 15.5 Hz, 1H) , 4.81 (q, J = 5.8 Hz, 2H) , 4.46 (s, 1H) , 4.29 (s, 1H) , 4.09 (s, 4H) , 3.76 (m, 2H) , 3.59 (t, J = 5.6 Hz, 1H) , 3.40 (m, 7H) , 3.19 (m, 3H) , 3.10 –3.05 (m, 2H) , 2.79 (m, 1H) , 2.75 –2.68 (m, 1H) , 2.36 (s, 2H) , 2.24 (s, 5H) , 2.08 (s, 2H) , 1.25 (s, 2H) . MS: m / z 892.4 [M+H] +
[0638] Compound 250
[0639] Following the preparation of compound 229, Compound 250 was prepared by Suzuki Coupling (General Procedure 3) of Intermediate I-23 with Intermediate I-26a. 1H NMR (400 MHz, Chloroform-d) δ 9.50 (d, J = 17.4 Hz, 1H) , 7.96 (s, 1H) , 7.75 (s, 1H) , 7.65 (s, 1H) , 7.17 –7.06 (m, 1H) , 6.95 (dd, J = 10.8, 6.2 Hz, 1H) , 6.86 –6.75 (m, 3H) , 6.75 –6.68 (m, 1H) , 6.42 (t, J = 8.9 Hz, 1H) , 6.13 (d, J = 16.2 Hz, 1H) , 5.34 (t, J = 5.1 Hz, 1H) , 4.78 (q, J = 5.9 Hz, 2H) , 4.45 (s, 1H) , 4.27 (s, 1H) , 3.97 (s, 4H) , 3.76 (t, J = 6.0 Hz, 1H) , 3.70 –3.62 (m, 1H) , 3.56 (t, J = 5.8 Hz, 1H) , 3.43 –3.29 (m, 3H) , 3.24 –3.12 (m, 3H) , 3.05 (dd, J = 10.5, 3.8 Hz, 6H) , 2.76 –2.57 (m, 2H) , 2.35 (d, J = 2.8 Hz, 2H) , 2.26 –2.17 (m, 2H) , 2.13 –2.10 (m, 3H) , 1.77 –1.72 (m, 3H) , 1.25 (s, 8H) . MS: m / z 892.4 [M+H] +
[0640] Compound 254
[0641] To a solution of tert-butyl 2, 9-diazadispiro [3.2.37.24] dodecane-2-carboxylate (65 mg, 0.24 mmol) and 4- (4-bromo-2, 3-difluorophenyl) -7-fluoro-N, N-dimethyl-6- (1- (3- (1H-pyrazol-1-yl) propanoyl) -1, 2, 5, 6-tetrahydropyridin-3-yl) -1H-indole-2-carboxamide (173 mg, 0.29 mmol) in DMF (5 mL) were added Cs2CO3 (313 mg, 0.96 mmol) and Pd-PEPPSI-IPent (19.1 mg, 0.024 mmol) . The mixture was stirred at 100 ℃ for 3 h. After cooling, the reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH 10: 1) to afford 254b (25 mg) .
[0642] To a solution of 254b (25 mg, 0.030 mmol) in DCM (5 mL) was added TFA (1.53 g) . The mixture was stirred at room temperature for 0.5 h. After concentration, the crude product was purified by preparative HPLC (C18, ACN / H2O with 0.1%TFA) to afford 254c (17 mg) .
[0643] To a solution of 254c (17 mg, 0.025 mmol) in DMF (1 mL) were added 3, 4-difluoronitrobenzene (7.95 mg, 0.050 mmol) and K2CO3 (13.8 mg, 0.10 mmol) . The mixture was stirred at room temperature for 2 h. The reaction was quenched with aq NH4Cl and extracted with EtOAc. The combined organic extracts were filtered, concentrated, and purified by silica gel column chromatography (DCM / MeOH 10: 1) to afford 254d (17 mg) .
[0644] To a solution of 254d (2.0 mg, 0.0024 mmol) in DMF (1 mL) were added hypodiboric acid (0.65 mg, 0.0072 mmol) and 4, 4'-bipyridine (0.075 mg, 0.00048 mmol) . The mixture was stirred at room temperature for 5 min, then quenched with H2O and filtered to afford the product as a solid.
[0645] To a solution of 254e (14 mg, 0.018 mmol) in H2O (0.5 mL) and AcOH (2 mL) were added acrylic acid (42.0 mg, 0.58 mmol) . The mixture was stirred at 130 ℃ for 1 h, then concentrated to give 254f, which was used in the next step without purification. To a solution of 254f (4.0 mg, 0.0046 mmol) in AcOH (1 mL) was added urea (6.6 mg, 0.11 mmol) . The mixture was stirred at 115 ℃ for 16 h, then concentrated. The residue was purified by preparative HPLC (C18, ACN / H2O with 0.1%TFA) to afford compound 254 (1.0 mg) . MS: m / z 892.4 [M+H] +
[0646] Compound 291
[0647] Following the preparation of Compound 229, compound 291 was obtained via Suzuki Coupling Reaction. 1H NMR (400 MHz, Chloroform-d) δ 9.41 (d, J = 20.1 Hz, 1H) , 8.06 (s, 1H) , 7.78 –7.73 (m, 1H) , 7.72 –7.67 (m, 1H) , 7.67 –7.63 (m, 1H) , 7.54 –7.50 (m, 1H) , 7.48 –7.44 (m, 1H) , 7.19 (dd, J = 7.9, 3.2 Hz, 1H) , 6.93 –6.86 (m, 3H) , 6.65 (s, 1H) , 6.15 –6.10 (m, 1H) , 6.08 –6.02 (m, 1H) , 4.83 –4.72 (m, 2H) , 4.46 (s, 1H) , 4.27 (s, 1H) , 3.95 (s, 4H) , 3.79 –3.68 (m, 5H) , 3.58 –3.50 (m, 1H) , 3.35 –3.12 (m, 6H) , 3.06 –2.93 (m, 6H) , 2.78 –2.58 (m, 2H) , 2.39 –2.29 (m, 2H) , 2.28 –2.17 (m, 2H) , 2.12 (s, 4H) , 1.75 –1.70 (m, 4H) . MS: m / z 886.4 [M+H] +
[0648] Compound 321
[0649] Following the preparation of Compound 1, compound 321 was obtained via Buchwald-Hartwig Cross Coupling Reaction and Suzuki Coupling Reaction:
[0650] To a solution of 3- (4- (9- (4-chloro-3-methoxyphenyl) -2, 9-diazadispiro [3.2.37.24] dodecan-2-yl) -3-fluorophenyl) piperidine-2, 6-dione (I-51) (1.70 g, 3.32 mmol) and 7-fluoro-N, N-dimethyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -6- (1- (3- (1H-1, 2, 3-triazol-1-yl) propanoyl) -1, 2, 5, 6-tetrahydropyridin-3-yl) -1H-indole-2-carboxamide (2.23 g, 4.15 mmol) in 1, 4-dioxane (34.0 mL) and H2O (3.4 mL) were added XPhos G3 (0.280 g, 0.332 mmol) and K3PO4 (2.10 g, 9.96 mmol) at room temperature under N2. The reaction mixture was stirred at 90 ℃ for 2 h. After filtration, the solid was washed with DCM / MeOH (10: 1, 7 mL) . The filtrate was extracted, and the organic layer was washed with H2O, dried (Na2SO4) , and concentrated. The crude product (4.0 g) was purified by silica gel column chromatography (DCM / MeOH 0–4%) to afford 6- (1- (3- (1H-1, 2, 3-triazol-1-yl) propanoyl) -1, 2, 5, 6-tetrahydropyridin-3-yl) -4- (4- (9- (4- (2, 6-dioxopiperidin-3-yl) -2-fluorophenyl) -2, 9-diazadispiro [3.2.37.24] dodecan-2-yl) -2-methoxyphenyl) -7-fluoro-N, N-dimethyl-1H-indole-2-carboxamide (2.6 g, 88.4%yield ) . 1H NMR (400 MHz, Chloroform-d) δ 9.36 (d, J = 13.4 Hz, 1H) , 7.95 (d, J = 5.5 Hz, 1H) , 7.75 (d, J = 4.4 Hz, 1H) , 7.65 (d, J = 3.5 Hz, 1H) , 7.22 (dd, J = 8.1, 4.0 Hz, 1H) , 6.93 (dd, J = 12.5, 6.3 Hz, 1H) , 6.86 –6.75 (m, 2H) , 6.67 –6.56 (m, 2H) , 6.42 (t, J = 8.9 Hz, 1H) , 6.12 (d, J = 17.8 Hz, 1H) , 4.78 (q, J = 6.2 Hz, 2H) , 4.50 –4.40 (m, 1H) , 4.26 (dd, J = 8.8, 2.3 Hz, 1H) , 3.97 (d, J = 1.9 Hz, 3H) , 3.75 (d, J = 2.0 Hz, 3H) , 3.66 (dd, J = 9.6, 5.1 Hz, 1H) , 3.56 (q, J = 5.6 Hz, 1H) , 3.38 –3.11 (m, 8H) , 3.07 –2.98 (m, 2H) , 2.74 –2.60 (m, 1H) , 2.39 –2.28 (m, 2H) , 2.26 –2.15 (m, 2H) , 2.11 (s, 3H) , 1.76 –1.68 (m, 3H) , 1.23 (s, 8H) .
[0651] Compound 324
[0652] Following the preparation of Compound 1, compound 324 was obtained. 1HNMR (400 MHz, ) δ 9.66 (d, J = 19.2 Hz, 1H) , 7.99 (s, 1H) , 7.85 (dd, J = 3.2, 1.2 Hz, 1H) , 7.74 (s, 1H) , 7.08 –7.01 (m, 1H) , 6.95 –6.89 (m, 1H) , 6.89 –6.81 (m, 2H) , 6.78 –6.72 (m, 1H) , 6.62 (t, J = 8.8 Hz, 1H) , 6.32 –6.22 (m , 1H) , 6.17 –6.08 (m , 1H) 4.81 (q, J = 6.0 Hz, 2H) , 4.45 (s, 1H) , 4.28 (d, J = 2.0 Hz, 1H) , 3.80 –3.74 (m, 8H) , 3.68 (dd, J = 10.0, 5.2 Hz, 1H) , 3.58 (t, J = 6.0 Hz, 1H) , 3.44 (s, 3H) , 3.19 (s, 3H) , 3.07 (dd, J = 13.8, 6.2 Hz, 2H) , 2.76 –2.63 (m, 2H) , 2.36 (s, 3H) , 2.27 –2.16 (m, 2H) , 1.78 (s, 8 H) .
[0653] Compound 356
[0654] Following the preparation of Compound 1 and the General Procedure for Metal-Catalyzed Cross-Coupling (General Procedure 3) , Compound 356 was prepared by coupling Intermediate I-1a with Intermediate I-26. 1H NMR (400 MHz, DMSO-d6 ) δ 12.15 (d, J = 9.2 Hz, 1H) , 10.75 (s, 1H) , 7.68 (dd, J = 11.5, 1.8 Hz, 1H) , 7.36 (d, J = 23.3 Hz, 1H) , 7.19 –7.10 (m, 1H) , 6.91 (dd, J = 20.6, 6.3 Hz, 1H) , 6.82 –6.75 (m, 1H) , 6.58 (s, 1H) , 6.46 (dd, J = 15.5, 1.6 Hz, 1H) , 6.42 –6.34 (m, 2H) , 6.18 –6.12 (m, 1H) , 6.11 –6.05 (m, 1H) , 5.76 (d, J = 7.7 Hz, 1H) , 4.36 –4.29 (m, 3H) , 4.28 –4.16 (m, 2H) , 3.98 (s, 3H) , 3.64 –3.50 (m, 2H) , 3.21 –2.97 (m, 6H) , 2.96 –2.88 (m, 2H) , 2.75 –2.67 (m, 4H) , 2.58 –2.50 (m, 1H) , 2.32 –2.18 (m, 2H) , 2.04 (s, 4H) , 2.00 –1.90 (m, 1H) , 1.86 –1.74 (m, 1H) , 1.58 (s, 4H) , 1.19 (s, 2H) .
[0655] Compound 360
[0656] Following the preparation of Compound 1 and the General Procedure for Metal-Catalyzed Cross-Coupling (General Procedure 3) , Compound 360 was prepared by coupling Intermediate I-1a with Intermediate I-26a. 1H NMR (400 MHz, DMSO-d6) δ 12.20 (d, J = 8.2 Hz, 1H) , 10.82 (s, 1H) , 8.11 (d, J = 11.6 Hz, 1H) , 7.69 (d, J = 12.0 Hz, 1H) , 7.26 –7.05 (m, 2H) , 6.95 (dd, J = 24.3, 6.0 Hz, 1H) , 6.68 –6.55 (m, 2H) , 6.53 –6.47 (m, 1H) , 6.46 –6.40 (m, 1H) , 6.19 –6.06 (m, 1H) , 4.67 –4.58 (m, 2H) , 4.40 –4.27 (m, 3H) , 4.03 (s, 3H) , 3.70 –3.64 (m, 2H) , 3.21 –3.13 (m, 3H) , 3.12 –2.99 (m, 8H) , 2.80 –2.64 (m, 1H) , 2.63 –2.53 (m, 1H) , 2.36 –2.25 (m, 2H) , 2.14 (s, 3H) , 2.10 –2.04 (m, 1H) , 2.02 –1.82 (m, 2H) , 1.74 (s, 4H) , 1.23 (s, 2H) .
[0657] Compound 380
[0658] Following the preparation of Compound 1 and the General Procedure for Metal-Catalyzed Cross-Coupling (General Procedure 3) , Compound 360 was prepared. 1H NMR (400 MHz, ) δ 9.58 (d, J = 17.6 Hz, 1H) , 8.00 (s, 1H) , 7.81 (d, J = 4.0 Hz, 1H) , 7.71 (s, 1H) , 7.25 –7.22 (m, 1H) , 7.09 –6.97 (m, 2H) , 6.92 (dd, J = 10.2, 6.0 Hz, 1H) , 6.73 (s, 1H) , 6.39 (d, J = 13.6 Hz, 1H) , 6.31 –6.23 (m, 1H) , 6.13 (d, J = 16.8 Hz, 1H) , 4.79 (q, J = 6.0 Hz, 2H) , 4.45 (s, 1H) , 4.27 (s, 4H) , 4.04 (dd, J = 12.0, 4.4 Hz, 1H) , 3.87 –3.82 (m, 3H) 3.76 (s, 5H) , 3.57 (t, J = 6.0 Hz, 1H) , 3.37 (s, 3H) , 3.18 (s, 3H) , 3.05 (dd, J = 14.8, 6.4 Hz, 2H) , 2.94 –2.76 (m, 4H) , 2.35 (s, 3H) , 2.04 –1.90 (m, 4H) , 1.79 (s, 4H) .
[0659] Compound 408
[0660] Following the preparation of Compound 229, compound 408 was obtained. 1H NMR (400 MHz, ) δ 9.63 (d, J = 12.0 Hz, 1H) , 8.58 (s, 1H) , 7.97 –7.90 (m, 2H) , 7.60 –7.52 (m, 2H) , 7.27 (s, 1H) , 6.99 –6.97 (m, 2H) , 6.92 –6.83 (m, 2H) , 6.26 (d, J = 11.0 Hz, 1H) , 6.13 (d, J = 12.4 Hz, 1H) , 4.61 (s, 2H) , 4.46 (s, 5H) , 4.25 (s, 1H) , 3.80 –3.71 (m, 2H) , 3.58 (s, 1H) , 3.40 (s, 3H) , 3.21 (s, 6H) , 3.03 (m, 2H) , 2.80 –2.70 (m, 1H) , 2.68 (s, 1H) , 2.35 (s, 2H) , 2.23 (s, 6H) , 2.05 (s, 2H) , 1.33 (s, 2H) .
[0661] Compound 426
[0662] Following the preparation of Compound 229 and the General Procedure for Metal-Catalyzed Cross-Coupling (General Procedure 3) , Compound 426 was obtained. 1H NMR (400 MHz, ) δ 9.70 (d, J = 16.5 Hz, 1H) , 8.59 (m, 1H) , 7.94 (m, 2H) , 7.81 (s, 1H) , 7.72 (d, J = 3.8 Hz, 1H) , 6.89 –6.80 (m, 4H) , 6.46 (t, J = 8.9 Hz, 1H) , 6.14 (d, J = 11.7 Hz, 1H) , 4.81 (q, J = 6.2 Hz, 2H) , 4.46 (s, 1H) , 4.28 (d, J = 6.7 Hz, 1H) , 4.13 (s, 4H) , 3.78 (t, J = 5.8 Hz, 1H) , 3.74 –3.64 (m, 7H) , 3.60 (t, J = 5.8 Hz, 1H) , 3.41 (s, 3H) , 3.20 (s, 3H) , 3.12 –3.03 (m, 2H) , 2.78 –2.61 (m, 2H) , 2.38 (s, 2H) , 1.80 (s, 8H) .
[0663] Compound 429
[0664] Following the preparation of Compound 229 and the General Procedure for Metal-Catalyzed Cross-Coupling, Compound 429 was obtained. 1H NMR (400 MHz, ) δ 9.78 (d, J = 17.7 Hz, 1H) , 8.37 (dd, J = 4.5, 1.8 Hz, 1H) , 7.99 (s, 1H) , 7.79 (d, J = 0.8 Hz, 1H) , 7.75 –7.63 (m, 2H) , 7.06 –7.00 (m, 1H) , 6.92 (t, J = 5.5 Hz, 1H) , 6.86 –6.78 (m, 2H) , 6.45 (t, J = 8.9 Hz, 1H) , 6.12 (d, J = 5.3 Hz, 1H) , 4.80 (q, J = 6.4 Hz, 2H) , 4.44 (s, 1H) , 4.23 (d, J = 17.3 Hz, 4H) , 3.78 (t, J = 5.8 Hz, 1H) , 3.73 –3.63 (m, 5H) , 3.60 (t, J = 5.8 Hz, 1H) , 3.45 (s, 3H) , 3.20 (s, 3H) , 3.14 –3.02 (m, 2H) , 2.72 (s, 2H) , 2.38 (s, 2H) , 2.28 –2.15 (m, 2H) , 1.81 (s, 8H) .
[0665] Compound 439
[0666] Following the preparation of Compound 229 and the preparation of Compound 429, compound 439 was obtained. 1H NMR (400 MHz, DMSO-d6) δ 12.15 (d, J = 7.7 Hz, 1H) , 10.81 (s, 1H) , 8.07 (dd, J = 11.6, 0.8 Hz, 1H) , 7.73 (s, 1H) , 7.65 (dd, J =11.6, 0.8 Hz, 1H) , 7.32 (dd, J = 13.4, 1.7 Hz, 1H) , 7.20 –7.10 (m, 1H) , 6.92 (dd, J =24.1, 5.9 Hz, 1H) , 6.64 –6.56 (m, 1H) , 6.46 –6.35 (m, 1H) , 6.14 –6.05 (m, 1H) , 4.64 –4.53 (m, 2H) , 4.30 (d, J = 19.7 Hz, 2H) , 3.79 –3.68 (m, 9H) , 3.64 –3.53 (m, 2H) , 3.21 –2.94 (m, 8H) , 2.71 –2.59 (m, 1H) , 2.52 –2.48 (m, 1H) , 2.35 –2.12 (m, 3H) , 1.97 –1.88 (m, 1H) , 1.76 –1.60 (m, 8H) .
[0667] Compound 459
[0668] Following the preparation of Compound 360, compound 459 was obtained. 1H NMR (400 MHz, ) δ 9.65 (d, J = 18.0 Hz, 1H) , 8.05 (s, 1H) , 7.85 –7.74 (m, 2H) , 7.72 (s, 1H) , 7.25 –7.23 (m, 1H) , 7.18 –7.09 (m, 1H) , 6.99 –6.93 (m, 1H) , 6.86 (t, J = 7.6 Hz, 1H) , 6.75 –6.69 (m, 1H) , 6.50 –6.42 (m, 2H) , 6.14 (d, J = 15.2 Hz, 1H) , 4.80 (dd, J = 11.6, 6.0 Hz, 2H) , 4.45 (s, 1H) , 4.27 (s, 1H) , 4.07 (dd, J = 12.4, 4.4 Hz, 1H) , 3.76 (t, J = 6.0 Hz, 1H) , 3.59 –3.50 (m, 5H) , 3.38 (s, 3H) , 3.20 (s, 3H) , 3.12 (s, 4H) , 3.08 –3.03 (m, 2H) , 2.95 –2.87 (m, 1H) , 2.81 –2.72 (m, 1H) , 2.55 –2.45 (m, 1H) , 2.35 (s, 2H) , 2.24 –2.02 (m, 3H) , 2.00 (s, 1H) , 1.95 –1.80 (m, 9H) .
[0669] Compound 462
[0670] Following the preparation of Compound 321, compound 462 was obtained via Buchwald-Hartwig Cross Coupling Reaction and Suzuki Coupling Reaction. 1H NMR (400 MHz, Chloroform-d) δ 9.52 (d, J = 27.0 Hz, 1H) , 8.17 (s, 1H) , 7.75 (d, J = 4.7 Hz, 1H) , 7.64 (d, J = 2.9 Hz, 1H) , 7.22 (dd, J = 8.1, 4.0 Hz, 1H) , 6.93 (dd, J = 12.4, 6.3 Hz, 1H) , 6.84 –6.76 (m, 2H) , 6.68 –6.56 (m, 3H) , 6.42 (t, J = 8.9 Hz, 1H) , 6.17 –6.06 (m, 1H) , 4.77 (q, J = 6.1 Hz, 2H) , 4.46 (s, 1H) , 4.27 (s, 1H) , 3.97 (s, 4H) , 3.74 (d, J = 2.0 Hz, 4H) , 3.65 (dd, J = 9.7, 5.0 Hz, 1H) , 3.55 (t, J = 5.7 Hz, 1H) , 3.45 –3.09 (m, 10H) , 3.03 (dt, J = 8.4, 6.3 Hz, 2H) , 2.76 –2.56 (m, 2H) , 2.39 –2.29 (m, 2H) , 2.27 –2.14 (m, 2H) , 1.71 (s, 5H) , 1.30 –1.18 (m, 3H) .
[0671] Compound 483
[0672] Following the preparation of Compound 321 and the General Procedure for Metal-Catalyzed Cross-Coupling, Compound 483 was obtained. 1H NMR (400 MHz, ) δ 9.70 (d, J = 13.4 Hz, 1H) , 8.69 –8.52 (m, 1H) , 7.97 (dd, J = 10.2, 6.9 Hz, 2H) , 7.64 –7.46 (m, 2H) , 6.97 –6.75 (m, 4H) , 6.47 (t, J = 8.9 Hz, 1H) , 6.25 (dd, J = 7.5, 5.6 Hz, 1H) , 6.13 (d, J = 13.1 Hz, 1H) , 4.68 –4.52 (m, 2H) , 4.46 (s, 1H) , 4.25 (s, 1H) , 4.00 (d, J =1.9 Hz, 4H) , 3.83 –3.61 (m, 7H) , 3.57 (t, J = 5.8 Hz, 1H) , 3.38 (s, 3H) , 3.21 (s, 3H) , 3.00 (dt, J = 12.7, 6.4 Hz, 2H) , 2.81 –2.57 (m, 2H) , 2.35 (s, 2H) , 2.21 (d, J = 4.8 Hz, 1H) , 2.15 (s, 4H) , 1.79 –1.69 (m, 4H) .
[0673] Compound 490
[0674] Following the preparation of Compound 321 and the preparation of Compound 230, compound 490 was obtained. 1H NMR (400 MHz, DMSO-d6) δ 11.89 (d, J = 8.7 Hz, 1H) , 10.81 (s, 1H) , 8.07 (dd, J = 10.1, 1.0 Hz, 1H) , 7.73 (d, J = 1.6 Hz, 1H) , 7.65 (dd, J = 11.3, 1.0 Hz, 1H) , 7.32 (dd, J = 13.3, 1.8 Hz, 1H) , 7.08 (d, J = 8.1 Hz, 1H) , 6.79 (dd, J = 20.2, 6.2 Hz, 1H) , 6.44 –6.42 (m, 1H) , 6.12 –6.00 (m, 3H) , 4.61-4.58 (m, 2H) , 4.29 (d, J = 22.9 Hz, 2H) , 3.74 (s, 5H) , 3.64 (d, J = 4.2 Hz, 4H) , 3.56 (s, 5H) , 3.08 -3.02 (m, 8H) , 2.70 –2.58 (m, 1H) , 2.50 (d, J = 3.9 Hz, 1H) , 2.30 (s, 1H) , 2.26 –2.12 (m, 2H) , 1.93 (dd, J = 10.0, 5.2 Hz, 1H) , 1.68 (s, 8H) .
[0675] Compound 508
[0676] Following the preparation of Compound 321, compound 508 was obtained. 1H NMR (400 MHz, CDCl3) δ 9.68 (s, 1H) , 8.33 (s, 1H) , 8.12 (s, 1H) , 7.92 (s, 1H) , 7.77 (s, 1H) , 7.67 (d, J = 4.4 Hz, 1H) , 7.56 (t, J = 12.6 Hz, 1H) , 7.22 (d, J = 12.4 Hz, 1H) , 7.01 –6.81 (m, 2H) , 6.12 (d, J = 11.1 Hz, 1H) , 4.78 (q, J = 6.2 Hz, 2H) , 4.43 (d, J =14.5 Hz, 5H) , 4.26 (s, 1H) , 3.77 (t, J = 5.8 Hz, 1H) , 3.65 (dd, J = 11.6, 4.9 Hz, 1H) , 3.59 (s, 1H) , 3.50 (s, 4H) , 3.30 (d, J = 86.9 Hz, 6H) , 3.14 –3.00 (m, 3H) , 2.74 –2.60 (m, 2H) , 2.35 (s, 2H) , 2.24 (s, 1H) , 2.19 (s, 4H) , 1.71 (s, 4H) .
[0677] Compound 517
[0678] Following the preparation of Compound 321, compound 517 was obtained. 1H NMR (400 MHz, ) δ 9.40 (d, J = 14.8 Hz, 1H) , 7.93 (s, 1H) , 7.76 (d, J = 4.1 Hz, 1H) , 7.66 (d, J = 3.6 Hz, 1H) , 7.29 (t, J = 8.3 Hz, 1H) , 6.91 (dd, J = 9.1, 6.2 Hz, 1H) , 6.86 –6.79 (m, 2H) , 6.71 –6.67 (m, 1H) , 6.44 (m, 1H) , 6.40 –6.34 (m, 1H) , 6.29 (s, 1H) , 6.23 (d, J = 12.6 Hz, 1H) , 6.14 (d, J = 19.0 Hz, 1H) , 4.79 (q, J = 6.0 Hz, 2H) , 4.46 (s, 1H) , 4.27 (s, 1H) , 3.77 (t, J = 5.8 Hz, 1H) , 3.69 (m, 5H) , 3.65 (s, 4H) , 3.57 (t, J = 5.8 Hz, 1H) , 3.35 (s, 3H) , 3.17 (s, 3H) , 3.05 (dd, J = 14.0, 6.4 Hz, 2H) , 2.69 (ddd, J = 15.2, 13.7, 8.9 Hz, 2H) , 2.35 (d, J = 3.9 Hz, 2H) , 2.31 –2.15 (m, 2H) , 1.78 (s, 8H) .
[0679] Compound 518
[0680] Following the preparation of Compound 321, compound 518 was obtained. 1H NMR (400 MHz, CDCl3) δ 9.76 (d, J = 11.7 Hz, 1H) , 8.09 (s, 1H) , 7.60 (d, J =22.3 Hz, 2H) , 7.30 (dd, J = 8.2, 4.0 Hz, 1H) , 7.09 –6.92 (m, 2H) , 6.88 –6.69 (m, 3H) , 6.46 (t, J = 8.7 Hz, 2H) , 6.27 (d, J = 6.5 Hz, 1H) , 6.13 (d, J = 10.3 Hz, 1H) , 4.89 -4.70 (m, 5H) , 4.61 (dd, J = 7.7, 4.4 Hz, 2H) , 4.43 (s, 1H) , 4.24 (s, 1H) , 4.12 (d, J =5.7 Hz, 2H) , 3.71 (s, 6H) , 3.55 (t, J = 5.6 Hz, 1H) , 3.24 (d, J = 61.0 Hz, 4H) , 3.01 (dd, J = 12.1, 6.2 Hz, 2H) , 2.81 –2.57 (m, 2H) , 2.33 (s, 2H) , 2.24 (dd, J = 11.0, 5.3 Hz, 1H) , 2.17 (d, J = 5.0 Hz, 3H) , 1.83 (d, J = 35.3 Hz, 8H) .
[0681] Compound 519
[0682] Following the preparation of compound 1. Compound 519 was prepared by Suzuki Coupling of Intermediate I-35 with Intermediate I-26a. 1H NMR (400 MHz, Chloroform-d) δ 9.77 (d, J = 30.4 Hz, 1H) , 8.12 (s, 1H) , 7.78 (d, J = 40.6 Hz, 2H) , 7.17 (q, J = 7.2 Hz, 1H) , 6.97 (dd, J = 9.3, 6.1 Hz, 1H) , 6.83 (t, J = 6.8 Hz, 2H) , 6.73 (dd, J = 8.3, 1.9 Hz, 2H) , 6.68 (d, J = 2.0 Hz, 1H) , 6.15 (d, J = 14.4 Hz, 1H) , 4.81 (q, J = 5.6 Hz, 2H) , 4.46 (s, 1H) , 4.34 –4.23 (m, 2H) , 4.14 –4.04 (m, 1H) , 3.85 –3.74 (m, 2H) , 3.69 (dd, J = 9.2, 5.1 Hz, 1H) , 3.60 (dt, J = 11.4, 7.0 Hz, 2H) , 3.49 –3.29 (m, 5H) , 3.19 (s, 3H) , 3.12 –3.02 (m, 4H) , 2.77 –2.62 (m, 3H) , 2.36 (s, 2H) , 2.26 (q, J = 7.2, 6.4 Hz, 2H) , 1.37 –1.21 (m, 3H) .
[0683] Compound 507
[0684] Following the preparation of Compound 321, compound 507 was obtained. 1H NMR (400 MHz, Chloroform-d) δ 9.73 (d, J = 15.5 Hz, 1H) , 8.10 (s, 1H) , 7.60 (t, J =2.3 Hz, 1H) , 7.56 (dd, J = 17.4, 2.1 Hz, 1H) , 7.51-7.45 (m, 1H) , 7.16 –7.05 (m, 2H) , 6.97-6.92 (m, 1H) , 6.88 –6.79 (m, 2H) , 6.72-6.69 (m, 1H) , 6.48 (t, J = 8.9 Hz, 1H) , 6.25 (dt, J = 10.0, 2.1 Hz, 1H) , 6.15-6.10 (m, 1H) , 4.59 (q, J = 6.4 Hz, 2H) , 4.44 (s, 1H) , 4.23 (s, 1H) , 4.01 (s, 4H) , 3.75 (t, J = 5.8 Hz, 1H) , 3.66 (dd, J = 10.0, 5.1 Hz, 1H) , 3.55 (t, J = 5.8 Hz, 1H) , 3.42 –3.29 (m, 7H) , 3.17 (s, 3H) , 3.02-2.96 (m, 2H) , 2.76 –2.59 (m, 2H) , 2.33 –2.32 (m, 2H) , 2.27-2.13 (m, 6H) , 1.96 –1.85 (m, 4H) .
[0685] Compound 508
[0686] Following the preparation of Compound 1, compound 508 was obtained. 1H NMR (400 MHz, CDCl3) δ 9.68 (s, 1H) , 8.33 (s, 1H) , 8.12 (s, 1H) , 7.92 (s, 1H) , 7.77 (s, 1H) , 7.67 (d, J = 4.4 Hz, 1H) , 7.56 (t, J = 12.6 Hz, 1H) , 7.22 (d, J = 12.4 Hz, 1H) , 7.01 –6.81 (m, 2H) , 6.12 (d, J = 11.1 Hz, 1H) , 4.78 (q, J = 6.2 Hz, 2H) , 4.43 (d, J = 14.5 Hz, 5H) , 4.26 (s, 1H) , 3.77 (t, J = 5.8 Hz, 1H) , 3.65 (dd, J = 11.6, 4.9 Hz, 1H) , 3.59 (s, 1H) , 3.50 (s, 4H) , 3.30 (d, J = 86.9 Hz, 6H) , 3.14 –3.00 (m, 3H) , 2.74 –2.60 (m, 2H) , 2.35 (s, 2H) , 2.24 (s, 1H) , 2.19 (s, 4H) , 1.71 (s, 4H) .
[0687] Compound 620
[0688] Following the preparation of Compound 321, compound 620 was obtained. 1H NMR (400 MHz, DMSO-d6) δ 12.09 (d, J = 7.9 Hz, 1H) , 10.80 (s, 1H) , 8.07 (d, J =11.8 Hz, 1H) , 7.73 (s, 1H) , 7.65 (d, J = 11.9 Hz, 1H) , 7.36 –7.30 (m, 1H) , 7.26 –7.19 (m, 1H) , 7.00 –6.88 (m, 2H) , 6.87 –6.78 (m, 1H) , 6.16 –6.05 (m, 1H) , 4.64 –4.54 (m, 2H) , 4.31 (d, J = 21.2 Hz, 2H) , 4.03 (s, 4H) , 3.76 (dd, J = 12.5, 4.6 Hz, 1H) , 3.64 –3.53 (m, 2H) , 3.10 –3.02 (m, 3H) , 3.01 –2.97 (m, 6H) , 2.71 –2.59 (m, 1H) , 2.54 –2.48 (m, 1H) , 2.35 –2.11 (m, 4H) , 2.06 (s, 4H) , 1.96 –1.88 (m, 1H) , 1.67 –1.58 (m, 4H) , 0.71 –0.65 (m, 2H) , 0.58 –0.50 (m, 2H) .
[0689] Compound 627
[0690] Following the preparation of Compound 321, compound 627 was obtained. 1H NMR (400 MHz, Chloroform-d) δ 9.51 (d, J = 18.4 Hz, 1H) , 8.05 –7.99 (m, 2H) , 7.74 (d, J = 3.3 Hz, 1H) , 7.64 (d, J = 3.5 Hz, 1H) , 6.92 –6.89 (m, 2H) , 6.88 –6.86 (m, 1H) , 6.60 (s, 1H) , 6.17 –6.05 (m, 1H) , 5.81 –5.74 (m, 1H) , 4.78 (q, J = 6.2 Hz, 2H) , 4.45 (s, 1H) , 4.30 –4.08 (m, 5H) , 3.81 (s, 3H) , 3.77 –3.73 (m, 1H) , 3.73 –3.67 (m, 1H) , 3.58 –3.53 (m, 1H) , 3.39 –3.10 (m, 6H) , 3.07 –3.01 (m, 2H) , 3.00 –2.92 (m, 4H) , 2.78 –2.58 (m, 2H) , 2.38 –2.31 (m, 2H) , 2.30 –2.18 (m, 2H) , 2.15 (s, 4H) , 1.75 –1.70 (m, 4H) .
[0691] Compound 321-A and compound 321-B
[0692] Note: *and #indicates that this atom is a single chiral center with either R or S absolute configuration. Compound 321-A and Compound 321-B are enantiomers of each other, that is, if *in Compound 321-A is S (i.e., Compound 630) , then #in Compound 321-B is R (i.e., Compound 629) ; conversely, if *in Compound 321-A is R(i.e., Compound 629) , then #in Compound 321-B is S (i.e., Compound 630) .
[0693] Compound 321 was resolved by chiral preparative HPLC to afford two enantiomers: compound 321-A (first eluting fraction) and compound 321-B (second eluting fraction) , using the General Chiral Preparative HPLC Method described in Resolution Methods for Chiral Compounds.
[0694] MeTHOD:
[0695] Column: Daicel CHIRALPAK IH, 250*4.6 mm, 5μm; Mobile phase A: CAN; Mobile phase B: IPA; Wavelength (nm) : 254nm;
[0696] Gradient:
[0697] Other chiral compounds can all be prepared and separated by General Chiral Preparative HPLC Method or General Chiral SFC Method described in Resolution methods, with appropriate adjustment of the mobile phase.
[0698] Following the preparation method disclosed herein, the disclosed compounds were prepared using appropriate starting materials and intermediates, along with suitable protective group chemistry when required, and were characterized by mass spectrometry.
[0699] Table 1 The mass spectrometry data of the disclosed compounds.
[0700] Example 2. In vitro activity evaluation
[0701] 1. STAT6-HiBiT in A549 cells
[0702] Degradation of STAT6 in endogenously tagged STAT6-HiBiT A549 cells was quantitatively measured using the HiBiT Lytic Detection System (Promega, 3040) . A549 (STAT6-HiBiT) cells were seeded in 384-well plates with a density of 1.25k cells per well in 20 μL fresh media. Compounds were then added to the assay plates using the Apricot S3 with a final top concentration of up to 10 μM in a 4-fold dilution series with total of 10 doses. The assay plates were then incubated for 24 hours at 37℃ under 5%CO2. At the assay endpoint, 20 μL of HiBiT Lytic Reagent was added to each well and agitated on a plate shaker at 300 rpm for 10 minutes at room temperature. Luminescence was read on PHERAStar FSX Instrument (1s integration time) . Data were analyzed by GraphPad Prism 8.0 and dose-dependent STAT6 degradation was fitted using the four-parameter inhibitor vs. response nonlinear regression.
[0703] Results: Compounds of the present disclosure showed DC50 values in the following ranges: 0 <DC50 <500 nM.
[0704] Table 2 DC50 values of compounds in STAT6-HiBiT in A549 cells
[0705] 2. Jurkat-HiBiT-STAT6 cells assay
[0706] Assay Procedure
[0707] a. Thawing Jurkat-HiBiT-STAT6 cell
[0708] 1) Thaw the vial by gentle agitation in a 37℃ water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 minutes) .
[0709] 2) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70%ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
[0710] 3) Transfer the vial contents to a centrifuge tube containing 9.0 mL complete growth medium and spin at approximately 300 × g for 5 minutes.
[0711] 4) Resuspend cell pellet with the recommended complete growth medium and dispense into a 25 cm2 or a 75 cm2 culture flask.
[0712] 5) Incubate the cells at a 37℃, 5% (v / v) CO2 incubator.
[0713] b. Jurkat-HiBiT-STAT6 cell cryopreservation
[0714] 1) Preparation of frozen medium: 10%DMSO + 90%FBS.
[0715] 2) Collect the cells into a clean 50 ml tube and centrifuge at 225 ×g for 10 min. Resuspend the cell pellet with appropriate volume of frozen medium and aliquot a sample for counting using the Automated Cell Counter. Dilute the cells to make sure the cell density is no more than 2-5× 106 cells / ml of freezing media. Transfer 1ml of cell to appropriately labelled vial (corning, 430659) . Transfer vials to Mr. FrostyTM Freezing Container (Thermo ScientificTM, 5100-0001) with Isopropyl alcohol, then transfering to -80℃ freezer for 24h.
[0716] 3) Next day, transfer to liquid nitrogen dewar for long-term storage.
[0717] c. Prepare Lysate samples
[0718] 1) Compounds are dissolved at 10 mM stock solution. Dilute the stock solution to 5 mM, transfer 36 uL of diluted solution to a 384 PP-plate. Perform 4 folds, 10-points dilution via transferring 8 uL compound into 24 uL DMSO. The compound source plate map is shown in the below.
[0719] 2) Transfer 40nl compounds from compound source plate into 384-well cell plate (Corning 3570) .
[0720] 3) On the day of experiment cells at passage 14 transfer the cells into a clean 50ml tube and centrifuge at 1200rpm for 5 min.
[0721] 4) Resuspend the cell pellet with appropriate volume of pre-warmed complete growth medium and aliquot a sample for counting using the Automated Cell Counter.
[0722] 5) According to the cell density, dilute cells to designed concentration (4000cells / 40ul / well) and seed cells into 384 well cell plates (Corning 3570) . Keep some wells for no cell control (only add medium) which will also be tested the HiBiT signal.
[0723] 6) Centrifuge at 1000rpm for 1 min. Incubate for 24 hrs at 37℃, 5%CO2 incubator.
[0724] d. HiBiT assay and plate Read
[0725] 1) Remove cell plate from the incubator and equilibrate to room temperature.
[0726] 2) Add a volume of Nano-Glo HiBiT Lytic Reagent equal to the culture medium in each well, Agitate on a plate shaker at 600 rpm for 15 minutes at room temperature.
[0727] 3) Read on Ensight.
[0728] e. Data Processing &Analysis
[0729] Average signal from ‘no cell’ wells was subtracted from experimental wells prior to calculating signal of sample, HC, LC, and %Relative
[0730] The HiBiT signals will be plotted using XLfit.
[0731] Calculate the DC50 by fitting the Curve using Xlfit (v5.3.1.3) , equation 201:
[0732] 4 Parameter Logistic Model
[0733] fit = (A+ ( (B-A) / (1+ ( (x / C) ^D) ) ) )
[0734] A: Bottom
[0735] B: Top
[0736] C: DC50
[0737] D: Slope
[0738] HC: The signal for DMSO treated cells
[0739] LC: The signal for Medium
[0740] f. Meet QC criteria: Z’ >0.6; %CV of Max <10%; SD of duplicates<20%;
[0741] or
[0742] The results was shown in table 3,
[0743] Table 3 DC50 and MaxDeg%values in Jurkat-HiBiT-STAT6 cell
[0744] Note: MaxDeg%denotes the maximum degradation efficiency
[0745] 3. HTRF assay to assess compound capability of STAT6-CRBN ternary complex formation
[0746] a. Methodology
[0747] 1) Reagent Stocks
[0748] 2) Consumables
[0749] 3) Instrument
[0750] b. Assay Procedure
[0751] 1) Assay condition:
[0752] 1.1 Assay Format: 384 well plate
[0753] 1.2 Reaction Volume: 15 μL
[0754] 1.3 STAT6, His tag: 50nM
[0755] 1.4 CRBN-DDB1, SA-tag: 100nM
[0756] 1.5 His-Tb: 1nM
[0757] 1.6 SA-XL665: 15nM
[0758] 1.7 CRBN-PROTAC pre-incubation: 30min at RT
[0759] 1.8 CRBN-PROTAC-STAT6 incubation: 30min at RT
[0760] 1.9 DMSO concentration: 1%
[0761] 1.10 HTRF reagents (donor and acceptor) incubation time: 30min
[0762] 2) Assay procedure:
[0763] 2.1 Dispense 150nL serial diluted PROTAC + DMSO to ProxiPlate-384 Plus, centrifuge the plate at 200*g for 1min at RT
[0764] 2.2 Transfer 5uL CRBN protein to each well, centrifuge the plate at 200*g for 1min at RT, shake the plate at 600 rpm for 1min
[0765] 2.3 Pre-incubate CRBN and PROTAC at RT for 30min
[0766] 2.4 Transfer 5uL STAT6 protein to each well, centrifuge the plate at 200*g for 1min at RT, shake the plate at 600 rpm for 1min
[0767] 2.5 Incubate the plate at RT for 30min
[0768] 2.6 Transfer 5uL detection pair to each well, centrifuge the plate at 200*g for 1min at RT, shake the plate at 600 rpm for 1min
[0769] 2.7 Incubate the plate at RT for 30min
[0770] 2.8 Read the plate using Envision (Ex=615nm, Em=665nm)
[0771] 2.9 Plot DRC with raw data by Xlfit and GraphPad
[0772] The results was shown in table 4,
[0773] Table 4 The results of HTRF assay to assess compound capability of STAT6-CRBN ternary complex formation
[0774] 4. STAT6 MSD in A549
[0775] a. Methodology
[0776] b. Cryopreservation and thawing
[0777] (1) Thawing A549 cell:
[0778] 1) Thaw the A549 vial (from ATCC, CRM-CCL-185) by gentle agitation in a 37℃ water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 minutes) .
[0779] 2) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70%ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
[0780] 3) Transfer the vial contents to a centrifuge tube containing 9.0 mL complete growth medium and spin at approximately 225×g for 10 minutes.
[0781] 4) Resuspend cell pellet with the recommended complete growth medium and dispense into a 25 cm2 or a 75 cm2 culture flask.
[0782] 5) Incubate the cells at a 37℃, 5% (v / v) CO2 incubator.
[0783] (2) A549 cell cryopreservation
[0784] 1) Preparation of frozen medium: 10%DMSO + 90%FBS.
[0785] 2) The cells in good growth state or in logarithmic phase were selected for cryopreservation. Discard the medium and wash cell with PBS, add 3ml TrypLETMExpress into the T225 flask and incubate fot 3 min at 37℃ incubator. Then add 7 ml medium to the T225 flask and transfer the cells into a clean 15 ml tube and centrifuge at 225×g for 5 min. Resuspend the cell pellet with appropriate volume of frozen medium and aliquot a sample for counting using the Automated Cell Counter. Dilute the cells to make sure the cell density is no more than 2-5× 106 cells / ml of freezing media. Transfer 1ml of cell to appropriately labelled vial (corning, 430659) . Transfer vials to Mr. FrostyTM Freezing Container (Thermo ScientificTM, 5100-0001) with Isopropyl alcohol, then transfering to -80℃ freezer for 24h.
[0786] 3) Next day, transfer to liquid nitrogen dewar for long-term storage.
[0787] (3) Prepare Lysate samples
[0788] 1) On the day of experiment cells, Discard the medium and wash cell with PBS, add 3ml trypsin into the T225 flask and incubate for 5 min at 37℃ incubator. Then add 7 ml medium to the T225 flask and transfer the cells into a clean 15 ml tube and centrifuge at 225×g for 5 min.
[0789] 2) Resuspend the cell pellet with appropriate volume of pre-warmed complete growth medium and aliquot a sample for counting using the Automated Cell Counter.
[0790] 3) According to the cell density, dilute cells to designed concentration (2*104 cells / 80ul / well) and seed cells into Corning 3599 cell plates, incubate overnight at 37℃incubator.
[0791] 4) Compounds are dissolved at 1 mM stock solution. Transfer 30 uL of diluted solution to a 384 pp-plate (LABCYTE, PP-0200) . Perform 3 fold, 10-point dilution via transferring 10 uL compound into 20 μL DMSO.
[0792] 5) The intermediate 2X compounds plate is prepared by acustic droplet dispense of 200 nL of serially diluted DMSO solution to 96-well plate (Corning 3894) per well by Echo 655, and then back-fill with 100ul medium to Corning 3894 plate.
[0793] 6) Transfer 80ul medium including 2X compounds into cell plate (Corning 3599) .
[0794] 7) To mix, manually (by hand) gently move the plate (Corning 3599) left-to-right and forward-and-back on a flat surface 3 times. Incubate for 24 hrs at 37℃incubator.
[0795] 8) Discard the medium. Add 70ul lysis buffer per well. Seal the plate, and shake at 600 rpm in 4℃ about 30 min.
[0796] (4) MSD assay and plate Read
[0797] 1) Coat the Bare MSD plate (L15XA-3) with capture antibody (Mouse Abnova H00006778 Lot#00046598, dilution ratio 1: 500) in PBS, at 40ul / well. Shake overnight at 600rpm in 4℃.
[0798] 2) Wash MSD coated bare plate 3x with 150ul / well of 1x TBST (CST#9997S) .
[0799] 3) Block MSD plates with 150ul of blocking buffer / well. Shake for 1hr at RT, 600rpm. Blocking buffer is 3%Bovine Serum Albumin in TBST.
[0800] 4) Wash MSD plate 1x with 150ul / well of 1x TBST.
[0801] 5) Add sample lysates to MSD plates by Apricot. 50ul / well. Shake for 1 hr at RT, 600rpm.
[0802] 6) Wash MSD plate 3x with 150ul / well of 1x TBST. Add Primary Detection antibody (Rabbit CST 5397 Lot#5, dilution ratio 1: 500) . 25ul / well. Shake for 1hr at RT, 600rpm.
[0803] 7) Wash MSD plate 3x with 150ul / well of 1x TBST. Add Secondary Detection antibody, SULFO-TAG anti-Rabbit antibody (R32AB-1 LotW0021059S) . Final [conc. ] : 1ug / ml. 25ul / well. Shake for 1hr at RT, 600rpm.
[0804] 8) Wash MSD plate 3x with 150ul / well of 1x TBST.
[0805] 9) Add 2X MSD reading buffer, 150ul / well. Diluted from 4X with water.
[0806] 10) Read on MESO SECTOR S 600.
[0807] c. Data Processing &Analysis
[0808] The MSD signals will be plotted using XLfit.
[0809] Calculate the DC50 by fitting the Curve using Xlfit (v5.3.1.3) , equation 201:
[0810] 4 Parameter Logistic Model
[0811] fit = (A+ ( (B-A) / (1+ ( (x / C) ^D) ) ) )
[0812] A: Bottom
[0813] B: Top
[0814] C: DC50
[0815] D: Slope
[0816] HC: The signal for DMSO treated cells
[0817] LC: The signal for lysis buffer
[0818] The results was shown in table 5.
[0819] Table 5 The DC50 and MaxDeg%values of STAT6 MSD in A549 cells
[0820] 5. STAT6 protac IL-4 luciferase reporter assay
[0821] a. Compound Dilution
[0822] Compounds were serially diluted 4-fold in dimethyl sulfoxide (DMSO) to generate an 8-point concentration gradient, with the top concentration set at 50 μM for this assay. The compound plate was sealed tightly and mixed by orbital shaking for 5 minutes to ensure homogeneous distribution.
[0823] b. Cell Culture and Preparation
[0824] The HEK293 IL-4 / IL-13 dual effector reporter cell line was employed in this assay. The complete growth medium for routine maintenance consisted of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v / v) fetal bovine serum (FBS) , 2 μg / mL puromycin, and 100 μg / mL hygromycin B. Cells were maintained at 37℃ in a humidified incubator with 5%CO2. The assay buffer used in subsequent steps comprised DMEM supplemented with 10%FBS
[0825] c. Assay Protocol
[0826] HEK293 IL-4 / IL-13 dual effector reporter cells were seeded into a 384-well assay plate (Cat. No. 761601, NEST) at a density of 4,000 cells per well using the assay medium. A volume of 40 μL of the cell suspension was added to each well of the assay plate, and the plate was incubated overnight at 37℃ to allow cell adherence. A 6x sample working solution was prepared, which included 8 final concentrations tested in triplicate, starting from 50 nM with 4-fold serial dilutions. A volume of 10 μL of the sample working solution was added to each well containing the cells. A 6x IL-4 working solution was prepared at a concentration of 0.6 ng / mL. A volume of 10 μL of the IL-4 working solution was added to each well containing the cells, after which the plate was incubated at 37℃ in a 5%CO2 atmosphere for 24 hours. Following the 24-hour incubation, 20 μL of prewarmed detection reagents was added to each well, and the luminescence signal was detected.
[0827] The results was shown in table 6,
[0828] Table 6 The results of STAT6 protac IL-4 luciferase reporter assay
[0829] 6. FLIPIN-293-T-REX-STAT6-HiBiT Degradation Assay
[0830] a. Compound Dilution
[0831] Test compounds were prepared as a 10-point, 4-fold serial dilution series in dimethyl sulfoxide (DMSO) . The top concentration was selected to achieve a final assay concentration of 100 nM upon dilution into the assay system, with subsequent dilution points decreasing sequentially by 4-fold. The compound plate was sealed and mixed by orbital shaking for 5 minutes to ensure homogeneity.
[0832] b. Cell Culture and Preparation
[0833] The FLIPIN-293-T-REX-STAT6-HiBiT cell line was maintained in complete growth medium consisting of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v / v) fetal bovine serum (FBS) . Cells were cultured at 37℃ in a humidified incubator with 5%CO2. The assay medium used for subsequent experimental steps was DMEM supplemented with 10%FBS.
[0834] c. Assay Protocol
[0835] FLIPIN-293-T-REX-STAT6-HiBiT cells were seeded into 384-well white opaque assay plates at a density of 4 × 103 cells per well in 40 μL of assay medium. Plates were incubated overnight at 37℃ in a humidified 5%CO2 incubator to allow cell adherence. Following overnight attachment, 6× working solutions of doxycycline and test compounds were prepared in assay medium. The doxycycline working solution was formulated to achieve a final assay concentration of 10 ng / mL, while test compound working solutions were prepared to yield final concentrations ranging from 100 nM in a 4-fold dilution series. A volume of 10 μL of the 6× doxycycline working solution was added to each well, immediately followed by 10 μL of the corresponding 6× test compound working solution. The plate was incubated at 37℃ in a humidified 5%CO2 atmosphere for 24 hours to enable compound treatment and doxycycline-induced STAT6-HiBiT expression. Following the 24-hour incubation, an equal volume (20 μL) of Promega HiBiT detection reagent was added to each well. After a 10-minute incubation at room temperature protected from light, luminescence signals (relative light units, RLUs) were quantified using a Molecular Devices SpectraMax iD5 multi-mode microplate reader in bottom-read mode to determine STAT6-HiBiT expression levels.
[0836] The results was shown in table 7.
[0837] Table 7 The results of FLIPIN-293-T-REX-STAT6-HiBiT Degradation Assay
[0838] Example 3. Pharmacokinetic (PK) study
[0839] 1. Intravenous (IV) and Oral (PO) Administration to Male SD Rats
[0840] A single-dose pharmacokinetic (PK) study was conducted in Sprague-Dawley (SD) rats following intravenous (IV) and oral (PO) administration. For IV administration, the test compounds were formulated in a vehicle consisting of DMA: PEG400: 10%Solutol in saline (10: 30: 60, v / v / v) at a concentration of 0.5 mg / mL and administered at a dose of 1 mg / kg. For PO administration, the compounds were formulated in Solutol: PEG400: Tween 80: saline (10: 40: 2: 48, v / v / v / v) at a concentration of 0.5 mg / mL and administered at a dose of 5 mg / kg. Blood samples were collected at the following time points: for IV, pre-dose, 0.0833, 0.25, 0.5, 1, 2, 4, 8, and 24 hours post-dose; for PO, pre-dose, 0.25, 0.5, 1, 2, 4, 8, and 24 hours post-dose. At each designated time point, approximately 0.2 mL of blood was collected from the jugular vein into EDTA-K2 anticoagulant tubes. Samples were centrifuged at 4,000 × g for 5 minutes at 4℃ to obtain plasma. Plasma concentrations were determined by liquid chromatography-tandem mass spectrometry (LC-MS / MS) . Pharmacokinetic parameters were calculated using Phoenix WinNonlin 8.0.
[0841] The disclosed compounds exhibit favorable pharmacokinetic profiles.
[0842] 2. Intravenous (IV) and Oral (PO) Administration to Male Cynomolgus Monkeys
[0843] A single-dose pharmacokinetic (PK) study was conducted in male cynomolgus monkeys following intravenous (IV) or oral (PO) administration. For IV administration, the test compounds were formulated in a vehicle consisting of DMA: PEG400: 10%Solutol in saline (10: 30: 60, v / v / v) at a concentration of 1 mg / mL and administered at a dose of 1 mg / kg. For PO administration, the compounds were formulated in Solutol: PEG400: Tween 80: saline (10: 40: 2: 48, v / v / v / v) at a concentration of 1 mg / mL and administered at a dose of 2.5 mg / kg. Blood samples were collected at the following time points: for IV, pre-dose, 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 hours post-dose; for PO, pre-dose, 0.25, 0.5, 1, 2, 4, 8, and 24 hours post-dose. Sample Collection and Processing: At each designated time point, approximately 0.6 mL of blood was collected by venipuncture of a peripheral vein into EDTA-K2 anticoagulant tubes. Samples were centrifuged at 2,000 × g for 10 minutes at 2–8℃ to obtain plasma. Bioanalysis and Data Analysis: Plasma concentrations were determined by liquid chromatography-tandem mass spectrometry (LC-MS / MS) . Pharmacokinetic parameters were calculated using Phoenix WinNonlin 8.0
[0844] The disclosed compounds exhibit favorable pharmacokinetic profiles, and the data are as follows,
[0845] Table 8 The results of Pharmacokinetic (PK) study in Cynomolgus Monkeys
[0846] 3. Oral (PO) Administration to Male CD-1 Mices
[0847] A single-dose pharmacokinetic (PK) study was conducted in male CD-1 mice following oral (PO) administration.
[0848] The test compounds were formulated in a vehicle consisting of Solutol: PEG400: Tween 80: saline (10: 40: 2: 48, v / v / v / v) at a concentration of 1 mg / mL and administered at a dose of 10 mg / kg. Blood Sampling Schedule: Blood samples were collected at pre-dose, 0.25, 0.5, 1, 2, 4, 8, and 24 hours. Sample Collection and Processing: At each designated time point, approximately 0.03 mL of blood was collected and placed into EDTA-K2 anticoagulant tubes. Samples were centrifuged at 4,000 × g for 5 minutes at 4℃ to obtain plasma. Bioanalysis and Data Analysis: Plasma concentrations were determined by liquid chromatography-tandem mass spectrometry (LC-MS / MS) . Pharmacokinetic parameters were calculated using Phoenix WinNonlin 8.0.
[0849] The disclosed compounds exhibit favorable pharmacokinetic profiles, and the data are as follows,
[0850] Table 9 The results of Pharmacokinetic (PK) study in CD-1 Mices
[0851] Example 4 Liver Microsomal Metabolic Stability
[0852] The compounds were incubated individually with liver microsomes from Beagle dog, Cynomolgus monkey and human. Reactions were initiated by addition of NADPH. At 0, 5, 15, 30, and 60 min, 20 μL aliquots were withdrawn and mixed with 200 μL acetonitrile containing internal standard to terminate the reaction. After protein precipitation, samples were centrifuged at 3, 700 rpm for 10 min. Supernatants were diluted 1: 1 with water and analyzed by LC-MS / MS.
[0853] Table 10 Incubation conditions
[0854] |
[0855] The peak-area ratio of analyte to internal standard (Aanalyte / AIS) is acquired directly from the instrument. The percentage remaining (%Control) is calculated for each non-zero time point by dividing its Aanalyte / AIS ratio by that of the t = 0 sample. Ln (%remaining) versus incubation time was plotted and fitted by linear regression. The elimination rate constant (k, min-1) , half-life (t1 / 2, min) , and intrinsic clearance (CLint, mL·min-1·mg-1 protein) were calculated as follows:
[0856] k = -slope
[0857] T1 / 2 = 0.693 / k
[0858] CLint = k / Cprotein
[0859] where Cprotein (mg·mL-1) is the microsomal protein concentration (mg·mL-1) in the incubation.
[0860] The results was shown in table 11,
[0861] Table 11 The results of Liver Microsomal Metabolic Stability
[0862] Note: “NA” means: no metabolism of the compound in this system, with 100%parent drug remaining after 60-minute incubation. Consequently, no valid kinetic parameters could be derived.
[0863] Example 5 MC903-Induced Atopic Dermatitis Model in C57BL / 6 Mice and Efficacy Evaluation of Test Articles
[0864] Animal Grouping and Experimental Design
[0865] On Day 0, C57BL / 6 mice were randomized into several groups (normal control, vehicle control, and several treatment groups, n = 8 per group) based on ear thickness and body weight.
[0866] Model Induction
[0867] From Day 0 to Day 15, mice in the normal control group received 25 μL of ethanol applied uniformly to the right ear, while mice in the vehicle control and treatment groups received 25 μL of 45 μM MC903 applied uniformly to the right ear to induce atopic dermatitis (AD) .
[0868] Dosing Regimen
[0869] From Day 4 to Day 15, the normal control and vehicle control groups were administered vehicle (Solutol: PEG400: Tween 80: saline = 10: 40: 2: 48, v / v / v / v) by oral gavage, and the treatment groups were administered test articles (8 mg / kg) by oral gavage.
[0870] Sample Collection and Analysis
[0871] Prior to the final dose, approximately 100 μL of non-anticoagulated blood was collected from the medial canthus of one eye for ELISA determination of serum total IgE levels. Subsequently, animals were euthanized, and spleen tissues were harvested, homogenized, and analyzed by Western blot for total STAT6 protein expression.
[0872] Conclusion: The disclosed compounds significantly reduced plasma IgE levels and markedly degraded total STAT6 protein in mouse spleen in the MC903 atopic dermatitis model.
[0873] Example 6 MC903-Induced Atopic Dermatitis Model in B-hIL4 / IL4RA mice
[0874] Animal Grouping and Experimental Design
[0875] On Day 0, B-hIL4 / IL4RA mice were randomized into several groups (normal control, vehicle control, n = 8 per group) based on ear thickness and body weight.
[0876] Model Induction
[0877] From Day 0 to Day 15, mice in the normal control group received 25 μL of ethanol applied uniformly to the right ear, whereas mice in the vehicle control, positive control, and treatment groups received 25 μL of 45 μM MC903 applied uniformly to the right ear to induce atopic dermatitis (AD) .
[0878] Dosing Regimen
[0879] From Day 4 to Day 15, the normal control and vehicle control groups were administered vehicle (Solutol: PEG400: Tween 80: saline = 10: 40: 2: 48, v / v / v / v) by oral gavage. The positive control group received dupilumab at 25 mg / kg via subcutaneous injection twice weekly. The treatment groups were administered test articles at 8 mg / kg by oral gavage.
[0880] Sample Collection and Analysis
[0881] Prior to the final dose, approximately 100 μL of non-anticoagulated blood was collected from the medial canthus of one eye for ELISA determination of serum total IgE levels. Subsequently, animals were euthanized, and spleen tissues were harvested, homogenized, and analyzed by Western blot for total STAT6 protein expression.
[0882] Conclusion: The disclosed compounds significantly reduced serum IgE levels and markedly degraded total STAT6 protein in mouse spleen in the MC903 atopic dermatitis model.
Claims
A compound of Formula I, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a deuterated compound thereof,wherein:X1 is selected from the group consisting of N and CH;ring A is a ring selected from the group consisting of aryl; 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, spiro, or bridged carbocyclyl, 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, tricyclic, spiro or bridged heterocyclyl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered monocyclic, or bicyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring C is a ring selected from the group consisting of aryl; 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring B is a ring selected from the group consisting of aryl; 4-7 membered saturated or partially unsaturated carbocyclyl, 4-7 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-10 membered saturated or partially unsaturated bicyclic heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-15 membered saturated or partially unsaturated tricyclic heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-15 membered tricyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;L1 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from the group consisting of aryl, 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl, 6-16 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl; 4-10 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 6-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 8-14 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;L3 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, -C0-6 alkyl-CO-, -C0-6 alkyl-CONR1-, -C0-6 alkyl-CONR1-C0-6 alkyl -CO-C0-6 alkyl-, -C0-6 alkyl-SO2-, -C0-6 alkyl-S (O) 2NR1-, or -C0-6 alkyl-NR1-;L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (O) NH-, -C (S) -, -CHF-. -CF2-, -NR1-, -O-, -S-, or -S (O) 2-;wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;each of Ra1, Ra2 and Ra3 is independently selected from the group consisting of CN, hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated carbocyclyl or heterocyclyl;wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;Ra1, Ra2, Ra3, R3 and R4 are optionally substituted by one or more R5;R5 is selected from the group consisting of oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated carbocyclyl or heterocyclyl;R5 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR3R4;each of Rb1, Rb2 and Rb3 is independently selected from the group consisting of CN, hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;each of Rc1, Rc2, Rc3 and Rc4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONR1-C0-6 alkyl, -C0-6 alkyl-SO2-C0-6 alkyl, -C0-6 alkyl-S (O) 2NR1R2, -C0-6 alkyl-NR1R2, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl; each of Rc1, Rc2, Rc3 and Rc4 is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated carbocyclyl, or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, and C1-6 alkoxy; andeach of n1, n2, n3, n4, n5, n6, n7, n8, n9 and n10 is independently selected from the group consisting of 0, 1, and 2.A compound of Formula VIII, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a deuterated compound thereof,wherein,X1 is selected from the group consisting of N and CH;ring A is a ring selected from the group consisting of aryl, and 5-10 membered monocyclic, bicyclic, or tricyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring C is a ring selected from the group consisting of aryl, 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring B is a ring selected from the group consisting of aryl, 4-7 membered saturated or partially unsaturated carbocyclyl, 4-7 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-10 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-15 membered saturated or partially unsaturated tricyclic heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 8-15 membered tricyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;L1 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR1-, -SiR1R2-, -Si (OH) R1-, -Si (OH) 2-, -P (O) OR1-, -P (O) R1-, -P (O) NR1R2-, -S-, -OC (O) -, -C (O) O-, -C (O) -, -S (O) -, -S (O) 2-, -NR1S (O) 2-, -S (O) 2NR1-, -NR1C (O) -, -C (O) NR1-, -OC (O) NR1-, or -NR1C (O) O-; wherein -Cy-is independently an optionally substituted bivalent ring selected from the group consisting of aryl, 8-10 membered bicyclic aryl, 3-7 membered saturated or partially unsaturated carbocyclyl, 6-16 membered saturated or partially unsaturated spiro carbocyclyl, 8-10 membered bicyclic saturated or partially unsaturated carbocyclyl, 4-10 membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 6-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 8-14 membered bicyclic saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 8-10 membered bicyclic heteroaryl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (O) NH-, -C (S) -, -CHF-, -CF2-, -NR1-, -O-, -S-, or -S (O) 2;L4 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, -C0-6 alkyl-CO-, -C0-6 alkyl-CONR1-, -C0-6 alkyl-SO2-, -C0-6 alkyl-S (O) 2NR1-, or -C0-6 alkyl-NR1-;wherein R1 and R2 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;each of Ra1, Ra2 and Ra3 is independently selected from the group consisting of CN, hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NR3C (O) -C1-6 alkyl, -C (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;Ra1, Ra2, Ra3, R3 and R4 are optionally substituted by one or more R5;R5 is selected from the group consisting of oxo, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;R5 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR3R4;each of Rb1, Rb2 and Rb3 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;each of Rc1 and Rc2 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, (C1-6 alkyl) carbonyl, -NR3S (O) 2-C1-6 alkyl, -S (O) 2NR3R4, -NHR3C (O) -C1-6 alkyl, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C1-6 alkyl, -C0-6 alkyl-CO-C1-6 alkyl, -C0-6 alkyl-CONHR1, -C0-6 alkyl-SO2-C1-6 alkyl, -C0-6 alkyl-S (O) 2NR1-C1-6 alkyl, -C0-6 alkyl-NR1R2, -CO-C1-6 alkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl; andeach of Rc1 and Rc2 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl, or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, and C1-6 alkoxy;each of L1, L2, and L4 is optionally substituted by one or more more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, and C1-6 alkoxy;ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring D is optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl; andCy1 is a ring selected from the group consisting of 12-16 membered saturated or partially unsaturated spiro carbocyclyl; 8-10 membered saturated or partially unsaturated monocyclic heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 12-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 2, wherein L1 is selected from the group consisting of phenyl and 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, L1 is optionally substituted by one or more more substituents independently selected from the group consisting of CN, halogen, oxo, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, C1-6 alkoxy and C1-6 haloalkoxy.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claim 2-3, wherein Cy1 is a ring selected from the group consisting ofThe compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 1, wherein the compound has a structure of Formula XIV,X1 is selected from the group consisting of N and CH;each of X6, X7, X8, X9, and X10 is independently selected from the group consisting of N and CRx;Z1 is selected from the group consisting of NRp, O, S, C (O) , S (O) , S (O) 2 and CRxRy;Z2 is absent or selected from the group consisting of NRp, O, S, C (O) , SO, S (O) 2 and CRxRy;Z3 is absent or selected from the group consisting of NRp, O, S, C (O) , SO, S (O) 2 and CRxRy;each of Rp, Rx and Ry is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalkyl;ring A is a ring selected from the group consisting of C6-10 aryl, and 5-10 membered monocyclic, bicyclic, or tricyclic heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring C is a ring selected from the group consisting of C6-10 aryl; 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring G is a ring selected from the group consisting of C6-10 aryl, 5-10 membered heteroaryl and 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl; wherein ring G is optionally substituted by one or more substituents independently selected from the group consisting of CN, halogen, oxo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C3-8 cycloalkyl and C1-6 haloalkoxy;L2 is selected from the group consisting of a covalent bond and C1-3 bivalent hydrocarbon chain, wherein 1-2 methylene units of the chain are independently and optionally replaced with -C (O) -, -C (O) NH-, -C (S) -, -CHF-. -CF2-, -NR1-, -O-, -S-, or -S (O) 2;L4 is selected from the group consisting of a covalent bond and an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, -C0-6 alkyl-CO-, -C0-6 alkyl-CONR1-, -C0-6 alkyl-SO2-, -C0-6 alkyl-S (O) 2NR1-, or -C0-6 alkyl-NR1-;each of Ra1, Ra2 and Ra3 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, -C1-6 alky-CO-, -S (O) 2NR3R4, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C1-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;wherein each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;Ra1, Ra2, Ra3, R3 and R4 are optionally substituted by one or more R5;R5 is selected from the group consisting of oxo, halogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic carbocyclyl or heterocyclyl;R5 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl and -C (O) NR3R4;each of Rc1 and Rc2 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, 5-to 10-membered heteroaryl, C1-6 alkyl-CO-, -S (O) 2NR3R4, -C (O) NR3R4, -OC (O) NR3R4, -NR3C (O) O-C0-6 alkyl and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic, carbocyclyl or heterocyclyl;each of Rc1 and Rc2 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxyl, C6-10 aryl, 5-to 10-membered heteroaryl, C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl, or heterocyclyl, wherein aryl, heteroaryl, cycloalkyl, heterocycloalkyl, monocyclic, bicyclic, bridged bicyclic, tricyclic, spirocyclic carbocyclyl and heterocyclyl are optionally substituted by one or more substituents independently selected from the group consisting of H, halogen, oxo, C1-6 alkyl, and C1-6 alkoxy.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claims 5, wherein ring G is a ring selected from the group consisting of C6-10 aryl and 5-6 membered heteroaryl, wherein C6-10 aryl and 5-6 membered heteroaryl are optionally substituted by one or more substituents independently selected from the group consisting of CN, C3-8 cycloalkyl, halogen, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 haloalkoxy.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claim 1-6, wherein ring A is 5-10 membered bicyclic heteroaryl with 1-4 nitrogen atoms.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 1-6, wherein ring A is a ring selected from the group consisting ofwherein each of X2, X3, X4 and X5 is independently selected from the group consisting of N and CH.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 1-8, wherein Ra1 and Ra2 are independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;Ra3 is -C (O) NR3R4, andR3 and R4 are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 1-4, wherein ring B is a ring selected from the group consisting of aryl and 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claim 1-10, wherein ring C is a ring selected from the group consisting of 5-6 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;or ring C is a ring selected from the group consisting ofwhereinis a single bond or a double bond.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claim 2-11, wherein ring D is 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 1-12, wherein L2 is selected from the group consisting of a covalent bond, -C (O) NH-and -NH-.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 2-13, wherein L4 is -C0-6 alkyl-CO-.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 1, wherein the compound has a structure of Formula IX,wherein,is a single bond or a double bond;X1 is selected from the group consisting of N and CH;ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring D is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;Cy1 is a ring selected from the group consisting of 8-14 membered saturated or partially unsaturated monocyclic heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 12-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,Cy1 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, and C1-6 alkyl;Cy2 is a ring selected from the group consisting of C6-10 aryl, 5-10 membered heteroaryl, 8-14 membered saturated or partially unsaturated carbocyclyl and 8-14 membered saturated or partially unsaturated heterocyclyl;Cy2 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalky;each of Ra1, Rb1, Rb2, Rb3 and Rb4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and CN;each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl;or R3 and R4 together with N atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic heterocyclyl; andR6 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 15, wherein the compound has a structure of Formula IX-1 or Formula IX-2,whereinring D, Ra1, Rb1, Rb2, Rb3, Rb4, R3, R4, R6, Cy1, and Cy2 are as defined in claim 15.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 1, wherein the compound has a structure of Formula X,wherein,is a single bond or a double bond;X1 is selected from the group consisting of N and CH;ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring D is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;Cy1 is a ring selected from the group consisting of 8-14 membered saturated or partially unsaturated monocyclic heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 12-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,Cy1 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, and C1-6 alkyl;Cy2 is a ring selected from the group consisting of C6-10 aryl, 5-10 membered heteroaryl, 8-14 membered saturated or partially unsaturated carbocyclyl, and 8-14 membered saturated or partially unsaturated heterocyclyl;Cy2 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalky;each of Ra1, Rb1, Rb2, Rb3 and Rb4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and CN;each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl;or R3 and R4 together with N atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic heterocyclyl; andR6 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 15-17, wherein Cy2 is selected from the group consisting of phenyl and 5-6 membered heteroaryl, wherein phenyl or 5-6 membered heteroaryl is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, CN, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, and C3-6 cycloalky.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claims 18, wherein Cy2 is selected from the group consisting of phenyl and pyridyl, wherein phenyl or pyridyl is optionally substituted by one or more substituents independently selected from the group consisting of F, Cl, -CH3, -CF3, -O-CH3, -O-CHF2, -O-CF3, cyclopropyl, and -CN.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 1, wherein the compound has a structure of Formula XIII (a) or XIII (b) ,wherein,is a single bond or a double bond;ring D is a ring selected from the group consisting of 3-10 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and 5-10 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;ring D is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl;Cy1 is a ring selected from the group consisting of 8-14 membered saturated or partially unsaturated monocyclic heterocyclyl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 12-16 membered saturated or partially unsaturated spiro heterocyclyl with 1-5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,Cy1 is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, and C1-6 alkyl;ring E and ring F are each independently selected from the group consisting of aryl and 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;each of ring E and ring F is optionally substituted by one or more substituents independently selected from the group consisting of oxo, CN, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, and C3-8 cycloalky;each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl, and 5-to 10-membered heteroaryl;or R3 and R4 together with N atom to which they are attached form 5-12 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, tricyclic, or spirocyclic heterocyclyl;Ra1 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, and CN; andR6 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -C1-6 alkyl-C3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 aryl and 5-to 10-membered heteroaryl.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 15-20, wherein ring D is 5-6 membered heteroaryl with 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, wherein 5-6 membered heteroaryl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 21, wherein ring D is selected from the group consisting ofring D is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C3-8 cycloalkyl, and 3-10 membered heterocycloalkyl.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 15-22, wherein Cy1 is 12-16 membered saturated tricyclic spiro heterocyclyl with 1-5 nitrogen atoms.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claims 23, wherein Cy1 iswherein m1, m2, m3, m4, m5 and m6 are each independently selected from integers of 1 to 2; and the sum of m1, m2, m3, m4, m5 and m6 is an integer from 8 to 12.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 15-22, wherein Cy1 is selected from the group consisting ofThe compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claim 20-25, wherein ring E and ring F are each independently selected from the group consisting of phenyl and 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; andeach of ring E and ring F is optionally substituted by one or more substituents independently selected from the group consisting of oxo, CN, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalky.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claims 26, wherein ring E and ring F are each independently selected from the group consisting of phenyl and pyridyl, wherein phenyl and pyridyl are optionally substituted by one or more substituents independently selected from the group consisting of F, Cl, -CH3, -CF3, -O-CH3, -O-CHF2, -O-CF3, cyclopropyl, and -CN.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 1, wherein the compound has a structure of Formula XV,wherein,is a single bond or a double bond;each of Z4, Z5, Z6, Z7, Z8 is independently selected from the group consisting of N and CRz;Rz is independently selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalkyl;each of R3 and R4 is independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, C3-8 halocycloalkyl, and 3-10 membered heterocycloalkyl;Ra1 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalkyl;L2 is absent, -C (O) NH-, or NH;X1 is selected from the group consisting of N and CH;each of X6, X7, X8, X9, and X10 is independently selected from the group consisting of N and CRx;Z1 is selected from the group consisting of NRp, O, S, C (O) , S (O) , S (O) 2 and CRxRy;Z2 is absent or selected from the group consisting of NRp, O, S, C (O) , SO, S (O) 2 and CRxRy;Z3 is absent or selected from the group consisting of NRp, O, S, C (O) , SO, S (O) 2 and CRxRy; andeach of Rp, Rx and Ry is independently selected from the group consisting of hydrogen, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C3-8 cycloalkyl.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 28, wherein each of X1, X6 and X7 is independently selected from the group consisting of N and CH.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 28-29, wherein each of X8, X9 and X10 is independently selected from the group consisting of N and CRx, and Rx is independently selected from the group consisting of CN, hydrogen, halogen, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, and C3-6 cycloalkyl.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 29-30, wherein Z1 is CH2; Z2 is selected from the group consisting of NH, O, and S; and Z3 is absent.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 15-31, wherein each of R3 and R4 is independently selected from the group consisting of methyl, ethyl and cyclopropyl.The compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 1, wherein the compound is selected from the group consisting ofA pharmaceutical composition, comprising the compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 1-33, and a pharmaceutically acceptable excipient.A method for treating an STAT6-mediated disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of the compound, the stereoisomer, the tautomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 1-33, or the pharmaceutical composition of claim 34.The method of claim 35, wherein the STAT6-mediated disease or condition is selected from the group consisting of cancer, a neurodegenerative disorder, a viral disease, an autoimmune disease, an inflammatory disorder, a hereditary disorder, a hormone-related disease, a metabolic disorder, conditions associated with organ transplantation, immunodeficiency disorders, a destructive or overgrowing bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, liver disease, pathologic immune conditions involving Τ cell activation, a cardiovascular disorder, a CNS disorder, Chronic obstructive pulmonary disease (COPD) , acute respiratory distress syndrome (ARDS) , atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, nasal polyps, chronic rhinosinusitis, eczema, urticarial, psoriasis, and alopecia.
